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1 Introduction  
 
Membrane proteins play an important role in cellular function as receptors, transporters, 
anchors and catalysts. About 20-30% of the human proteome is associated with cell or 
organelle membranes by at least one membrane spanning domain,[1] yet, only 3 % of 
characterized proteins are membrane proteins.[2] Tendency to aggregate when isolated 
outside of a lipid bilayer is only one of the many challenges researchers are faced with 
when working on membrane proteins. To access the multitude of biophysical and 
biochemical factors that drive protein-lipid and protein-protein interactions inside of 
biological membranes, it is helpful to break down research targets into well-defined and 
well characterized model systems.[3,4] This includes the need for transmembrane peptides 
that can mimic certain properties as polarity, dipole, geometric characteristics or featuring 
whole sequence fragments, while still preserving the ability to insert into a lipid bilayer.[5–
7] Peptides and proteins with natural amino acid composition can be available by 
recombinant techniques with low error rate, courtesy of the well-functioning DNA-
translation and transcription machinery in live cells.[8] When artificial modifications are 
required however, enzyme scope is usually exceeded while chemical peptide synthesis – 
although being vulnerable to errors in synthesis – excels. Solid phase peptide synthesis 
(SPPS) can accommodate a wide array of modifications if they are compatible with 
synthetic conditions of SPPS.[9,10] With no correction mechanisms in place however, the 
achievable length is limited by the yield of each reaction step, as errors accumulate 
exponentially over the course of the synthesis. While for soluble peptides the desired 
product can often be easily isolated even from an excess of byproducts by high 
performance liquid chromatography (HPLC), transmembrane peptides tend to be less 
forgiving, complicating commonly used purification techniques with solubility issues and 
emphasizing the importance of good quality crude product.[11,12]  
SNARE-mediated (soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor) fusion of biological membranes can be found in a wide array of organisms 
ranging from yeast over plants to mammals, including humans.[13] The highly regulated 
process essential to transport of material across biomembranes has long been under 
thorough investigation and since the first characterization of SNARE proteins in the late 
80s their central role in the secretory pathway of eukaryotic cells is undisputed.[14,15] For 
neuronal exocytosis complementary SNARE proteins syntaxin-1A and synaptobrevin-2 
are located in the membranes of transmitter-filled synaptic vesicles and the presynaptic 
membrane, respectively, anchored by transmembrane domains.[16] Together with 25 kDa 
synaptosome-associated protein (SNAP 25), which is attached to the plasma membrane 
by a lipid anchor, upon contact, the soluble domains form a tight four-helix bundle, 
pulling the opposite membranes into close proximity. SNARE complex formation is 
followed by membrane fusion and transmitter release.[16] A plethora of model fusogens 
have been developed to imitate the structure and function of the membrane associated 
proteins, most focusing on the recognition units tethering the opposite membranes 
together.[17,18] Instead of transmembrane domains, many fusion protein mimetics use lipid 
anchors or other hydrophobic organic molecules to secure the fusogens inside the lipid 





DNA duplex formation to structurally SNARE-motif-related coiled coil forming peptides 
E3 and K3.[19–22] These model systems are usually limited to the aspect of membrane 
approximation achieved by the recognition units but only superficially address the role of 
the transmembrane domain reducing it to its anchoring function. De novo design of 
fusogenic transmembrane peptides has shown that conformational flexibility of the 
membrane spanning peptide achieved by mixed Leu/Val sequences is beneficial for 
fusion efficiency.[23,24] Furthermore, amino acid exchange in synaptobrevin-2 was found 
to modulate fusion rates, accelerating fusion pore formation when isoleucine and valine 
content was increased and slowing it down with α-helix-stabilizing leucine.[25] This 
highlights that exceeding the hydrophobic properties of the residues, amino acid sequence 
of the transmembrane section impacts the fusion process on a molecular level.  
In the DIEDERICHSEN group, a model system has been established, that combines coiled 
coil forming peptides E3 and K3 with the transmembrane domain and linker region of 
neuronal SNAREs synaptobrevin-2 (Syb) and syntaxin-1A (Sx) to obtain E3Syb and 
K3Sx.[26] The topologically homogeneous fusogens allow to address the zippering 
hypothesis, a potential key aspect of membrane fusion in which dimerization starts at the 
N-terminus of the SNARE motif and continues beyond the linker into the transmembrane 
region in a zipper like fashion.[27,28] The peptidic model fusogens were shown to induce 
full fusion in large lamellar vesicles by bulk FRET based fusion assays.[26] One objective 
of this work is to reversibly halt vesicles reconstituted with E3Syb and K3Sx in a docking 
or hemifusion state and restart the process with a fast and clean trigger. Photolabile 
protecting groups (PPGs) are a popular tool to provide spatial and temporal control in 
biochemical processes and therefore ideal modulators for this project.[29] Targeting the 
membrane-proximal region of the coiled coils, a photoprotection strategy is developed to 
disrupt the attractive interactions between the heterodimer forming pair by spanning 
sterically demanding PCGs through the hydrophobic core of the coiled coil. Inspired by 
all-hydrocarbon stapled peptides developed in the VERDINE group,[30,31] photocleavable 
units equipped with allyl linkers are incorporated into peptide E3 at different distances 
and bridged by Grubbs I catalyzed ring closing metathesis (RCM). The new PPG is 
characterized by spectroscopic, chromatographic and mass spectrometry methods. A 
selection of unprotected and photocleavably protected E3Syb and K3Sx derivatives are 
synthesized and compared regarding their fusogenicity. Fusion activity is assessed by 
bulk FRET based fusion assays in large unilamellar vesicles (LUVs).  
Inter- and intracellular trafficking is likewise central for the activation of adaptive 
immune responses. For a cytotoxic T cell to be able to destroy potentially dangerous cells 
it has to be activated by recognizing short peptide fragments of about 9 amino acids on 
the surface of dendritic cells (DCs).[32,33] The task of DCs is to scan their surroundings 
for signs of disease by taking up pathogens and cell material. After processing their 
findings, DCs present short peptide fragments of the digested proteins on their surface on 
major histocompatibility complex I (MHC-I) in a process called cross-presentation. 
Recognition of the epitopes by naїve CD8+ T cells prompts cellular immune response. 
For antigens originating from soluble proteins the mechanisms leading to an immune 
response are well understood.[34] Two principal pathways, the phagosome-to-cytosol 
(P2C) pathway and the vacuolar pathway, that are considered to be majorly responsible 





little research is directed towards the immune response activated by membrane buried 
epitopes[39] and the known pathways have not yet been shown to include crucial steps that 
would be required to extract, process and transport epitopes from membrane proteins.  
Artificial peptides have been designed in the VAN DEN BOGAART1 group to contain known 
tumor epitope NY-ESO1[157-165] flanked by hydrophobic amino acids to form an alpha 
helix inside lipid bilayers. The epitope is equipped with a small bio-orthogonal linker to 
bear the potential for fluorescent labeling for intracellular tracking without interference 
with peptide processing. A variety of peptides with different positioning of the epitopes 
within the transmembrane helix and different amino acids of the epitope substituted for 
propargylglycine ({pra}) are synthesized, reconstituted into liposomes and scanned for 
being processed by monocyte derived dendritic cells isolated from human donor blood. 
Cross-presentation is verified by quantification of cytokine interferon γ (INFγ) secreted 
by CD8+ T cells upon activation. Employing pharmaceuticals that selectively inhibit 
metabolic processes involved in cross-presentation, suitable peptides are then utilized to 
gradually dissect cross-presentation of membrane-buried epitopes. Additionally, the 
{pra} linker is exploited in soluble antigens as an alternative assay for quantifying cross-
presentation by fluorescent labeling developed for mouse models by PAWLAK et al.[40] 
The assay is translated to use on primary human cells with clinically relevant epitopes 
and adapted in the study of phosphoinositide kinase PIKfyve involvement in cathepsin-S 
mediated MHC-II antigen presentation in human derived dendritic cells.[41] Peptide 
synthesis and purification are performed as part of the scope of this thesis. All peptide 
designs and ex vivo studies are executed by FRANS BIANCHI, ELKE MUNTJEWERFF, 
MAKSIM BARANOV and SJORS MAASSEN.1   
 
The research targets taken on in this work are partially connected by synthetic and 
chromatographic challenges related to difficult peptides which are solved similarly across 
projects. Otherwise, the motivations, synthetic approaches and used techniques are 
specific to the distinct project. Therefore, the following sections will generally introduce 
to membrane fusion and pathways of antigen presenting cells. Motivations and objectives 
will then be presented in the beginning of each chapter.  
 






1.1 Membrane fusion 
 
Biomembranes serve as physical boundaries to cells but they also constitute essential 
elements of their interior providing spatially and functionally defined reaction chambers 
known as organelles. Lipids, which assemble into a bilayer of approximately 5 nm 
thickness form the main structural feature of membranes. Additionally, they are crowded 
with proteins, which occupy about 50% of the plasma membrane surface[42] and 
biomolecules such as saccharides are displayed on cell surfaces as essential markers for 
cell-cell recognition.[43] Far from only being passive separating layers they are important 
for many other functions such as generation of energy, signaling, and directed transport 
of material. 
Lipid bilayers, composed of large numbers of individual and diverse lipid molecules, owe 
their high structural integrity to the amphipathic nature of their components. The polar 
headgroups facing outwards shield the hydrophobic tails on the inside from entropically 
unfavorable interactions with water molecules. At the same time, the bilayers are subject 
to three main strains – stretching, tilt, and curvature[44] – which are in turn influenced by 
osmotic pressure between the enclosed and surrounding medium, interactions with 
membrane proteins and adjacent proteins, and adhesion forces to surfaces.[45] How well 
the bilayers can respond to these strains, i.e. how much they can take and still maintain 
their integrity, is majorly determined by the preferred arrangement of the given lipid 
composition (see Figure 1.1).[46,47] For instance, lipids with the headgroup 
phosphatidylcholine (PC) such as dioleylphosphatidylcholine (DOPC) typically have a 
cylindric molecular shape and favor planar architectures. Cone-shaped lipids (e.g. 
dioleylphosphatidyletanolamine (DOPE)) and inverted-cone-shaped lipids have a 
negative and positive intrinsic curvature, respectively.[46] Membranes containing 
cholesterol have an increased cohesion which is expressed in increased stiffness and 
decreased permeability to water.[48–50]  
 
Figure 1.1: Left: Preferred architectures of selected phospholipids.[46,47] Inverted-cone-like lipids spontaneously 
assemble into inverted micelles or inverted cylindrical micelles (hexagonal phase). Cylinder shaped lipids form stable 
planar bilayers (lamellar phase). Right: Molecular structures of lipids used in this work. Cholesterol interacts with the 
acyl groups via hydrogen bonds (dashed lines). Cholesterol reduces fluidity and increases thickness of membranes by 
favoring of trans-conformation of the acyl chains and decreases permeability to water by filling the empty spaces 
between acyl chains.[48–50] 
While maintaining the macroscopic structure, lipids (and to some extent other membrane 
components) are still allowed to diffuse and deform laterally (fast) and across the bilayers 





in 1972, lipids, proteins, and other membrane components were described to be 
homogeneously distributed in the membrane.[52] However, observations of phenomena 
like hierarchically built supramolecular protein complexes,[53,54] restricted diffusion of 
membrane-proteins[55,56], and domains with distinct lipid compositions termed “rafts”[57] 
have shaped a new understanding of the structure of biomembranes. A modern 
interpretation views membranes to be highly structured and transversely asymmetrical, 
with the cytosolic side of plasma membranes supported by a skeleton of cortical actin.[58] 
How the high degree of organization is achieved and maintained is not entirely 
understood, but an interplay of physical factors such as membrane curvature and lipid 
miscibility, cytoskeletal interaction, and enzymatic interventions e.g. through ATP-
requiring flippases appears plausible.[58,51]  
Spatially and temporally controlled exchange of material is a fundamental task of 
biomembranes that must be reconciled with the effective separation of cells and their 
compartments. As one of several transport mechanisms, membrane trafficking transfers 
biomolecules through small lipid vesicles budded from the membrane of the source 
compartment. Large and polar cargo is carried inside the volume enclosed by the vesicles 
and released by mixing of the volumes with the destination compartment. Besides, 
membrane-bound components like ion channels, enzymes, and lipids can be transported 
to a target membrane and become part of it. Membrane fusion between the vesicle and 
target membranes is a highly regulated process. Diverse proteins facilitate the correct 
recognition of the membranes destined to fuse and approximate them to where their 
intrinsic stability is overcome, and lipids start to mix. Proteins of the SNARE-family have 
been recognized as fusion mediators in physiological fusion processes involved in 
intracellular transport and neurotransmitter release in neuronal exocytosis.[59–61] 
Pathological fusion events as found in viral infection typically require less regulation and 
precision and are often promoted by a single type of protein e.g. hemagglutinin (HA) of 
influenza A.[60]  
 
1.1.1 Mechanics of membrane fusion 
 
When two biomembranes merge this leads to mixing of their lipids as well as of the 
enclosed volumes, in other words, two previously separate lipid bilayers become one 
continuous bilayer with a single enclosed volume. Before this can happen, a steep energy 
barrier must be overcome. Dipolar headgroups of the bilayers interact strongly with water 
molecules which must be displaced in order to bring the bilayers into close enough 
distance to fuse. The actual energetic cost of membrane fusion is highly dependent on the 
lateral membrane tension (strains acting on the membrane) at the fusion site.[62,45,63] In 
living organisms, the energy needed for fusion is usually raised by specialized fusion 
proteins, however, the pathways by which a connection between two membranes is 
formed are more extensively studied in protein-free models both theoretically and 
experimentally.  
Depending on the used methods and settings, the suggested sequences of events differ 
from each other (see Figure 1.2) and it is conceivable that fusion pathways may be 
dependent on the applied conditions e.g. the lipid composition. Two stages of fusion are 
commonly agreed upon: The first connection between the two membranes is referred to 





(cis) layers of the two membranes destined to fuse. Although usually short-lived, the stalk 
can become a stable structure under the right conditions like low hydration and negative 
spontaneous curvature and is commonly identified in X-ray studies though the 
rhombohedral diffraction patterns of the hexagonal phase in stalk lipids.[64,65] A late stage 
that establishes an aqueous connection between the two compartments is accepted to 
involve at least one fusion pore, formed by lipid rearrangement of the inner (trans) layers 
into a shared continuous layer (E and G).  
KOZLOV and MARKIN first proposed the so-called stalk model in 1983 which would shape 
the understanding of membrane fusion in the following decades.[66] With the initial 
assumptions concerning the shape of the fusion stalk the energy needed for fusion was 
vastly overestimated so the model was overhauled to allow the tilting of lipids for a better 
approximation of the energy cost in biological membrane fusion with about 40 kBT.
[67–69] 
The stalk model of membrane fusion – or fusion-through-hemifusion as denoted by the 
authors[70] – follows a continuum approach model and is described as a series of the 
following steps: When the apposed membranes come into close enough distance (A), a 
thermally powered point-like protrusion (B) transforms into the axially symmetric 
hemifusion stalk (C). From here, the stalk can radially expand into a hemifusion 
diaphragm (D) – formed from the originally trans monolayers – which then ruptures, or 
directly forms the fusion pore (E). Both options assume accurate separation between the 
lipids of the cis and trans layers and also fusion without content leakage. Hemifusion 
diaphragms[71] have been verified experimentally, however the direct progression from 
diaphragm to fusion pore has been questioned because of the high stability of the 
intermediate.[72]    
 
Figure 1.2: Possible pathways of protein-free membrane fusion, annotations in the text. Adapted in accordance with 
CHERNOMORDIK et al.[70] and FUHRMANS et al.[73] 
Corse grained simulations have offered explanations on how less neat fusion could take 
place. Passing the stalk (C) and hemifusion diaphragm (D), fusion-through-rupture 
(F→I→G) has been proposed.[74,75] This route allows the leakage of content and mixing 





pathway to a cis and trans mixed fusion pore has been published by RISSELADA et al., 
demonstrating a longitudinal elongation of the fusion stalk (C), which then collapses on 
itself to encapsulate a small volume in an inverted micelle intermediate (H).[76] Two pores 
must be opened to connect all compartments, one to create a hemifusion diaphragm-like 
intermediate (I) and the final fusion pore (G).  
In studies on protein mediated membrane fusion, the concepts described above are often 
embraced. This was supported by the finding, that a single set of SNARE-proteins 
suffices to induce membrane fusion in vitro.[77] Within the assumed transitions between 
intermediates, the proteins are thought to bring the membranes into close distance and to 
support the rearrangement of lipids by perturbing lipid packing. Modulation of membrane 
curvature by peptides is also considered a contributing factor.[78] In the controversial 
transition from hemifusion diaphragm to fusion pore – with diaphragms having been 
visualized in protein-mediated fusion[79] – the proteins may restrict the lateral expansion 
of the diaphragm, thus limiting its stability and promoting the opening of a pore.[80] 
However, a different concept has emerged in the early 90s which imagines a direct 
involvement of the fusion proteins in the formation of the fusion pore.[81,82] A 
proteinaceous fusion pore, similar to gap-junctions and ion channels, was proposed to 
form the initial aqueous connection between two compartments and precede the mixing 
of lipids. Only gradually the pore-forming proteins drift apart, allowing lipids to line the 
fusion pore and expand it.[83,84] This concept was supported by the observation that 
aqueous connection preceded mixing of lipids in hemagglutinin (viral) promoted cell 
membrane fusion by several minutes.[85,86] It is not entirely clear how the hydrophobic 
transmembrane domains of fusion proteins could form a pore that allows polar water 
molecules to traverse. Lately, the interaction of transmembrane and juxtaposing protein 
domains with the membrane lipids has come into focus which was conceptualized in the 
image of a proteolipidic fusion pore.[87–89] So far, no concept was proven universally 
superior to the others. It is possible that several mechanisms are biologically relevant 
considering that fusion proteins act under diverse requirements for precision (viral vs. 
exocytosis) and temporal control (cell-cell fusion vs. neuronal exocytosis). 
 
1.1.2 Neuronal exocytosis 
 
Chemical neurotransduction in nerve terminals of vertebrate neurons is one of the most 
studied physiological events in the context of membrane fusion and fusion proteins. In 
their pioneering works, KATZ and coworkers have laid the foundation for uncovering the 
pathways of synaptic transmission as early as the 1950s and 60s.[90–92]  
The connection between two nerve endings is called synapse which is where neuronal 
exocytosis occurs (Figure 1.3). Signals arriving at the nerve terminal as action potentials 
are passed on to the postsynaptic neuron by release of neurotransmitters into the synaptic 
cleft. From there, they contribute to building an action potential in the next neuron. To 
transfer the neurotransmitters across the presynaptic membrane, they are enriched inside 
of synaptic vesicles during resting phases. When the action potential arrives, voltage-





synaptic vesicles with the presynaptic membrane within one millisecond.[16] In the 
synaptic cleft the neurotransmitters initiate building of the next action potential. Fusion 
pore dynamics influence the number of released neurotransmitters. Initially only few nm 
wide, the pore can flicker open and closed multiple times before resealing  (kiss and run) 
or committing to full dilation.[93] Recently, this behavior has been identified as an intrinsic 
aspect of membrane fusion.[94] Full merger of the vesicles causes the increase of surface 
area of the presynaptic membrane, but this change is not permanent. Membrane lipids and 
proteins are recycled into new vesicles by clathrin-dependent endocytosis.[95]  
 
 
Figure 1.3: Schematic illustration of the synapse demonstrating the principles of chemical neurotransmission. Vesicles 
filled with neurotransmitter molecules are mostly found in the cytoplasm, but some are translocated to the active zone 
of the presynaptic membrane to be primed for fusion. The incoming action potential opens voltage-gated calcium 
channels and the influx of Ca2+ triggers synchronous fusion of all primed vesicles within <1 ms. In the synaptic cleft 
neurotransmitters travel to the postsynaptic membrane and interact with receptors to build a new action potential. 
Based on JAHN et al. [95]  
 
While being part of the secretory pathway and sharing multiple regulatory protein 
families with other intracellular processes involving membrane fusion, neuronal 
exocytosis has always stood out for its impressive performance regarding spatio-temporal 
control and speed. Particularly, neuronal SNARE proteins syntaxin-1A, SNAP-25 and 
synaptobrevin-2 – being identified as key fusion mediators and minimal fusion 
machinery[96] – have been in the center of countless studies e.g. structural and biophysical 
characterizations and cell free assays. Furthermore, they have inspired the structures of 






1.1.3 Neuronal SNARE proteins 
 
SNARE proteins catalyze membrane fusion along the secretory pathway in eukaryotic 
cells. More than 120 distinct representatives of this highly conserved protein family have 
been discovered in animals, plants and fungi.[13] Inarguably, the most characteristic 
feature of all SNAREs is a stretch of 60-70 amino acids organized in heptad repeats 
known as the SNARE motif. Four SNARE motifs (from different SNARE protein groups) 
recognize each other to form a parallelly aligned tetrameric coiled coil – the SNARE 
complex – and induce membrane fusion. The attraction between the helices is mostly 
based on hydrophobic interactions (15 layers in total), except for the central – “zero” – 
interaction layer which is formed by polar interactions, almost always between three 
glutamine (Qa, Qb, Qc) and one arginine (R) residues. This has also inspired the 
classification as Q- and R-SNAREs (see Figure 1.4 A and B).  
Neuronal SNAREs Synaptobrevin-2, syntaxin-1A and SNAP-25 (25 kDa synaptosome 
associated protein) have become known as the minimal fusion machinery as a result of 
reconstitution experiments in vitro.[96] As few as one set of these proteins was 
demonstrated to be sufficient for observing membrane fusion.[77] Their simplified 
structure is illustrated in Figure 1.4 A.  
 
 
Figure 1.4: A) Schematic illustration of protein domains in neuronal SNARE proteins. Colored rods represent (mostly) 
helical structures while plain lines indicate unstructured sections and  flexible linkers. Wavy lines depict palmitoyl 
anchors. Based on JAHN et al.[97]. B) Ribbon diagram of the SNARE complex formed by the SNARE motifs of 
synaptobrevin-2 (blue), syntaxin-1A (red) and SNAP-25 (green) and extended by the linker regions and TMDs of 







SNARE complex interactions are indicated in yellow. The helical structure of the SNARE complex is extended to the 
previously unstructured linker regions and is continued in the TMDs. The figure was generated with UCSF Chimera. 
Synaptobrevin-2 is anchored in the synaptic vesicle by a transmembrane domain (TMD), 
earning it the alternative name VAMP (vesicle associated membrane protein) and the 
categorization as v-SNARE (vesicle). Syntaxin-1A (secured by a TMD) and SNAP25 
(anchored by palmitoylation of cysteine residues) are known to be colocalized at the 
presynaptic membrane and are therefore classified as t-SNAREs (target). Syntaxin-1A 
additionally bears an N-terminal domain – a three-helix bundle known as Habc domain 
extended by a shirt unstructured sequence referred to as N-peptide – which plays a role 
in the regulation of SNARE complex assembly (see section 1.1.4).[95] 
When the SNARE complex is formed, synaprobrevin-2 and syntaxin-1A each contribute 
one α-helix whereas one SNAP-25 supplies two SNARE motifs. Assembly is thought to 
proceed in distinct zippering phases, beginning at the N-terminal end of the SNARE 
complex.[27] A partially zippered SNARE complex is assumed as a functional 
intermediate in docked vesicles (see section 1.1.4). Several biophysical studies have 
independently characterized the half zippered intermediates, all suggesting that the first 
stage of assembly halts at the -1 or 0 layer.[99,28,100] Progression to the second stage of 
SNARE complex zippering was measured to release a significant amount of energy – 
36 kBT – coming in the range of energy cost for biological membrane fusion.
[99,69] 
However, the fully zippered complex only approximates the v- and t-membranes up to 2-
3 nm, too far for spontaneous fusion stalk formation (~1 nm).[99,65] Furthermore, arrest of 
zippering just short of full SNARE complex formation by mutation in the +8 layer was 
shown to halt giant unilamellar vesicles in a tightly docked or hemifused state without 
progression to fusion.[79] LINDAU and coworkers suggested that the contribution of 
SNAREs to membrane fusion may exceed the interactions of the SNARE motifs and that 
zippering could continue via the linker regions down to the TMDs of synaptobrevin-2 and 
syntaxin-1A.[87,88] The progression of zippering would bring the membranes closer 
together and the assumed movement of charged C-termini inside the membrane was 
proposed to destabilize lipid interactions, lowering the energy barrier for stalk 
formation.[87] This vision is supported by a crystal structure obtained of the neuronal 
SNARE complex with linker regions and TMDs attached (Figure 1.4). Notably, the 
TMD-bearing SNAREs exhibit a continuous α-helical structure whereas their monomers 
were shown to be unstructured in the linker region at conditions where the SNARE motifs 
at least partially exhibit α-helical structure.[101,102] The depicted arrangement is suggested 
to be representative of the post-fusion state of the so-called cis-SNARE complex, 
indicating the fusion stage when v- and t-SNAREs are localized in the same membrane.[95]  
The linker regions connecting SNARE motifs and TMDs are thought to play an important 
role as hinges, ensuring that the work performed by SNARE complex assembly is 
transmitted to the membrane. Increasing the length of linker regions was shown to inhibit 
fusion in vivo and in vitro.[103,104] Furthermore, the polybasic KARRKK sequence of 
syntaxin-1A seems to have multiple responsibilities. Interactions with the anionic lipid 
headgroups of the membrane might disrupt the organization of water molecules at the 
water/lipid interface.[105] This was proposed to facilitate dehydration between the 





phosphatidylinositol-4,5-bisphosphate (PIP2) play a role in the regulation of vesicle 
priming at the active zone of the presynaptic membrane (see section 1.1.4). 
Presence of transmembrane domains is not mandatory to observe fusion, as illustrated by 
the numerous model fusogens with lipid anchors (see section 1.1.5).[17,18] This was even 
more impressively evidenced in a recent study by ZHOU et al. that demonstrated efficient 
Ca2+ triggered fusion in cultivated neurons using lipid anchored syntaxin-1A and 
synaptobrevin-2 mutants that lacked their TMDs. On the other hand, studies with altered 
SNARE TMDs commonly report a reduction in fusion efficiency compared to the native 
sequences. For example, in an inquiry by NGATCHAU et al. synaptobrevin-2 extension by 
even one lysine reduced fusion efficiency by 80%.[87] This surprising result was 
interpreted as evidence for fusion promoting interactions of the C-terminus with the inside 
of the bilayers which would be inhibited through anchoring of lysine to the polar 
headgroups. Lately, flexibility of secondary structure in TMDs has come into focus. After 
HOFMAN et al. presented de novo designed fusogenic peptides consisting of only a TMD, 
the design rules have been tested on synaptobrevin-2. Systematic exchange of amino 
acids in favor of either α-helix stabilizing leucin or β-sheet promoting isoleucine or valine 
were tested with regard to exocytosis efficiency. The extent of exocytosis could be 
positively correlated to the fraction of β-branched amino acids.[25] The notion, that TMDs 
might exist in a β-sheet conformation up until full SNARE complex assembly occurs, has 
been summarized as the β-to-α transition model, short BAT.[106] Transition to α-helical 
structure as a consequence of SNARE zippering is thought to promote lipid perturbations 
thus promoting the formation of a fusion pore. In vitro reconstitution of synaptobrevin-2 
TMD in lipid multilayers could indeed verify the presence of β-sheet content between 7 
and 53% depending in peptide-to-lipid ratio and lipid composition by ATR-
spectroscopy.[107]  
In conclusion, although the minimal fusion machinery has been identified over 20 years 
ago, the molecular mechanism by which it mediates membrane fusion is controversially 
discussed. Some of their structural features may only be understood in relation to 
regulatory mechanisms of Ca2+ dependent transmitter secretion.  
 
1.1.4 Regulation of Ca2+ dependent neuronal exocytosis 
 
Rapid response to an incoming action potential requires the preparation of some of the 
vesicles into a “readily releasable” state by a tightly cooperating ensemble of structurally 
conserved proteins. Docking and priming produces a pool of vesicles with partially 
assembled SNARE complexes at the active zone of the presynaptic membrane which can 
immediately respond to Ca2+ influx.[95] 
Along with the SNAREs, the proteins regulating neuronal exocytosis belong to 
structurally conserved protein families. Docking and priming is guided mainly by four 
key regulators with potentially multiple functions: Sec/Munc18 proteins (SM, e.g. 
Munc18), CATCHR (in particular Munc13), complexins and synaptotagmins as Ca2+ 
sensors. A wealth of information on the roles of these proteins has become available 





of neurotransmitter release.[108] Figure 1.5 summarizes one of the currently discussed 
sequences of protein interactions which leads to the correct assembly of the trans-SNARE 
complex. 
Binding of Munc18 which contains three domains forming an arched-shaped structure to 
a self-inhibiting locked conformation of syntaxin-1A marks the beginning of the priming 
stage.[109,108] Thereby, the Habc domain is folded over on the SNARE motif, preventing its 
interaction with other SNAREs. For a long time, the apparent inhibitory function of the 
SM protein seemed to contradict the complete loss of exocytosis in deletion mutants.[110] 
However, recent findings of HE et al. suggest, that Munc18 prevents the premature 
disassembly of SNARE complexes by NSF and α-SNAP.[111] Munc13, a large 
multidomain protein (200 kDa), has been suggested to contribute to opening the locked 
conformation. The notion that acceptor complex formation – consisting of syntaxin-1A 
and SNAP-25 – precedes docking of the synaptic vesicle has been widely accepted.[97],74] 
However, evidence is accumulating suggesting that the 1:1 complexes may not be a part 
of the assembly stage. Instead, Munc13 was suggested to promote vesicle docking by 
spanning a bridge between vesicles and target membrane and then guide parallel assembly 
of synaptobrevin-2 and syntaxin-1A SNARE motifs together with Munc18.[112,113,108] 
Only after, the two SNARE motifs of SNAP-25 are now thought to contribute to the 
SNARE complex. It is still unclear if Munc18-1 and Munc13 remain bound to the SNARE 
complex.  
 
Figure 1.5: Recent concept of regulation of SNARE complex assembly. Starting from the top right and following the 
arrows: Munc18 binding to a closed conformation of syntaxin-1A initiates the assembly and prevents premature NSF/α-
SNAP disassembly. Munc13 bridges the vesicular and the plasma membrane and releases the Habc domain of syntaxin-
1A. Munc18 guides the parallel arrangement of synaptobrevin-2 and syntaxin-1A SNARE motifs. In the last step, SNAP-





Temporal control over membrane fusion likely is achieved through an interplay of 
complexins and synaptotagmins. The small protein complexin binds to the assembling 
SNARE complex in an antiparallel fashion, successively promoting N- to C-terminal 
zippering up to a certain point and then acting as a clamp – possibly through the N-
terminal accessory helix – and arrests the trans-SNARE complex in a half-zippered 
state.[114] Thereby it reduces spontaneous transmitter release significantly yet doesn’t 
completely eliminate it.[115] The calcium sensor synaptotagmin is  eventually responsible 
for the synchronous response to Ca2+ influx. It is composed of a transmembrane domain 
anchoring it in the vesicle membrane and two C2 domains which can bind two and three 
Ca2+ ions, respectively. Several modes of action were proposed by which Ca2+-dependent 
conformational and electrostatic changes in synaptotagmin translate to triggering 
membrane fusion. The complexin clamp is released upon Ca2+ influx which is thought to 
occur through interactions with the activated synaptotagmin, so that the SNARE complex 
can proceed to C-terminal zippering and unleash its full fusogenic potential.[116] The 
fusion efficiency may be enhanced by the activated synaptotagmin as it interacts with 
anionic phosphoserine lipids and even partially inserts into the plasma membrane, thus 
connecting vesicle and target membrane.[117] This way, it may aid in pulling the 
membranes closer together. Additionally, membrane penetration was suggested to induce 
a positive curvature, thereby reducing the energy barrier for fusion stalk formation.[118] 
Furthermore, an interaction between a polybasic lysine stretch of synaptotagmin and 
syntaxin-1A was proposed which is thought to occur via PIP2 clusters arranged around 
the polybasic linker region of syntaxin-1A.[119]  
When zippering of the SNARE complex is completed and membrane fusion has occurred, 
all SNARE proteins are located in the same membrane and now referred to as the cis-
SNARE complex. The crystal structure depicted in Figure 1.4 B is widely accepted to 
represent the arrangement of the SNAREs at this point. The cis complex is highly stable 
and requires ATP consuming disassembly to be recycled. This task is accomplished by 
NSF (N-ethylmaleimide-sensitive factor) and up to four of its α-SNAP (soluble NSF 
attachment protein) cofactors. In a cryo-EM based study, recently the structure of the so-
called 20S complex was reported.[120] It shows the SNARE four-helix bundle surrounded 
by four α-SNAP molecules, which are in contact with NSF at the N-terminal end of the 
SNAREs. The α-SNAPs were shown to twist around the SNAREs in the opposite 
direction to the left-handed supercoil. ATP hydrolysis is thought to power structural 
changes in NSF which is then translated to the α-SNAPs to unwind the SNARE complex. 
After disassembly, synaptobrevin-2 is endocytosed to be recycled in new synaptic 
vesicles.  
SNAREs are the widely accepted fusion engines of exocytosis.[97] Yet, as presented here, 
at least two more proteins – Munc13 and synaptotagmin – establish connections between 
the vesicle and plasma membrane and may directly contribute to the acceleration of fusion 
pore opening compared to other SNARE driven fusion events of the secretory pathway. 







1.1.5 Model systems for SNARE-mediated membrane fusion 
 
Membrane fusion is a complex process involving diverse components, the interplay of 
which is far from being understood to date. Genetic screens were used to identify the 
proteins involved in neuronal exocytosis and complemented by their biophysical and 
structural analysis. However, the complexity of a living cell makes observations of 
functional relationships made in vivo subject to ambiguous interpretations. Artificial 
model systems comprised of only few components are therefore powerful tools for 
elucidating the mechanisms of membrane fusion. They allow systematic manipulations 
that would not be possible in vivo e.g. for viability reasons. 
Various model membranes are available to mimic synaptic vesicles and the presynaptic 
membrane. By selecting liposomes of different sizes and/or planar membrane setups such 
as planar supported lipid bilayers or pore spanning membranes membrane tension can be 
modulated. Also, the choice of fusion assay dictates the appropriate model membrane. 
Ensemble (or bulk) vesicle fusion assays, first presented by STRUCK et al. in 1981, have 
given insight to average vesicle fusion behavior by measurement of fluorescence 
changes.[121] Fusion can either be monitored by lipid mixing or by content mixing. For 
lipid mixing, two vesicle populations are prepared, and the membrane lipids are laced 
with lipids modified with two types of fluorophores that constitute a FRET pair (see more 
in detail in section 3.3.1). Upon membrane fusion, FRET efficiency is either decreased 
(dequenching setup where both fluorophores are in the same population and the second 
vesicle population is left unlabeled) or increased (quenching setup where each population 
is laced with one type of fluorophore). To verify true fusion in contrast to hemifusion or 
mixing of inner lipid leaflets caused by spontaneous lipid flip-flop, content mixing is 
measured. This has been achieved by filling vesicles with contents that will increase in 
fluorescence upon fusion. The Tb(DPA)3
3- chelation complex as well as self-quenching 
dyes like sulphorhodamine B have been exploited for this purpose.[122,123] Despite their 
popularity, ensemble fusion assays have some drawbacks. For example, content mixing 
assays notoriously suffer from leakage or rupture of the vesicles, which results in a false 
positive result that is hard to distinguish from fusion events. In lipid mixing assays, the 
observed time scales (minutes) are not suitable to zoom into the sub-millisecond 
velocities of Ca2+ triggered exocytosis and they do not report on docked states. Single 
vesicle fusion assays that overcome some disadvantages of ensemble assays have recently 
been reviewed by BRUNGER et al.[124] A new study by MÜHLENBROCK et al. even reports 
a setup that differentiates between rupture/leakage and fusion.[94] 
Generally, two approaches in the choice of fusion mediators can be used when SNARE-
induced membrane fusion is studied in vitro. The first approach uses native SNARE 
proteins (predominantly the neuronal SNARE machinery) extracted and purified after 
expression in a suitable organism (e.g. E. coli). Reconstituted into liposomes, they have 
been used to identify the minimal fusion machinery.[96] Yet, with the native structures 
being dependent on the interactions with various agents present in the neuronal cytosol 
i.e. for guidance of the SNARE assembly,[108] it can be difficult to isolate their effect 
inside of artificial setups. With regard to fusion kinetics, a major progress was made, 





syntaxin-1A [183-288] lacking the Habc domain was paired with a SNAP-25 mutant with 
all cysteines replaced by alanines so that side reactions during expression would be 
reduced. The 1:1 complex was stabilized by a fragment of the synaptobrevin-2 [49-96] 
SNARE motif which would later be displaced by the full-length synaptobrevin-2. The 
preorganized complex accelerated fusion to be completed within few minutes instead of 
hours which was ascribed to preventing the spontaneous formation of an inactive 2:1 
complex in absence of the inhibitory Habc domain. It has been used in different model 
membrane setups to e.g. to investigate fusion pathways or the effect of membrane tension 
on fusion kinetics. [79,126,94,63]  
The second approach to in vitro studies uses artificial fusogens, designed to mimic 
different aspects of the SNAREs. Relatively easy synthetic access and high control over 
the connectivity and geometry of the SNARE analogues provides the opportunity for 
systematic variation to study different facets of membrane fusion on a molecular level. 
SNARE analogues – similar to their native archetype – typically consist of three parts: 
recognition units, flexible linkers, and membrane anchors. The artificial fusogens 
presented in the following paragraphs (grouped by interactions exploited in the 
recognition units) have been used for detailed investigations of the roles that each module 
plays in promoting membrane fusion.  The late 2000s and early 2010s marked a boom 
phase for targeted membrane fusion. Multiple new artificial SNARE mimetics have been 
presented within a period of approximately 4 years.[17,18]   
 
Small molecule recognition 
Diverse small molecule interactions have been successfully used to efficiently mediate 
membrane fusion. Specific recognition between boronic acid (linked by a PEG spacer to 
a stearic acid anchor) and cis-diols as found in the sugar-like head group of 
phosphatidylinositol has been exploited by KASHIWADA et al. to promote 
liposome/liposome fusion.[19] Complemented by pH-responsive coiled coil peptides, 
boronic acid/cis-diol recognition could be used to generate temporal control over 
liposome fusion, triggered by pH change.[127] Hydrogen bonding between cyanuric acid 
and melamine, attached to liposome membranes via a lipid anchor was another reported  
model system showing fusogenic properties.[128] Within this group, also a recent fusogen 
based on strain-promoted azide-alkyne cycloaddition may be noted.[129] The covalent 
connection introduced by click-reaction was reported to promote fusion between 
liposomes.         
The winning arguments for these kinds of model fusogens are their simplicity and 
biocompatibility, making them an interesting target for drug delivery. However, the 
SNARE-mimicking aspects are rather limited as the directionality and zippering of 
SNARE complex assembly cannot be addressed. 
 
Nucleobase-pairing 
To mimic zipper-like assembly of the SNARE complex, several model fusogens with 





al. presented a model system in 2007 that places complementary DNA strands in separate 
liposome populations, anchoring them with cholesterol (see Figure 1.6 A).[20] A zipper-
like orientation was achieved by connecting the lipid at the 5’ and 3’ end, respectively. 
Efficient lipid mixing was observed, but only ~30% could be attributed to inner lipid 
mixing, i.e. full fusion. In a follow-up study, the effects of varying the length of the duplex 
and introduction of either a mono-anchor (composed of PEG4 and cholesterol) or a double 
anchor (two chains of PEG4-cholesterol per single strand) were probed.
[130] Regarding the 
duplex length, between the used 12-, 27- and 42mers the 27mer showed the strongest 
fusogenicity, further elongation did not improve fusion. A double anchor, in this case, 
proved essential to full fusion while single anchors mostly produced outer leaflet mixing. 
This effect was attributed to an increased stiffness of the double linker, expressed in better 
force translation to the lipids. A similar construct was used to induce targeted fusion 
between liposomes and SLBs.[131] Liposomes docked to the SLBs by DNA duplex 
formation could be selectively promoted to fusion by addition of Ca2+. The divalent cation 
is known to interact with phospholipid headgroups, perturbing the organization of the 
bilayer and can by itself induce membrane fusion in appropriate setups.[132]  DNA-base 
pairing was also used by CHAN et al. to show the importance of duplex orientation.[133] In 
ensemble fusion assays complementary strands both anchored to the liposomes via the 5’ 
end (resulting in non-zipper-like dimerization) did not produce membrane fusion contrary 
to the corresponding zipper-like setup.   
 
Figure 1.6: A) DNA-based model system presented by STENGEL et al.[130] B) PNA/SNARE hybrids by LYGINA et al. with 
duplex orientation and stability easily modulated by the PNA sequence.[134] 
A different backbone topology was exploited with the development of a model system 
based on peptide nucleic acid (PNA) recognition by LYGINA et al.[134] These model 







highly thermally stable recognition units to linker regions and TMDs of native neuronal 
SNAREs syntaxin-1A and synaptobrevin-2 as shown in Figure 1.6 B. A characteristic 
feature of the PNA duplexes is that orientation of duplex assembly can be readily defined 
by the nucleobase sequence which was also used for the described PNA/SNARE hybrid. 
In ensemble fusion assays, parallel orientations could produce a higher rate of membrane 
fusion than antiparallel orientation. Additionally, the important role of TMD sequences 
could be highlighted by the observation that the use of identical TMDs or truncated TMDs 
significantly reduced fusion efficiency. TMDs were further investigated by WEHLAND et 
al., reporting a significant enhancement in fusogenicity when C-terminal amino acids 
(usually anionic because of the carboxy-terminus) were exchanged for neutral net charge 
amino acids as lysine and reduction in fusogenicity when dianionic amino acids  as 
glutamic acid were used.[135]  HUBRICH et al. later demonstrated the potency of the model 
system, showing that as few as 5 (aeg) PNA monomers were sufficient to generate 
efficient membrane fusion.[136] Another variation of the PNA/SNARE hybrid was 
presented by SADEK et al. with β-peptide/β-PNA as recognition units. The additional 
methylene units in the peptidic backbone produce a stable and highly rigid 14-helix, with 
a very predictable sequence-to-structure relation. Every fourth residue of the recognition 
unit was decorated with a nucleobase, yielding a Watson-Crick interaction site. This setup 
was used to study the distance dependence of antiparallel duplex assembly. With an 
antiparallel 4-basepair recognition unit, full fusion could be verified. However, when a 
rigid β-peptide spacer was placed at the C-terminal end of the recognition units, only 
hemifusion was achieved.  
 
Coiled-coil interactions 
The first model fusogen based on interactions of coiled coil forming peptides E3 
((EIAALEK)3) and K3 ((KIAALKE)3) was presented by MARSDEN et al. in 2009.
[137] 
They exploited the heterospecific duplex designed by LITOWSKI et al. to obtain targeted 
recognition of liposomes.[22] The peptides were incorporated into liposomes by a lipid 
anchor, DOPE, bridged by a short PEG12 (spacer LPE and LPK, see Figure 1.7 A). It was 
proposed that parallel heterodimer assembly would dock the liposomes together, 
mimicking the zippering of SNARE complexes as shown in Figure 1.7 B. Efficient lipid 
mixing and content mixing could be demonstrated in ensemble fusion assays. 
Observations from cryo electron microscopy and optical microscopy of 100 nm and 1 µm 
liposomes which both demonstrated signs of fusion led to the conclusion that curvature 
stress determined by liposome size was not the main driving force for fusion. In follow-
up studies, the mechanism by which membrane-bound E3 and K3 mediate fusion was 
investigated more in depth by CD and IR spectroscopy and membrane compression 
analyses.[138,139] In addition to the vesicle docking by duplex formation proposed earlier, 
it was found that K3 more than E3 interact strongly with the external lipid monolayer, 
incorporating as α-helical monomers parallel to the lipid plane. This interaction mode was 
suggested to facilitate membrane fusion by induction of curvature and disruption of lipid-






Figure 1.7: A) Illustration of lipopeptides LPE and LPK developed by Marsden et al. B) Proposed course of liposome 
fusion promoted promoted by LPE and LPK. Modified in accordance with MARSDEN et al.[137] 
The impact of different modifications to the lipopeptides have been tested in several 
studies. Variations of anchoring lipid and spacer lengths showed asymmetric effects on 
E3 and K3 lipopeptides.[140] While in K3 bound to cholesterol a decreased linker length 
(PEG4 or PEG8) led to stronger interactions with the membrane, the same tendency could 
not be found in DOPE bound K3. In E3 lipopeptides, increased linker length (PEG16) 
proved beneficiary for membrane fusion. Generally, cholesterol-bound lipopeptides were 
more fusogenic than their DOPE counterparts. The significance of orientation of the 
coiled coil assembly has also been a subject of investigation. Antiparallel assembly has 
been pursued by two approaches, a – by attaching linker and lipid to the N-terminus of 
one of the peptides which still yields a parallel coiled coil complex but with non-zipper-
like peptide orientation – and b – by sequence inversion, leading to true antiparallel 
duplex orientation.[141,142] On the other hand, a publication by PÄHLER et al. reported 
contradictory results[143] Constructs of E3, K3 and inverted sequences iE3 and iK3 were 
extended by a short peptidic linker containing a cysteine at the C-terminus were 
investigated by CD spectroscopy as monomers and as combinations forming parallel and 
antiparallel coiled coils. Furthermore, the peptides were bound in situ to separate 
populations of liposomes (exploiting cysteine/maleimide reactivity) and parallel and 
antiparallel combinations were tested regarding fusogenicity in ensemble lipid mixing 
assays. While in all heterodimeric combinations dissociation constants calculated from 
CD titrations were similar (between 2 µM and 7 µM), the propensity to induce lipid 
mixing was drastically lower in antiparallel complexes than in parallel combinations.  
The E3/K3 lipopeptides have also found practical applications directed towards drug 
delivery. Delivery of the cytotoxic drug doxorubicin encapsulated into liposomes could 
be achieved by liposome/cell membrane fusion in vivo.[144] Furthermore, temporal control 
over liposome/liposome fusion could be achieved employing a photolabile protection 
strategy.[145]  
In 2011, another SNARE mimetic adopting E3/K3 recognition has been presented.[26] 
MEYENBERG et al. used the native SNARE TMDs and linker regions of synaptic syntaxin-
1A and synaptobrevin-2 and replaced the SNARE motives with the coiled coil forming 
peptides yielding the SNARE mimetic pair E3Syb and K3Sx as shown in Figure 1.8 A 






to the ~20 amino acid long heterodimeric coiled coil. The continuous topology of fully 
peptidic SNARE analog was proposed to more closely reflect the buildup of SNARE 
proteins compared to other model fusogens, allowing conclusions more relevant to 
membrane fusion in vivo. The constructs have some drawbacks, for example, the 
attachment of the recognition units has been chosen in a way that does not allow the 
continuation of interactions between linker and TMD amino acids as they would be found 
in the native SNAREs. Also, considering the findings made in the KROS group for K3 
lipopeptides,[138–140] the K3Sx peptides likely exhibit membrane destabilizing properties 
that are not found in the native system. Nevertheless, the fusion pair has been found to 
heterospecifically promote membrane fusion in ensemble fusion assays with kinetics that 
are comparable to the ΔN49 complex and has since been used to study the roles of linker 
amino acids and TMDs for membrane fusion.[26,146,147] In this thesis, the peptidic SNARE 
analog will be used to obtain temporal control over membrane fusion applying 
appropriate photolabile protection strategies.  
 
 
Figure 1.8: Fully peptidic SNARE mimetic developed by KARSTEN MEYENBERG. A) Illustration of the proposed 
interactions of model peptides reconsttituted into liposomes. B) Comparison of the structures of the putative cis-
















1.2 Cross-presentation on MHC-I 
 
All proteins produced in an organism are closely monitored by the immune system for 
signs of disease. While most proteins are catabolized back to amino acids in proteasomes 
on a regular basis, a small portion of semi-processed oligopeptides is transported by the 
transporter associated with antigen processing (TAP) to the endoplasmic reticulum 
(ER).[148,149] There, they are cut down to peptides of 8-11 amino acids[32] and loaded onto 
major histocompatibility complex I (MHC-I) to be presented on the cell surface and 
inspected by CD8+ T-cells. CD8+ T-cells are trained to be tolerant to autologous proteins, 
but when a cell expresses mutated sequences or is infected by a virus, antigenic peptides 
are identified, and the cell is eliminated.[150] CD8+ T-cells do not patrol the organism 
themselves before being activated. There is an immense number of different CD8+ T-
cells, specific to every antigenic amino acid combination, but of every type only a limited 
number is kept in stock, distributed in secondary lymphoid tissues and concentrated in 
lymph nodes.[151] It is the task of dendritic cells to collect cell samples from peripheral 
tissues by endocytosis and phagocytosis,[152] transport them to the lymph nodes and 
present them on MHC-I to the naïve CD8+ T-cells.[33] This process is called cross-
presentation. When an antigen is recognized by a CD8+ T-cell it is activated which 
dominoes into a series of adaptive immune responses to eliminate the diseased cells. After 
uptake by the dendritic cell, different mechanisms are known by which exogenous 
proteins are processed and loaded on MHC-I for cross-presentation. The phagosome-to-
cytosol and the vacuolar pathway are discussed below. Similar to the CD8+ T-cells, there 
are many different MHC-I variants with slightly different binding grooves. Polymorphic 
human leucocyte antigen-A and B code for the antigen presenting molecules and more 
than 8500 individual haplotypes have been be identified so far.[153] The different 
haplotypes bring along preferences for polarity and charge of the individual amino acid 
positions building up the presented epitope.[154] 
 
1.2.1 Phagosome-to-cytosol (P2C) pathway 
 
Antigens from exogenous proteins taken up inside phagosomes can leave the endocytic 
compartment to be processed by proteasomes in the cytosol (Figure 1.9). Once broken up 
by the proteasome, peptides are transferred inside the ER by TAP or back into the 
phagosome to be loaded on MHC-I by peptide loading complex (PLC). Several steps of 
the P2C pathway have been suggested to involve the localization of components in 
phagosomes that are usually found in the ER. Among others, MHC-I, TAP and tapasin, 
all part of the PLC, have been verified in phagosomes by mass spectrometry, however 
their functionality in the phagosome is under debate.[36] Some components may be 
transferred from the ER by a process involving Sec22b, a vesicle trafficking protein from 
the SNARE family.[155] This has been supported by silencing Sec22b, which leads to 
reduced cross-presentation. With this finding it has been discussed if ER-associated 
degradation (ERAD) mechanisms might play a role in transporting antigen out of the 





ubiquitin-conjugating enzyme which marks proteins for degradation – was demonstrated 
to inhibit cross-presentation.[157] This step may be complemented by occasional rupture 
of the phagosome membrane due to radical oxygen species releasing yet undigested and 
functional exogenous proteins to the cytosol.[35,158] Once transported back inside the 
eligible organelles (phagosome or ER) by TAP, proteasome-degraded oligopeptides may 
require further trimming to fit the receptor of MHC-I. This task is fulfilled by insulin-
regulated and ER aminopeptidases (IRAP and ERAP).[157] The origin of MHC-I in 
proteasomes can be twofold, being recycled from the cell surface or newly synthesized 
from the ER. However, for the P2C pathway transport from the ER seems to contribute 
the bigger portion.[157] 
 
Figure 1.9: Cross-presentation by the phagosome-to-cytosol pathway. Foreign material is taken up by the dendritic 
cell inside of an enclosed compartment, the phagosome. Predegraded or intact protein is transferred to the cytosol 
where it is broken up by proteases. TAP delivers the peptides to phagosomes or ER, where they may require a final 
trimming before being loaded on MHC-I. [34] 
 
1.2.2 Vacuolar pathway 
 
Rather than leaving the phagosome, foreign proteins can also be converted to MHC-I 
appropriate bites by protein catabolism inside the endocytic compartment (Figure 1.10). 
This pathway is neither proteasome nor TAP dependent, which makes proteasome and 
TAP inhibition good tools for identifying how a specific antigen is generated. Instead, 
proteases (especially Cathepsin S) and proton pumps are delivered to the phagosome by 
fusion with lysosomes.[38] Acidification of the compartment activates the proteases and 
thereby facilitates proteolysis. Final trimming of the peptides is accomplished by IRAP 
if required before loading onto MHC-I. For the vacuolar pathway, recycled MHC-I from 





Interestingly, MHC-II molecules are loaded with antigens to present to CD4+ T cells by 
similar mechanisms.[159] In a recent study functional proteasomes were found to be active 
in endocytic organelles disputing the fact that one can distinguish the vacuolar pathway 
from the P2C pathway by proteasome inhibition.[160]  
 
Figure 1.10: Cross-presentation by the vacuolar pathway. Antigen filled phagosomes fuse with lysosomes which deliver 
proteases. Proteolysis requires the compartment to be acidified by proton pumps. MHC I may be recycled from the cell 
surface before being reloaded with antigen and transported to the plasma membrane to present their cargo to CD8+ T 
cells. [34] 
 
1.2.3 Cross-presentation of membrane buried epitopes 
 
The preference of MHC-I for binding a specific epitope is predefined by their HLA-A or 
B haplotype, the multitude of which can be grouped in five HLA-A and seven HLA-B 
super types.[154] Bioinformatic tools have been found to be accurate predictors for the 
epitopes which are bound by these super types.[161,162] In a study by BIANCHI et al, 
epitopes predicted to be presented by the different haplotypes were correlated with typical 
transmembrane helix (TMH) compositions and a major overlap was found (Figure 
1.11).[39] Especially in HLA-A02, the most abundant haplotype among the Caucasian 






Figure 1.11: Left) Predicted epitopes derived from the human proteome bound by all HLA-A and HLA-B super types 
that overlap with predicted TMHs by minimum one residue. Red bars mark the threshold for random correlation. Right) 
Percentage of epitope middle positions plotted against their distance (aa residues) to the nearest TMH central 
position.[39] 
 
Analysis of epitopes naturally presented in B lymphoblastoid cell lines partly supports 
this connection, showing that about 1% of the presented epitopes can be predicted to 
originate from TMHs.[163] To be loaded on MHC I, antigens of both endogenous and 
exogenous origin would need to be extracted from the lipid membrane they are embedded 
in and delivered to proteolytic entities e.g. proteasome in the cytosol or lysosomes. The 
presentation and cross-presentation mechanisms described above have not yet been 
reported to include such steps. TMHs need to meet specific requirements for length and 
amino acid composition to insert in the right membranes with the right orientation and 
are therefore often highly conserved.[164] Cross-presentation of membrane buried epitopes 







2 Synthesis and purification of difficult peptides 
 
About 70% of the peptides synthesized in this work can be considered as “difficult 
peptides”. The term has been coined in the late 1980s to summarize the phenomenon of 
sequence dependent synthesis failure in solid phase peptide synthesis (SPPS).[165] In any 
given sequence, the reaction efficiency is never 100% for each of the reaction steps. 
Formation of side products with only one or two missing chain members with respect to 
the full-length sequence and accumulation of errors in long sequences is therefore 
routinely observed. However, repetition of amino acids or the abundance of β-branched 
amino acids threonine, isoleucine and valine have been shown to aggravate synthetic 
problems by inter-chain association of the growing oligomer or interactions with the 
matrix of the solid support.[165,166] Nowadays, peptides that are hard to purify are also 
considered representatives of this group.[167] Poor solubility in common solvents such as 
aqueous buffers or mixtures of water and MeOH or MeCN can originate in different 
properties of the peptides (Table 2.1). High content of hydrophobic amino acids is typical 
in transmembrane peptides such as TM9_pra8 (1). Self-assembling behavior can be based 
on the amphiphilic character of a peptide like in E3Syb (2) or the abundance of hydrogen 
bond forming amino acids glutamine, serine and threonine like in NY-ESO1_long_pra5 
(3). 






























and aggregation in 
solution. 
 
Peptides used in this work were mostly synthesized by automated SPPS supported by 
microwave irradiation with the Fmoc protection strategy (Scheme 2.1). The used 
protocols were adapted from methods published by the manufacturer of the peptide 
synthesizer.[168,169] Related protocols have previously been used to produce peptides of 




high hydrophobic content and length.[147,170] As solid support either low load Wang resins, 
preloaded with the first amino acid, or H-Rink-Amide Chemmatrix® resin were used. 
The Wang resins provided carboxy C-termini and were used with low loading density 
(0.27-0.32 mmol/g) to reduce aggregation of the peptides on resin. Amide C-termini were 
only used on medium length soluble peptides and thus a medium loading density was 
applied (0.5 mmol/g). Both resin types are considered high swelling in N,N-
dimethylformamide (DMF) and contribute to the success of peptide synthesis.  
In automated SPPS, deprotection of N-terminal Fmoc was always accomplished with 20% 
piperidine in DMF within 90 s at 90 °C. To choose the method for building block coupling 
the length of the peptide was considered and whether the peptide could subsequently be 
purified by chromatographic methods. For peptides that would be soluble in water or a 
mixture of water and MeCN or MeOH, single coupling was performed. The commercially 
available building blocks (5 eq.) were added to the resin together with activator DIC 
(5 eq.), racemization preventing additive Oxyma Pure (5 eq.) and DIPEA (1 eq.) which 
restricted the formation of Oxyma Pure derived precipitate. Coupling was completed 
within 120 s by MW irradiation at 90 °C. For the synthesis of peptides that would be hard 
to purify or that would have to be used crude, the CarboMAX™ method, developed by 
CEM, was employed.[169] The use of excess carbodiimide with respect to the amino acid 
was shown to be beneficial in the synthesis of difficult peptides. Additionally, with the 
CarboMAX™ method the amino acids were coupled twice.  
It was reported that by using excess carbodiimide in absence of base, otherwise 
observable epimerization of susceptible amino acids like cysteine could be suppressed 
even at high temperatures.[169] We therefore tried to conduct the synthesis of E3Syb (2) 
without the addition of DIPEA and couple all amino acids at 90 °C. Without base, the 
synthesis reproducibly failed after position 17 or 18 of the peptide due to the buildup of 
precipitate that hampered free flow of reactants and solvent. The precipitate could not be 
removed even by multiple washing steps with DMF, only washing with aqueous solvent 
could free the filter of the reaction vessel. With addition of DIPEA, this precipitate was 
not observed so the tradeoff was made to couple cysteine at 50  C for prolonged periods 
(10 min vs 2 min). 
Synthesized building blocks were chosen to be coupled manually for two reasons. Firstly, 
the coupling behavior in microwave assisted SPPS was mostly unknown, so the reaction 
would need to be followed by KAISER-test and access to resin samples is more convenient 
in manual synthesis than in the pressurized peptide synthesizer. Secondly, excess of 
building blocks could be more easily collected to be recycled. In a related bachelor thesis, 
it was observed that coupling conditions with DIC/Oxyma (5 eq. each, 5 eq. aa, 90°C) 
that worked well in automated synthesis could not be directly translated to manual 
coupling in an open reaction vessel.[171] Instead, manual coupling was achieved by 
activation with HATU/HOAt (5 eq./4.5 eq) and DIPEA (10 eq.) as activator base and 
microwave heating to 75  C. Removal of Fmoc in manual cycles was adapted from a 
previously established two-step deprotection with 20% piperidine.[146] 
Global deprotection and cleavage of peptides from the dried resin was achieved with 
TFA/TIS/H2O (95:2.5:2.5, v/v) or TFA/TIS/EDT/H2O (94:2.5:2.5:1, v/v) where EDT was 





were modified after linear synthesis of the amino acid sequence and before acidic 
cleavage. This includes acetylation to remove charge from the N-terminus, N-terminal 
fluorescent labeling and ring-closing metathesis.  
 
Scheme 2.1: Simplified representation of solid phase peptide synthesis. 
The standard method for post SPPS purification is high performance liquid 
chromatography on reverse phase (RP-HPLC) with a gradient of aqueous buffer mixed 
with acetonitrile or methanol, often adjusted to acidic pH with 0.1% TFA.[172] However, 
standard purification protocols can often not be employed for aggregation-prone peptides 
due to poor solubility. Removable backbone modification with polyArg solubility tags 
has been reported to improve peptide behavior during HPLC[173] and while synthetic 
effort is acceptable in a single peptide, it can accumulate to be inconvenient when many 
different peptides must be purified. Instead, we tested trifluoroethanol (TFE) containing 
eluent mixtures developed for transmembrane peptides by HARA et al. with our peptides 
dissolved in TFE.[12] While the peptide solutions appeared completely homogenized, 
purification was not successful. Only a small portion of injected crude material could be 
recovered after elution during the washing step with pure organic solvent. Further 
analysis revealed that no separation could be achieved. We concluded, that incomplete 
monomerization of putative peptide aggregates were the cause of failure to purify.  
Proper solubilization was achieved with 1,1,1,3,3,3-hexafluoroisopropanol (HFIP). The 
strong H-bond donor is known for inducing and stabilizing α-helical structure and thus 
separating inter-chain associations.[174] HFIP was not the first choice as solvent for HPLC 
samples because of anticipated preelution of samples and because it is not miscible with 
H2O/organic solvent mixtures at all ratios. Still, dilution of peptide/HFIP solutions with 
H2O right before injection proved beneficial for retention of crude peptides on C18 




columns and the peptides could be eluted and separated with gradients of H2O and MeOH 
or H2O and  MeOH/1-PrOH 4:1 (Figure 2.1).  
4 6 8 10 12 14
E3Syb crude
t / min     




4 6 8 10 12 14
t / min
E3Syb purified
    







Using HFIP for sample preparation, SNARE analoga like E3Syb (2) and artificial 
transmembrane peptides with incorporated antigens like TM9_pra8 (1) could be routinely 
purified on HPLC using standard eluents H2O and MeOH and modifying hydrophobicity 
with varying contents of 1-PrOH if needed. However, the method has its limitations. 
15 amino acid peptide NY-ESO1_long_pra5 (3) and various derivatives that were 
synthesized as presumably soluble antigens could not be fully homogenized in HFIP. 
Mixtures of 3 with the fluorinated solvent appeared clear but could not pass through a 
syringe filter (45 µm pore size). We attempted to solubilize the peptides with a protocol 
developed by BURRA et al. for polyGln peptides.[175] For this, the peptides were pretreated 
with TFA/HFIP to monomerize aggregates and after solvent removal by gentle N2 stream, 
formic acid was added. The solution was to be diluted to 20% formic acid by addition of 
H2O, however, any addition of H2O caused immediate visible precipitation. Only minor 
side products of SPPS could be observed by ESI mass spectrometry (Figure 2.2), so this 
peptide class was used crude after thorough washing with Et2O. 
Figure 2.1: Left) UPLC chromatograms of E3Syb prior to purification and after HPLC. Elution from column 1 was achieved 
by a gradient of 70 to 100% B (solvent system II) with a flow of 0.4 mL/min in 8 min and subsequent isocratic elution with 
100% B. Right) HPLC chromatograms of crude TM9_pra8 (column 5, 70 to 100% B in 30min, flow 10 mL/min, solvent system 
















3 Modulating E3Syb/K3Sx fusion with common 
photocleavable protecting groups 
 
In this study, SNARE protein analogs developed from neuronal synaptobrevin-2 and 
syntaxin-1A were used. The tetrameric recognition motif of the native fusogens was 
replaced with coiled coil forming peptides E3 and K3 to form the model fusion pair 
E3Syb/K3Sx. In bulk fusion experiments, E3Syb/K3Sx developed by MEYENBERG et al. 
had been shown to induce full fusion of large unilamellar vesicles[26] and was now used 
as a base system to control membrane fusion by a photolabile protection strategy. In 
previous studies mutations in the minimal fusion machinery were used to control giant 
unilamellar vesicles in docking and hemifusion stages.[79,176] In absence of a suitable 
trigger, no recovery of fusogenicity was attempted. Temporal control of membrane fusion 
has been achieved by KONG et al. using photocleavable PEGylation and artificial 
fusogens with coiled coil forming recognition units.[145] The steric shielding in this 
approach completely suppressed interactions between recognition units and vesicles and 
could not be used to study intermediate states of fusion.  
It was aimed to develop a protection strategy that would suppress lipid mixing but still 
allow docking of vesicles. Arresting the model system in a preorganized state would 
provide an immediate response to a photo-trigger, mimicking primed SNARE complexes 
responding to calcium influx. Later, if a hemifusion state can be stabilized, this would 
allow to test whether the intermediate can be converted to full fusion (see section 1.1.1). 
The use of the native TMDs and linkers of neuronal SNAREs then allows studying their 
influence on transitions between fusion stages. To accomplish this kind of control, the 
recognition units of E3Syb/K3Sx were targeted as depicted in Figure 3.1 A and C. Two 
N-terminal heptads of the coiled coils were to remain unchanged and, in the membrane-
proximal heptads, coiled coil interactions were to be disturbed with PPGs.  
 
Figure 3.1: A) Illustration of the pursued protection principle and control over vesicle fusion. Caged E3Syb (E3 green, 
linker and TMD of synaptobrevin-2 blue) and K3Sx (K3 yellow, linker and TMD of syntaxin-1a red) reconstituted into 





proximal heptads are inhibited by PPGs (up to four individual PPGs, represented by the yellow star) so lipid 
mixing/membrane fusion is suppressed. Upon release of the PPGs by UV irradiation activity of the preorganized fusion 
pair is restored and leads to vesicle fusion. B) Helical wheel representation of interactions in dimeric coiled coils. C) 
Peptide sequences of E3Syb and K3Sx (recognition units with pale green and pale yellow background, linker regions 
and TMDs with pale blue and pale red backgrounds. Electrostatic interactions of E3 and K3 are depicted as dashed 
lines. Amino acids, that can be reasonably caged in the membrane-proximal heptad are highlighted in yellow. The 
assignment of the heptad register can be seen below the recognition unit of K3Sx.  
When trying to reversibly inhibit coiled coil interactions in E3 and K3,[177] two main 
contributions have to be considered: charged amino acids in positions e and g (Figure 3.1 
B and C) exhibit electrostatic attraction when paired with the complementary binding 
partner and electrostatic repulsion when approached by a peptide of the same kind, thus 
guaranteeing heterospecificity. Hydrophobic interactions between isoleucine and leucine 
(a and d) stabilize the duplex. Within the amino acid composition of E3 and K3 only 
lysine and glutamic acid are synthetically approachable to be caged by PPGs. Therefore, 
several Fmoc-L-Lys(PPG)-OH and Fmoc-L-Glu(PPG)-OH derivatives were synthesized 
and tested for the desired application.  
 
3.1 Photocleavably protected amino acid building blocks 
 
3.1.1 6-Nitroveratryl-based caged amino acids 
 
The nitroveratryl (NV) group  is a derivative of the o-nitrobenzyl group first introduced 
as a PPG in 1970.[178] Methoxy groups in 4- and 5- positions induce a bathochromic shift 
of the absorption maximum enabling cleavage at ~360 nm. However, shorter wavelengths 
are more effective.[179] Photolysis occurs under the mechanism shown in Scheme 
3.1Scheme 2.1.[180] 
 
Scheme 3.1: Photorelease mechanism of NV protected groups.[180] 
Irradiation of a NV-caged compound (a) elevates the nitroveratryl group to an exited state 
(b). Through intramolecular proton shift the aci-intermediate (c) is formed which converts 
to the isoxazolidin-1-ol intermediate (d) by irreversible cyclization. Ring opening product 
hemiacetal (e) is hydrolyzed in the rate-limiting step releasing the leaving group. 
Byproduct of the photolysis is o-nitroso veratraldehyde (f), a potential toxin to 




surrounding bioprocesses. Despite poor quantum yield (Φ = 0.006, 365 nm),[179] NVOC 
is one of the most popular PPGs both for applications in solution and on solid support. 
Due to its straightforward and cost-effective synthesis it was tested in this project.  
Fmoc-L-Lys(NVOC)-OH (4) was synthesized as part of a related master thesis in a two-
step procedure (Scheme 3.2).[181] 6-nitroveratryl alcohol (5) was reacted with 4-
nitrophenyl chloroformate (6) to produce activated anhydride (7). Nucleophilic attack 
from the ε-amino group of Fmoc-L-Lys-OH at the carbonate gave Fmoc-L-Lys(NVOC)-
OH (4) with an overall yield of 42%. 
 
 
Scheme 3.2: Synthesis overview of Fmoc-L-Lys(NVOC)-OH.[181] 
Deprotection rate was evaluated with the available cleavage setup by method a) (see 
section 7.1.5) in methanol (3.4 mM) and followed by analytical HPLC (see the appendix, 
Figure-A 1). Solvent and concentration were chosen diverging from the final application 
conditions (HEPES buffer, ~0.7 µM) to effectively dissolve the amino acid and clearly 
observe it in analytical HPLC.  After 10 min of irradiation only a trace of the caged amino 
acid could be detected.  
Despite being a common protecting group for carboxylic acids, NV was disqualified from 
being used on glutamic acid for not withstanding reaction conditions of solid phase 
peptide synthesis.[182] Alternatively, the closely related 3-(4,5-dimethoxy-2-nitrophenyl)-
2-butyl (DMNPB) group was chosen to protect the glutamic acid residues.[183,184] It has 
been developed to overcome some of the drawbacks of NV by having a higher quantum 
yield (Φ = 0.26, 365 nm) and a less toxic photolysis byproduct.[184] In literature, DMNPB 
protected carboxylic acids (g) are reported to traverse aci-nitro intermediate (h) and 
finally release free carboxylic acid and nitrostyrene derivative (i) (Scheme 3.3).[184] 
However, uncaging tests in methanol (3.4 mM) revealed multiple product peaks in 
analytical HPLC analysis (see the appendix, Figure-A 2), suggesting a more diverse 
byproduct composition. On the other hand, the caged amino acid was completely 






Scheme 3.3: Photorelease of a DMNPB protected carboxylic acid.[184] 
Synthesis of the SPPS-ready Fmoc-L-Glu(DMNPB)-OH (8) was adapted from WIRKNER 
et al.[183] with minor changes and performed by HOA NAM NGUYEN for his bachelor thesis 
(Scheme 3.4).[185] 
 
Scheme 3.4: Synthesis overview of Fmoc-L-Glu(DMNPB)-OH.[185] 
First, commercially available 3,4-dimethoxy-phenylacetone (9) was methylated with 
NaH and methyl iodide to give ketone (10) as a racemic mixture. Postponing reduction 
of the carbonyl until after nitration allowed the use of aggressive nitrating acid to give 
compound 11 in high yields. Reduction to 12 could then be chemoselectively achieved 
with NaBH4. STEGLICH esterification connected the protecting group to the glutamate side 
chain to produce 13 and acidic hydrolysis of tBu and Boc followed by Fmoc protection 
of the amine yielded Fmoc-L-Glu(DMNPB)-OH (8) as a threo/erethro mixture with a 
total yield of 19%. It is important to note, that loss of more than 50% in yield in the final 
exchange of protecting groups could have been avoided by use of commercially available 








3.1.2 7-Diethylamino-4-methylcoumarin (DEACM) protected amino acids 
 
After NVOC and DMNPB protected SNARE-analogs were tested in fusion experiments 
and were found to be released too slowly (see section 3.3.3), a different type of caging 
group had to be chosen. DEACM was predicted be a good choice, especially to substitute 
NVOC, for its high quantum yield, high excitation wavelength (DEACM-cAMP, Φ = 
0.24, 395 nm) and ultrafast release.[186,187] Uncaging can be efficient at wavelengths as 
high as 420 nm making it suitable for future microscopic applications as many confocal 
microscopes are equipped with a 405 nm laser. Furthermore, DEACM had already been 
established for caging both amines and carboxylic acids.[188,189]   
In the mechanism of photolysis which is accepted to be common for (coumarin-4-
yl)methyl esters (Scheme 3.5)[190,187], water plays a critical role. The heterolytically 
cleaved methylene-O-bond (l) will recombine if not scavenged by a nucleophile, for 
example water.   
 
Scheme 3.5: A) Proposed mechanism of photocleavage for (coumarin-4-yl)methyl esters. In photoexcited k heterolytic 
bond cleavage can occur (k1) or deactivation  by fluorescence or nonradiave procecces (kfl+knr). Recombination of l 
(krec) competes with solvent separation (kesc) and subsequent reaction with water (khyd).  Published in: J. Phys. Chem. 
A  2007, 111, 5768-5774. Copyright © 2007 American Chemical Society.[190] B) Translation of the proposed 
mechanism to DEACM caged amine. Final decarboxylation reveals the free amine. 
 
As the utilization of DEACM caged glutamic acid in SPPS had previously been 
reported[188] and DEACM caged lysine was not yet literature known, first, Fmoc-L-
Lys(DEACM)-OH (14) was synthesized (Scheme 3.6) and tested with regard to SPPS 
and photocleavage. Following a synthesis procedure by ZHANG et al,[191] 7-Diethylamino-
4-methylcoumarin (15) was oxidized with SeO2 in xylene by heating to reflux for two 
days and the intermediate aldehyde was reduced to alcohol 16 with sodium borohydride. 
The use of these specific experimental conditions is emphasized, as other procedures with 
lower boiling point solvents and longer reaction times have been published,[192,193] but 
this procedure gave the best effort to yield ratio. Also, upscaling to more than 5 g is not 
recommended as selenium side products accumulate at the glass walls and stirring rod, 
interfering with stirring, and yields are reduced. Activation of the alcohol and conjugation 






Scheme 3.6: Synthesis route to produce Fmoc-L-Lys(DEACM)-OH. 
Short test peptide 18 (Scheme 3.7) was synthesized by manual SPPS and no major side 
reactions were observed. The caged peptide was used to determine photocleavage 
efficiency under the available experimental setup (method a, section 7.1.5). Owing to the 
high extinction coefficient of DEACM (16000 mol-1 cm-1)[194] a lower concentration was 
traceable by UPLC. Furthermore, considering the photorelease mechanism, the uncaging 
was expected to proceed best in aqueous medium so a 3.6 µM solution in HEPES buffer 
pH 7.4 was tested (see the appendix, Figure-A 3). Within 1 min, the caged peptide was 
consumed and the formation of photocleavage byproduct DEACM-OH was completed. 
Additionally, peptides 19-21 (Scheme 3.7) were synthesized, to determine whether the 
cage would be available for photocleavage if the coiled coil was formed. The coiled coils 
were also chosen to test cleavage with a hand-held 405 nm 100 W laser pointer (method 
c, section 7.1.5), that would allow to condense the cleavage procedure in the fusion 
experiments. Uncaging proved to be complete within one minute (see the appendix 
Figure-A 4). 
 





Scheme 3.7: Overview of test peptides used to assess photocleavage efficiency of DEACM caged lysine. 
DEACM caged glutamic acid was synthesized by STEGLICH esterification of DEACM-
OH (16) and Fmoc-L-Glu-OtBu as depicted in scheme 5.8. Acidic deprotection of the C-
terminus produced Fmoc-L-Glu(DEACM)-OH (23) in an overall yield of 50%. 
 
Scheme 3.8: Synthesis of Fmoc-L-Glu(DEACM)-OH. 
 
3.2 Synthesized SNARE-mimicking peptides 
 
Following the considerations illustrated in the beginning of this chapter, a selection of 
caged K3Sx and E3Syb derivatives were synthesized by microwave assisted SPPS. Target 
peptides are summarized in Table 3.1. K3Sx (25) and E3Syb (2) were needed for positive 
control experiments. 
Table 3.1: Overview of peptides intended to assess the modulating effect of common PPGs in fusion experiments. 
Caging groups are indicated by bold lettering and placed on the right of the amino acid they are attached to. Peptides 
marked with green checkmarks were successfully synthesized and purified by HPLC using the conditions described in 































Synthetic principles described in chapter 2 could be successfully applied to the synthesis 
of the peptides listed in Table 3.1, except for E3(DEACM)2Syb (30). Here, synthesis 
failed with major truncation products accumulated around the coupling positions of caged 
glutamic acid. At the time of synthesis, it was assumed that incomplete coupling caused 
by a combination of peptide aggregation on resin and steric hindrance of the caged 
building block sealed the fate of the peptide. However, considering the observations made 
in section 4.2, pyroglutamate formation in the successive coupling step is more likely.  
 
3.3 Assessment of fusogenicity 
 
3.3.1 Total lipid mixing assay 
 
E3Syb and K3Sx derivatives caged by literature known PPGs (Table 3.1) were tested for 
their fusogenicity by a bulk total lipid mixing assay which exploits the physical 
phenomenon of fluorescence resonance energy transfer (FRET).[121] When the emission 
spectrum of a donor fluorophore overlaps with the absorption spectrum of an acceptor 
fluorophore a nonradiative transfer of energy is possible.[195] The efficiency of FRET is 
inversely proportional to the sixth power of the distance between the fluorophore pair 









where ηFRET is the FRET efficiency, r is the distance between the fluorophores and R0 is 
the FÖRSTER radius of the FRET pair which is defined as the distance at which ηFRET is 
50%.[195]  
Donor dye (NBD) and acceptor dye (lissamine rhodamine (Rh)), attached to the 
headgroups of phospholipids, are located in one population of liposomes at a 
concentration appropriate to produce efficient FRET (Figure 3.2). Upon merger of the 




liposomes with an unlabeled population, their lipids mix and the average distance 
between the dyes increases. This distance change can be read out by the increase of donor 
emission or the decrease of acceptor emission. Increase of donor emission is a more 
sensitive and accurate representation of the distance change, as in donor emission direct 
excitation can contribute to the total fluorescence value. Without modification, the assay 
cannot distinguish between full fusion of the liposomes and hemifusion where only the 
outer leaflet of lipids is mixed. However, deactivation of NBD by reduction with 
dithionite renders the merger of outer leaflets invisible and thus inner lipid mixing (ILM) 
can be assessed.[196] 
 
Figure 3.2: Simplified representation of bulk lipid mixing assays based on FRET. 
For the peptides synthesized in this work, only total lipid mixing (TLM) experiments 
were carried out. Experimental parameters and procedures were employed in accordance 
with experiments from previous works.[134,197] Large unilamellar vesicles (LUVs) with 
the lipid composition DOPC/DOPE/cholesterol (50/25/25) were prepared following 
literature protocols[198] by extrusion of rehydrated and homogenized peptide/lipid films 
that were obtained by direct mixing of peptide and lipid stock solutions and drying in an 
N2 stream. Labeled vesicles were doped with NBD-DOPE (1.5 mol%) and Rh-DOPE 
(1.5 mol%) while preserving the total DOPE concentration. E3Syb based peptides were 
reconstituted into the labeled population and the K3Sx based peptides were located in the 
unlabeled vesicles each with a peptide to lipid ratio of 1:200. Labeled and unlabeled 
vesicles were mixed at a ratio of 1 to 4 to obtain a final lipid concentration in the cuvette 
of 180 µM (calculated from the theoretical lipid content of homogenized vesicle 
emulsions before extrusion). Vesicle preparation and fusion experiments were carried out 
in HEPES buffer (20 mM HEPES, 100 mM KCl, 1 mM EDTA, 1 mM DTT) at pH 7.4.  
In a time course measurement, NBD was excited at 460 nm and change of fluorescence 
followed at 535 nm over 20 min for experiments without uncaging and up to 120 min for 
experiments with uncaging. With increasing number of protecting groups the slope of the 
fusion curves was expected to become less steep or at best to follow the same course as 
the control experiment if the protecting groups were efficient at reducing coiled coil 





liposome preparation, for promising combinations, triplicates of the measurements were 
performed with vesicles obtained from extruding separate peptide/lipid films. 
 
3.3.2 TLM of fusion pairs with one NV caged peptide 
 
Total lipid mixing (TLM) experiments for peptides 2 + 25, 2 + 26, and 2 + 27, were 
performed with 2 + 2 as negative control (Figure 3.3 A).  The caged peptides showed no 
significant underperformance compared to the uncaged combination. 2 + 26 even 
exhibited a steeper increase of NBD fluorescence than 2 + 25, which could be a peptide-
related effect but is more probable to be caused by a higher insertion rate of the peptide 
or less loss of peptide/lipid film during proteoliposome preparation by extrusion. Despite 
limited evidence for the effective inhibition of coiled coil recognition in the peptide 
combination 2 + 27 (Figure 3.3 B), the peptide pair was investigated again regarding 
changes induced by UV irradiation (method a, see section 7.1.5). The fluorescence change 
was followed over a period of 2 h and the samples were irradiated at different time points 
for 10 s throughout the measurement. The irradiation time was kept short to be able to 
measure quickly after the trigger was set and to limit photobleaching of the fluorophores, 
even if the photorelease was probably incomplete. To account for photobleaching in the 
fusion curves the difference between last datapoint before and first datapoint after 
irradiation was added to all values after irradiation. The fusion curves after irradiation are 
corrected for photobleaching. In 2 + 27 (1) the phototrigger was applied after 1200 s for 
10 s. A slight increase in slope of the fusion curve could be observed after irradiation. In 
the remaining experiments the curve progression was allowed to converge towards an 
equilibrium to observe a more distinct change of slope. In 2 + 27 (2) the irradiation 
appeared to cause an increase in fusion efficiency, while 2 + 27 (3) showed no change in 
curve progression after irradiation. 
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Figure 3.3: A: TLM of 2 + 25, 2 + 26 and 2 + 27 with 2 / 2  as negative control. Fusion curves 2 + 25 and 2 + 27  are 
an average of three repetitions. 2 + 26 was measured once. B: TLM of 2 + 27, three repetitions. The samples were 
irradiated for 10 s by method a) at different timepoints. The light blue line accounts for a measuring error of the 
spectrofluorometer during the measurement of the blue curve.  




Overall, the combination of 2 + 27 was assessed to have a minimal modulating effect on 
the fusion efficiency that could be increased by photocleavage of the NVOC PPGs. 
However, the aim to suppress fusion activity with the PPGs was not achieved with this 
combination of peptides, so in subsequent experiments a more aggressive approach was 
considered. 
 
3.3.3 TLM of fusion pairs with two peptides caged with NV based PPGs 
 
The effect of removing two positive charges in K3(NVOC)2Sx (27) did not produce the 
desired magnitude of reduction in fusion efficiency. It was then considered to modify the 
complementary heptad in E3Syb by introducing PPGs at the glutamic acids in e and g 
positions. The alteration would remove two more charges but more importantly introduce 
more bulk between the coiled coils as the glutamate residues are shorter than lysine 
residues and therefore less flexible. Thus, sterically demanding PPGs in these positions 
have the potential to insert between the coiled coils and disturb hydrophobic core 
formation. For this section, all experimental work has been executed by HOA NAM 
NGUYEN as part of his bachelor thesis.[185] 
As control experiment, this time a combination of E3(DMNPB)2Syb (28) in labeled 
vesicles with empty vesicles were measured. This was expected to represent the vesicles 
not interacting rather than being electrostatically repulsed by each other through the 
negatively charged peptides. Instead of the NBD fluorescence staying constant after the 
addition of unlabeled liposomes and throughout the measurement a significant increase 
in donor fluorescence was observed in the first 120 s of the measurement (Figure 3.4). 
This effect has also been noticed by HUBRICH and WEHLAND from the DIEDERICHSEN 
group who used analogous control experiments.[170,147] It could be attributed to the high 
sensitivity of NBD fluorescence to polarity changes which is given here by the 
introduction of a fourfold excess of lipids. The vesicles in this experiment can come in 
close proximity by BROWNian motion in contrast to the previous control where the 
proteoliposomes with the negatively charged peptide reconstituted in both populations 
would repulse each other. This initial gain in fluorescence was observed to be variable 
and is possibly a representation of absolute lipid concentration fluctuating by lipid loss in 
extrusion. The initial jump was followed by a slow, approximately linear increase in 
fluorescence. To test the response of the non-fusogenic proteoliposome/liposome mixture 
to light, irradiation for 120 s was performed. The length of UV exposure was expanded 
for this set of experiments to be able to completely release all PPGs. Upon continuation 
of the measurement a small jump in fluorescence was noted, possibly an artefact from 
opening and closing the measurement chamber, followed by linear, almost flat 
progression of the curve at about 3.5% fluorescence.  
The combination of 28 + 27 was then tested in the TLM assay (Figure 3.4), mostly 
conserving the parameters of previous measurements. The fusion curves quickly reached 
a plateau similar to the curve shape of the control. In all three repeats, after about 120 s 
only a very shallow increase in F was monitored, indicating that the vesicles did not 





to ensure complete release. Continued monitoring showed a significant increase of on 
average 3% in 1200 s after irradiation in donor fluorescence in all measurements, 
following the shape characteristic for fusion curves. When comparing this value of 
fluorescence increase to the pairing of 2 + 25 which had 10% F after 1200 s, the initial 
jump by polarity change must be taken into account. In Figure 3.3 the contribution of the 
fluorescence change by polarity shift cannot be quantified exactly as it is superimposed 
by fluorescence dequenching. Considering the control experiment, a generous 
contribution of up to 3% may be assumed. This would still leave a discrepancy of 3% 
between the unprotected 2 + 25 (Figure 3.3 A) and 28 + 27 after uncaging despite long 
irradiation times. On the other hand, the fluorescence values after irradiation are affected 
by photobleaching, the absolute value of which seems to be variable and was only 
corrected for by the minimal amount, to reach the fluorescence value before irradiation.  
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Figure 3.4: TLM of 28 + 27 and 28 + empty vesicles as negative control with (left) and without (right) correction for 
photobleaching. 
In conclusion, the pairing two PPGs each in the membrane-proximal heptad of the 
recognition motifs produces a good inhibition of fusogenic peptides E3Syb and K3Sx. 
Photorelease by UV light is slow and does not completely restore function verified by 
fluorescence dequenching. Yet, the direct quantitative comparison to the original system 
is unreliable. Long deprotection times not only affect fluorescence by photobleaching of 
the dyes, but also obstruct access to the data that cannot be collected during irradiation. 
Therefore, the time required for uncaging was to be shortened by PPGs that would cleave 
more efficiently and a less time-consuming irradiation setup. 
 
3.3.4 TLM of fusion pairs with one peptide caged with DEACM 
 
A different type of PPG, that would be uncaged faster had to be found. DEACM was 
estimated to be a good choice for its faster photolysis and absorption maximum at 
~380 nm. Synthesis of both 29 and 30 was attempted but could only be achieved for 29. 
Although the effect of two removed charges in only one of the peptides was expected to 
be minimal considering the results of previous measurements, 29 was tested in TLM with 
2 as fusion partner (Figure 3.5).  




















Figure 3.5: TLM of E3Syb/K3(DEACM)2Sx, one measurement. The curve is not corrected for photobleaching.  
The first 1700 s show a curve shape comparable to the positive control (E3Syb/K3Sx, 
Figure 5.2) with about 5% increase of NBD-fluorescence after 1200 s compared to 
E3Syb/K3Sx with 12%. The fusion efficiency seems to be hampered here, however, the 
difference lies within the conceivable fluctuations of the experiment. To assess the 
inhibitory effect of the caging groups on fusogenicity, the curve progression after 
irradiation is more meaningful. First, a 1 min of irradiation by method c) was performed. 
The hand-held laser pointer could be directly applied to the sample upon opening of the 
measurement chamber. As the time needed before to remove the cuvette from the 
spectrofluorometer and transport it to the Hg lamp and back could be saved, 60 s of 
irradiation was acceptable with regards to access to datapoints. From the assessment of 
photocleavage properties (see section 3.1.2), it can be concluded, that all DEACM would 
be released by this time. Positively, only very mild photobleaching was notable. However, 
the curve progression showed only a slight increase of slope in fluorescence. The 
following minutes of the measurement were therefore used to observe the effect of 
prolonged irradiation on NBD fluorescence. Additional 150 s of irradiation lowered F 




In this section the fusogenicity of synthesized E3Syb and K3Sx derivatives with literature 
known PPGs was assessed. Photocleavable protection of four amino acids in the 
membrane-proximal heptads of the recognition units by NV based PPGs could inhibit 
lipid mixing in LUVs measured by total lipid mixing, but this proved to be unfavorable 
in time-resolved measurements due to the prolonged irradiation times required for 
deprotection. DEACM was envisioned as an alternative PPG with more suitable uncaging 
kinetics. Transfer of the previously identified caging pattern could however not be 
achieved as only K3(DEACM)2Sx (29) could be synthesized by SPPS. The reasons for 
synthesis failure in E3(DEACM)2Syb (30) were not determined but can likely be traced 
back to pyroglutamate formation after coupling of the building block Fmoc-L-
Glu(DEACM)-OH. DEACM uncaging conditions in TLM of 2 + 29 were observed to be 





The number of PPGs that was needed to inhibit fusogenicity was presumably so high, 
because the electrostatic interactions that could be addressed by common PPGs are not 
primarily responsible for the strong attraction of E3/K3 coiled coils. We therefore aimed 
to develop a photoreversible protection strategy that would more precisely target the 








4 Development of a novel photocleavable protection 
strategy for coiled coil interactions 
 
In chapter 3, the attempt to control coiled coil interactions by targeting charged amino 
acids in positions e and g was described (see Figure 4.1 D for a helical wheel 
representation). However, amino acids leucin and isoleucine in positions a and d form a 
tightly packed hydrophobic core at the contact area between the peptides which provides 
a major contribution to stabilizing the left-handed supercoil.[199] Removing electrostatic 
attractions from the equation can be straightforward by using widely established caging 
groups.[29] For leucine and isoleucine on the other hand, no simple protection strategy was 
found. It was envisioned that introduction of a bulky entity in between the coiled coils 
might disturb the formation of a hydrophobic core.  
To introduce said bulk and secure it in place, stapled peptides were taken as an inspiration. 
Covalent connection of two (usually unnatural) amino acid residues is a technique used 
to stabilize secondary structure in alpha helix forming peptides[200,201] and has recently 
been applied to investigate drug targets for protein-protein interactions.[202,203] All-
hydrocarbon stapled peptides, bridged by olefin metathesis, have been presented by the 
group of VERDINE.[30,31,204] Olefin bearing non-natural amino acids were used for ring 
closing metathesis (RCM) by Grubbs I catalyst to span over one (i,i+3 and i,i+4) or two 
(i,i+7) helix turns (Figure 4.1 A) of the investigated peptides.[30,31,204] Different chain 
lengths (x) and stereochemistry (R or S) of the used olefin bearing amino acid influenced 
RCM yield and conformational stability, with Ri,i+7S(11) and Ri,i+7S(12) showing highest 
conversion and strongest helix stabilization. For the design of stapled peptides, it is 
commonly recommended to avoid positioning the staple over a known interaction 
site.[31,205] The opposite principle has been employed in the design of photocleavably 
cross-linked peptide 31. Peptide E3 was chosen over K3 for modification. Due to the side 
chain length of the glutamic acid residues a lower flexibility of the moieties was expected, 
possibly restricting the number of product conformations. DEACMallyl protected glutamic 
acids (e and g on the helical wheel, Figure 4.1 D) in a terminal heptad of E3 were used to 
form a connection (Si,i+6S(14)) spanning over hydrophobic amino acids leucine and 
isoleucine. As a stapled peptide, this was anticipated to enhance α-helicity for the single 
peptide but destabilize coiled coil formation in combination with K3. For comparison, 
peptide 32 with a linkage via lysine residues (Si,i+7S(20)) in f position of the central and 
terminal heptads was pursued. This linkage was expected to enhance single helix stability 
without disturbing coiled coil formation. In both peptides changing α-C stereocenters of 






Figure 4.1: A: All-hydrocarbon stapled peptide nomenclature as presented by SCHAFMEISTER et al.[30].  B: Schematic 
illustration of E3/K3 coiled coil with E3 photocleavably cross-linked via glutamate residues (top) to weaken 
hydrophobic interactions and via lysine residues (bottom) as putative non-interfering comparison. C: Sequence and 
structure of photocleavable cross-link of 31 and 32. D: Helical wheel representation of geometry and interactions in 
coiled coils. 
 
4.1 Building blocks for photocleavable cross-link 
 
A new DEACM based photoactive group, that can be used simultaneously as PPG and 
PCL was developed for the application in reversible intramolecular cyclization. For this 
purpose, the DEACM base structure was equipped with an allyl linker that can be 
selectively addressed in olefin metathesis. GRUBBS I catalyst has been used for ring 
closing metathesis of olefins and alkynes in resin bound peptides before.[31,30,204,206] The 
so called stapled peptides have been used to provide conformational stability to peptide 
drugs and thereby enhance their performance.[206] Photo-switchable staples based on 
cis/trans photoisomerization have been published before to reversibly control peptide 
secondary structures.[207,208] To our knowledge, no photoreleasable stapling technique has 
been presented to this date that recovers the native sequence after irradiation.  
To synthesize DEACMallyl-OH (33, Scheme 4.1), DEACM (15) was oxidized with SeO2 
and the aldehyde (34) was isolated. The aldehyde was further reacted with allyl stannane 
35, a very toxic but very effective allylation reagent, to obtain 33 in 46% overall yield as 
a racemic mixture.  





Scheme 4.1: Synthesis of amino acid building blocks 37 and 38  for phocleavable peptide cross-linking. 
The alcohol was then used with the established conjugation procedures to obtain Fmoc-
L-Lys(DEACMallyl)-OH (37) with 7% yield and Fmoc-L-Glu(DEACMallyl)-OH (38) with 
67% yield.  
PPG/PCL conjugated lysine 37 was further transformed to assess photochemical 
properties of the new DEACM derivative. Water soluble compounds 39 and 40 were 
synthesized to measure extinction coefficients of 39 and 40 and photocleavage rates and 
byproducts of 40. 39 was produced from 37 by Fmoc deprotection in solution. Compound 
40 was obtained from GRUBBS I catalyzed metathesis of 37 in solution and subsequent 
Fmoc deprotection. 
 
Figure 4.2: Water-soluble compounds 39 and 40 used to investigate photophysical and photochemical properties of 
the novel PCL. 
Extinction coefficients εmax for 39 and 40 were obtained from UV measurements of 





absorption maximum was determined at 380 nm for both compounds, thus, ε380 was 
measured. For both compounds a mixture of all obtained stereoisomers was used. ε was 
obtained from the slope of absorption plotted against concentration.  
Table 4.1: Extinction coefficients measured from dilution series of compounds 39  and 40  in MeCN and H2O. 
Compound ε380 [M-1 cm-1] in 
MeCN 
ε380 [M-1 cm-1] in H2O 
39 17018 ± 188 16181 ± 348 
40 25972 ± 377 23121 ± 395 
 
While the ε380 of 39 was similar to ε385 of DEACM,[194] ε380 of metathesis product 40 
could not have been predicted by ε summation of the two chromophores. This reduction 
in extinction coefficient suggests ππ-stacking of the chromophores enabled by the 
proximity within the molecule and probably varies between the different stereoisomers. 
Nonetheless, the average values obtained from measuring the mixtures of isomers were 
used in all applications.  
40 was used as a model to examine uncaging chemistry and rates of (DEACM)2
butenyl 
bridged compounds. For DEACM the uncaging byproduct is known to be well defined 
(Scheme 3.5),[187] so a similar behavior was anticipated. Uncaging products were 
identified by LC-MS analysis. A 100 µM solution in ultrapure water was uncaged with 
irradiation setup c) (see section 7.1.5) for 30 min and samples drawn at different time 
points were analyzed by LC-MS (corresponding LC-MS analysis is shown in the 
appendix Figure-A 5, Figure-A 6, Figure-A 7). Over the course of the irradiation the 
formation of precipitate was noticed, presumably composed of insoluble uncaging 
byproducts. Peaks at different retention times with the same mass could be attributed to 
the presence of multiple stereoisomers. The assignment is summarized in Table 4.2. 
Table 4.2: Molecular ion peaks calculated from LC-MS signals obtained by uncaging of 40. 
0 min 3 min 30 min 
Rt [min] m/z  Δ m/z  Rt 
[min] 
m/z Δ m/z Rt 
[min] 
m/z Δ m/z  
   0.7 146.0 774.4 0.7 146.0 774.4 
5.9 890.4 0 5.9 890.4 0 6.5 718.3 172 
   6.5 718.4 172 6.8 672.4 218 
   7.3 700.3 190.1 7.5 700.3 190.1 
   7.5 700.3 190.1 7.9 546.3 344.1 
   7.9 546.3 344.1 8.0 546.3 344.1 
   8.0 546.3 344.1 8.2 528.4 362 
   8.2 528.4 362 8.4 528.4 362 
   8.4 528.4 362 8.7 500.3 390.1 
   8.7 500.3 390.1 9.1 528.4 362 
   9.1 528.4 362 9.5 528.4 362 
   9.5 528.4 362    
 
At 0 min irradiation the peak at Rt = 5.9 min with m/z = 890.4 was detected which 
matches the educt. After 3 min of irradiation, the educt was still present and after 30 min 




it was completely consumed. Beyond that the compounds detected after 3 and 30 min 
mostly have coinciding  m/z values and shall only be discussed qualitatively. In both 
analyses, the mass of free lysine, 146.0, could be identified in the elution peak at 0.7 min. 
The peaks with m/z = 718.4 and 546.3 have a Δ m/z of 172 and 344.1 from the educt 
respectively. The mass changes are in accordance with the photolysis mechanism of 
DEACM by heterolytic cleavage of one or both carbamate lysins and successive 
nucleophilic attack of water at the resulting carbocation. The link between coumarins 
stays intact and in place of the carbamate they bear a hydroxy function. Two possibly 
related peaks are m/z = 700.3 (Δ m/z = 190) and 528.4 (Δ m/z = 362). The molecules each 
have a Δ m/z = 18 from the previously discussed photolysis products which matches a 
water molecule. This could be a result of direct elimination of the carbamate unit 
accompanied by H+ abstraction or first formation of the hydroxylated molecules and 
subsequent water elimination, in both cases creating an unsaturated bond conjugated to 
the neighboring coumarin system. Notably, there is no evidence that the same reaction 
takes place at the second hydroxy group. However, this could be explained by the reaction 
being disadvantaged due to insolubility of the product in aqueous environment. The last 
prominent pair of products has a m/z = 672.4 (Δ = 218) and 500.3 (Δ = 390.1). Starting 
from 700.3 and 528.4 a net loss of CO can be calculated. Plausible molecular structures 
for the photorelease of the DEACM-based crosslink are summarized in Scheme 4.2. 
 
Scheme 4.2: Plausible molecular structures for the photolysis products observed in LC-MS.  
To estimate the effect of concentration on the required irradiation times, corresponding 
uncaging experiments were performed at different concentrations (Figure 4.3). 





photolysis kinetics was performed with 0.1% pluronic F127 in H2O to help solubilize the 
photolysis products and minimize scattering of the laser beam. For analysis, two types of 
events were considered. Disappearance of all lysin-carrying molecules, including 
intermediates 41 and 43 was representative for the full recovery rate of native peptide. In 
addition, release of at least one lysin and thus, reduction of peak area of only 40 reflects 
the ring opening rate in a cyclized peptide. At all concentrations except 115 µM, full 
deprotection was completed after 3 min and release of at least one lysine was 
accomplished after 2 min. Between 71 µM and 115 µM there could be a solubility 
threshold in the used medium, slowing down the photochemical reaction.  





















































Release of one lysin
 
 
Figure 4.3: Uncaging of  40  at different concentrations in 0.1% pluronic in water with uncaging setup c). Left: For 
complete deprotection the peak area of the educt and all identified intermediates still bound to one lysine were 
considered. Right: Only the peak area of 40  was plotted, representative of ring opening rate in a peptide.  
 
4.2 Synthesis of photocleavably cross-linked testpeptides 
 
Synthesis of both pre-macrocyclization peptides 45 and 46 was attempted by automated 
SPPS using DIC/Oxyma as activators with exception of photocleavable building blocks 
37 and 38 which were coupled manually with HATU/HOAt (Scheme 4.3). While 46 was 
obtained in good quality, very little product was obtained for 45 although the manual 
coupling steps had been followed by KAISER test and suggested complete coupling.  
 
Scheme 4.3: 45 could not be obtained  from automated SPPS/manual SPPS. Synthesis of 46  was straightforward. The 
yellow stars represent DEACMallyl. 
Therefore, a more thorough investigation of the reaction was undertaken. All steps before 
coupling the first caged glutamate (see Figure 4.4 (A)) were performed by automated 




SPPS. All other steps were carried out manually and resin samples for test cleavage were 
drawn at different stages of the synthesis. After test-cleavage, the peptides were analyzed 
by UPLC and ESI-MS (Figure 4.4). The presence of several product peaks at later stages 
is owed to diastereomeric building block 38. 
From the progression of the synthesis it can be observed that neither the coupling of the 
caged glutamate (B) nor the Fmoc deprotection (C) produce any side product in 
significant amounts. Also, it appears that peptide cleavage at strongly acidic conditions 
does not contribute to the side product formation as the conditions were the same for 
every stage of the synthesis and side products were only verified at the later stages. 
Interestingly, at stage (C) only one product peak was observed despite expecting two 
diastereomers. Possibly the two products cannot be separated at the applied conditions, 
as the following test cleavage analysis shows the expected number of peaks again. The 
next test cleavage was performed only after four more full coupling cycles (D) so the 
conclusion may not be undisputable, yet, the detection of the 1822.0 g/mol peak at this 
stage suggested side product formation during the coupling of the first aa after (C), more 
precisely leucin. The mass corresponds to pyroglutamate formation under the loss of 
DEACMallyl-OH. Detection of a single side product peak is plausible as will be discussed 
further down below. Coupling of the second caged glutamate (D) did not produce any 
further side product and the expected number of product peaks were detected. After 
finalization of the sequence and N-terminal acylation a side product with 2588.4 g/mol 
matching the mass of pyroglutamate formation from the second caged glutamate was 
measured. Furthermore, two additional peaks with molar weights 1864.0 g/mol and 










Figure 4.4: Synthesis tracking of 45 with UPLC analysis (top) with solvent system II and a linear gradient of 10-80% 
B in 20 min and corresponding deconvoluted ESI MS spectra (bottom). Samples were drawn after completion of the 
indicated reaction stage and cleaved following SOP (7). (E)2  signifies the two repetitions of EIAALEK and the yellow 
stars represent DEACMallyl . Signals of target products for each stage are highlighted in green and identified side 
products are highlighted in red. 
Pyroglutamate formation in fully deprotected peptides in aqueous solution is known to 
occur in N-terminal glutamic acids and glutamines in mildly acidic conditions.[209] The 
reaction takes place by nucleophilic attack of the primary amine at the γ-CO and is 
concluded by release of H2O or NH3, therefore being promoted by presence of a mild acid 
providing the proton. Strong acids would completely protonate the amine leaving the 




electron pair unavailable for nucleophilic attack. In SPPS following Fmoc/tBu strategy 
unwanted pyroglutamate formation from glutamate is usually not a problem. Typically, 
the side chain is protected with tBu, which can shield the carbonyl from nucleophilic 
attack by steric hinderance. With other protecting groups however, pyroglutamate 
formation has been known to occur, in those cases it is attributed to the Fmoc deprotection 
stage.[210] 
In case of Fmoc-L-Glu(DEACMallyl)-OH (38) coupling, pyroglutamate formation in 
Fmoc deprotection could only be observed if 0.1 eq of formic acid or HOBt, both weak 
acids, were added to the 20 % piperidine in DMF solution as is common to suppress 
aspartimide formation (not shown). In the successive coupling step both the acid function 
of the amino acid and the activator additives HOAt in manual coupling or Oxyma in 
automated SPPS have the potential to catalyze the side reaction. It appears that in the 
competition between coupling and cyclization the coupling is favored if the coupling 
cocktail is allowed to incubate for a few minutes thereby preactivating the aa prior to 
addition to the resin. In automated SPPS, where the solutions of amino acid, DIC and 
Oxyma are combined in the reaction vessel to concurrently meet the free amines of on-
resin peptides no product formation was observed. On the other hand, product formation 
was observed employing manual coupling with preactivation. Pyroglutamate formation 
terminates the peptide sequence and no further oligomerization can take place (Scheme 
4.4). However, the amide-N is susceptible to acylation as can be seen from Figure 4.4 (F). 
The cyclisation products lose their stereo ambiguity and the UPLC peak number is halved 
as the undefined stereocenter is located at the cleaved DEACMallyl-OH (33). 
For future applications preactivation of the amino acid coupled after the modified 
glutamate should be the minimal precaution and the yield might be improved by use of 
more efficient activators. If full conversion at this step is crucial for a project preparation 
of an NHS-ester or a similarly activated amino acid derivative might be considered in 
place of in situ activation as to avoid the presence of any acid. 
 
 
Scheme 4.4: Formation of cyclic pyroglutamate by nucleophilic attack and release of DEACMallyl-OH catalyzed by 





Despite the synthetic obstacles in the linear peptide synthesis, both resin-bound target 
peptides 45 and 46 could be successfully synthesized. RCM was then performed taking 
advantage of Grubbs I catalyst. For 31, common HPLC solvent systems III and IV (with 
0.1% TFA) could not separate the product peaks from pyroglutamate peaks even at very 
flat gradients. In pre-purification with neutral buffer TEAA and acetonitrile the truncated 
peptides eluted distinctly after the product peaks. In a second semipreparative RP-HPLC 
step with system III a mix of diastereomeric product peaks was isolated with satisfactory 
purity (Figure 4.5 left). For 32, standard purification methods could be applied to isolate 
two main product peaks (Figure 4.5 right). 
 
Figure 4.5: UPLC analysis and deconvoluted ESI-MS with HR-MS spectra of purified peptides 31 (left) and 32 (right). 
Chromatogramms were recorded with solvent system I and a gradient of 40 to 80% B in 15 min and a flow of 
0.45 mL/min. Absorption was observed at 390 nm. 
 
4.3 Properties of photocleavably cross-linked testpeptides 
 
After isolation of 31 and 32, some of their properties were investigated. First, it was tested 
if photolysis would release the native peptide without side reactions. For this, small 
amounts of peptide were dissolved in ultrapure water and irradiated by method b) (see 
section 7.1.5) for 2 min. The solutions were analyzed by UPLC before and after 
irradiation (Figure 4.6). For both photocleavably cross-linked peptides, release of the 
fully deprotected peptide Ac-G(EIAALEK)3G-NH2 could be verified my ESI-MS. 


















Figure 4.6: UPLC analysis of 31 and 32 before and after irradiation. Chromatogramms were recorded with solvent 
system I and a gradient of 40 to 80% B in 15 min and a flow of 0.45 mL/min. Absorption was observed at 215 nm. The 
newly formed peak was identified by mass spectrometry.  
 
Circular dichroism (CD) spectroscopy is a common method for analyzing coiled coil 
interactions. Conformationally fixed chromophores of chiral molecules absorb right-hand 
and left-hand circular polarized light to different extents which can be measured as CD 
signal. Many oligomeric biomolecules and their structural mimetics produce 
characteristic CD spectra by which their secondary structure can be distinguished.[211–213] 
Coiled coil peptides E3 and K3 show the characteristic curve shape of α-helices, with 
equally intense minima at 208 nm and 222 nm and a maximum at 192 nm when combined 
at a 1:1 ratio.[214,215,212] However, when the individual peptides are isolated, they form 
random coils at neutral pH with a minimum at about 200 nm. Owing to this dichotomy, 
dissociation of the heterodimeric coiled coils at elevated temperatures can be read out by 
the gradual disappearance of the signal at 222 nm and the unfolding temperature Tunfl is 
equated with the melting temperature Tm of the dimer.  
Cross-linked peptides 31 and 32 were analyzed by CD as solutions of the individual 
peptides and compared with an unlinked E3 derivative (Ac-GEIAALEW(EIAALEK)2G-
NH2, 47) (Figure 4.7 A). Furthermore, CD spectra of the E3 derivatives as 1:1 mixtures 
with a K3 derivative (Ac-GKIAALKW-(KIAALKE)2G-NH2, 48) (Figure 4.7 B) were 
measured. The analysis was completed by unfolding curves of the complexes recorded 
by observing the CD signal at 222 nm between 5 and 95 °C. For all measurements the 
total peptide concentration was adjusted to 20 µM in 10 mM phosphate buffer pH 7.0, 
with the concentration being limited by the solubility of 32. CD signals were normalized 
to mean residue ellipticity [θ]. 47 and 48 were kindly provided by PIRAJEEV 
SELVACHANDRAN2.  
Cross-linked peptides 31 and 32 were expected to show distinct signs of organization in 
comparison to unlinked peptides 47 and 48. In fact, 31 does produce a signal 
of -12.1 deg cm-1 dmol-1 at 222 nm, that is significantly more intense than in the unlinked 
peptides (-3.9 deg cm-1 dmol-1 for 48 and -7.0 deg in 47). Also, the minimum at shorter 
 






wavelengths is shifted to 205 nm. In 32 on the other hand, the only distinct difference to 
47 was detectable by the shift of the minimum to 204 nm and a slightly less intense signal.  
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Figure 4.7: CD spectra of individual peptides 31, 32, 47 and 48 (A) and of 1:1 mixtures of E3 derivatives with 48 (B). 
Spectra of 20 µM solutions in 10 mM phospate buffer pH 7 were recorded at  25 °C. 
In the 1:1 mixtures with 48, 31 was anticipated to disturb dimer formation while the cross-
link in 32 should not have influenced the coiled coil interaction. Differing from this 
prediction, CD-curves of 31 + 48 and 47 + 48 were nearly congruent, while 32 + 48 
showed an overall less intense signal but with the same curve shape. This could indicate 
that in 31 with the cross-link introduced at the N-terminus, the former is flexible enough 
to move out of the hydrophobic core of the coiled coil and thus not interfere with the later. 
Alternatively, the coumarins might participate in the hydrophobic interactions rather than 
disturbing them. For 32, the macrocycle produced by the cross-link consists of more units 
than the staples reported to have helix stabilizing effects.[30] This could produce 
unintended strain or a bend to the coiled coil of 32 + 48, thus reducing helical content.  
Considering the curve shapes of recorded CD spectra, unfolding behavior at elevated 
temperatures is more indicative of the stability of secondary structure introduced in the 
E3 derivatives by the cross-link than of the stability of coiled coil interactions (Figure 
4.8). The calculated turning points are therefore indicated as Tunfl instead of Tm.  





















 47 + 48  T
m
= 51°C
 31 + 48 T
m
= 53 °C




Figure 4.8: Thermal unfolding of 20 µM solutions in 10 mM phospate buffer pH 7 of 47 + 48, 31 + 48 and 32 + 48 
followed via the CD-signal at 222 nm.  




In conclusion, a photoreversible intramolecular cross-linking strategy has been 
developed, which can induce α-helical structure depending on the size of the formed 
macrocycle. To verify effects on coiled coil interactions, for future experiments either the 
central heptad should be targeted, or the peptide should be extended by a few amino acids 
to further reduce flexibility of the cross-link. Although significant effects of the 
photocleavable cross-link for soluble coiled coils could not yet be determined, a putative 
effect on fusogenicity of E3Syb/K3Sx is also not excluded. From a synthetic point of 
view, Fmoc-L-Lys(DEACMallyl)-OH (37) was much less problematic than the glutamic 
acid counterpart (38) and was therefore used to translate the new PPG/PCL strategy to 
K3Sx and synthesize a cross-linked K3Sx derivative.  
 
 
4.4 Synthesis of a photocleavably cross-linked K3Sx derivative 
 
Previous findings concerning synthesis and structure of photocleavably cross-linked 
peptides were translated to the synthesis of a SNARE analog derivative. The choice 
between targeting E3Syb and K3Sx was easily made by the argument of synthetic 
approachability. Fmoc-L-Lys(DEACMallyl)-OH (37) was found to be applicable to 
standard Fmoc-SPPS without major side reactions while Fmoc-L-Glu(DEACMallyl)-OH 
(38) was susceptible to pyroglutamate formation which was a major source of truncated 
sequences in 31 (see section 4.2). Thus, synthesis of K3((DEACM)2
butenyl)Sx (49) was 
attempted, with the cross-link introduced via the lysine residues of the membrane-
proximal heptad of K3.  
Synthesis of the pre-macrocyclization peptide (50) was achieved analogous to previous 
peptides (chapter  2) by automated SPPS with the CarboMAX activation method and 
microwave assisted coupling at 90 °C, with the exception of Fmoc-L-Lys(DEACMallyl)-
OH (37) (Scheme 4.5). Coupling of the photocleavable building block was performed 
manually (with HATU/HOAt as activators) to be able to recycle excess equivalents of the 
building block. For this synthesis, the N-terminus was supposed to be an amine, so no 
acylation was performed. The N-terminal Fmoc was left on the peptide to exclude side 
reactions of the amine in the following macrocyclization step. After successful formation 
of the intermediate 50 was confirmed by ESI-MS, ring-closing metathesis was performed 
on resin promoted by Grubbs I catalyst. After Fmoc deprotection and acidic cleavage 






Scheme 4.5: Synthesis of photocleavably cross-linked K3((DEACM)2butenyl)Sx (49).  
Because of the length and difficulty of the sequence, the crude product contained the 
target peptide only to a small percentage as could be determined by LC-MS (Figure 4.9). 
Employing the sample preparation methods described in chapter 2, purification of 49 
could be achieved in a two-step RP-HPLC. Individual diastereomers were not resolved 
by chromatography, however, up to eight isomers are conceivable. 
 
Figure 4.9: LC-MS analysis of K3((DEACM)2butenyl)Sx (49) crude (left) and after purification by HPLC. Mass spectra 
were accumulated over the time period marked with red and signals corresponding to the target peptide are highlighted 
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In this section the development of a novel photocleavable intramolecular linker as a 
photocleavable protection strategy for coiled coils was described. The approach was 
inspired by stapled peptides developed in the group of VERDINE, which is why the 
developed linker is also referred to as staple. A PPG/PPL consisting of DEACM equipped 
with an allyl linker for olefin metathesis was designed and synthesized. The novel PPG 
was applied to the caging of the side chains of Fmoc-L-Glu-OH and Fmoc-L-Lys-OH. 
Extinction coefficients were measured and photocleavage behavior was investigated 
using soluble derivatives of the caged lysine monomer. For metathesis product 40 an 
unexpected reduction of extinction coefficient and a diverse side product ensemble after 
photocleavage was observed.    
In the synthesis of peptides 31 and 32 the suitability of the amino acid derivatives for 
SPPS was assessed. While caged lysine could be incorporated without major side 
reactions, pyroglutamate formation could be identified as a major side reaction in the 
oligomerization step following the coupling of  Fmoc-L-Glu(DEACMallyl)-OH (38). 
Despite synthetic challenges, after Grubbs I catalyzed ring-closing metathesis, two 
stapled derivatives of E3, representing one half of the recognition pair used in the SNARE 
analogs developed by MEYENBERG, could be isolated. One derivative was linked via two 
caged glutamic acids, spanning hydrophobic amino acids in the N-terminal heptad of the 
peptide and one peptide was linked via caged lysins on the site which is exposed to the 
solvent when a coiled coil is formed. Both peptides could be completely recovered to 
their uncaged form by irradiation with a 405 nm laser beam. 
The effect of the staples placed in different positions of E3 on the secondary structure 
was investigated in peptides 31 and 32 by CD spectroscopy. In contrast to anticipated 
behavior, peptide 31 showed enhanced α-helicity compared to unstapled 47 when isolated 
but did not significantly interfere with coiled coil formation in combination with 48. On 
the other hand, in 32 the effect of the staple on the isolated peptide was less distinct, but 
coiled coil formation with K3 was hampered. It was concluded that in 31 the positioning 
of the staple allows for high flexibility preventing an inhibiting effect on coiled coil 
formation while in 32 the staple may induce a bend of the peptide, thus reducing attractive 
interactions by a changed geometry.  
The lessons learned from the synthesis of the peptides 31 and 32 were applied to the 
synthesis of photocleavably stapled K3Sx derivative 49. Employing the HPLC conditions 
optimized for the purification of difficult peptides, 49 could be isolated with satisfactory 
purity. The peptide is now ready for future lipid mixing measurements analogous to 
section 3.3. If the peptide can be shown to efficiently inhibit lipid mixing and to be 
restored to its full function within a reasonable time frame, further fusion experiments 
can be performed to distinguish between mixing of the proximal lipid leaflets, mixing of 
proximal and distal leaflets, and content mixing. The peptide can then be used to study 
different stages of zippering as is observed in the native SNAREs. It is of interest how 
fusion intermediates are affected by exchanging amino acids in the linker region of the 





5 Tracking membrane buried and soluble antigens using 
artificial peptides  
 
In the following sections the results of antigen binding studies are presented and 
discussed. Peptides required as antigen source were mostly provided by solid phase 
synthesis as part of the scope of this thesis. All ex vivo experiments were planned and 
carried out by FRANS BIANCHI, ELKE MUNTJEWERFF, MAXIM BARANOV AND SJORS 
MAASSEN  in the VAN DEN BOGAART group3. As this thesis is presented with a focus on 
chemistry, detailed workflow concerning the handling of live cells is not provided. 
Instead, information is displayed in an abstracting fashion to be suitable for the non-
specialized reader. 
Firstly, a general sequence of experiments (Scheme 5.1) performed on live cells from 
human donor blood can be summarized as follows: 
Monocyte-derived dendritic cells (MoDCs) of the appropriate HLA haplotype (HLA 
A02:01) isolated from donor blood were combined with the respective peptide (as 
solution, proteoliposome suspension or conjugated to beads) and incubated for the 
indicated time periods. The unabsorbed antigen was washed from the cell surface and the 
cells were prepared for detection of MHC-bound epitopes.  
 
Scheme 5.1: Schematic representation of immunological experiments performed on live dendritic cells. 
 
T cell activation assay 
A classic quantification method for presentation or cross-presentation of antigen in live 
cells is the T cell activation assay. It is executed by addition of cytotoxic T cells that have 
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been transfected with specific receptors which are available for many commonly 
investigated epitopes. Recognition by a T cell receptor, being selective to epitopes bound 
to MHC and highly sensitive, causes multiple downstream effects including the synthesis 
and secretion of pro-inflammatory molecules called cytokines. IFNγ, a homodimeric 
protein of approximately 40 kDa, is one type of cytokines released by the T cells to 
activate macrophages as part of the adaptive immune response. IFNγ can be quantified 
by enzyme-linked immunosorbent assay (ELISA). ELISA a detection method based on 
specific antibody-antigen interactions (Scheme 5.2). It requires multiple coating and 
washing steps inside of a well plate during which reaction sites are gradually  built up on 
the surface of the wells. The number of these reaction sites is proportional to the amount 
of antigen (in this case IFNγ) in the sample. The final coating involves an enzyme which 
can be quantified by conversion of a substrate which can be detected photometrically. A 
popular choice for the enzyme is horseradish peroxidase which catalyzes the oxidation of 
3,3’,5,5’-tetramethylbenzidine. At acidic pH, the resulting diimine has an absorption 
maximum at 450 nm.  
 
Scheme 5.2: Schematic representation of  ELISA used to indirectly quantify presentation and cross-presentation of 
antigen on the surface of dendritic cells.[216] IFNγ secreted by activated T cells is adsorbed to the surface of a reaction 
well which was precoated with a capture antibody. A detection antibody binds to the cytokine and by streptavidin/biotin 
interaction horseradish peroxidase is attached. The enzyme catalyzes the conversion 3,3’,5,5’-tetramethylbenzidine to 
the yellow diimine, which can be quantified spectroscopically. Thorough washing steps ensure quantitative correlation 
of substrate conversion and IFNγ, the total concentration of which can be determined with the help of a calibration 
series. 
 
Bio-orthogonal labelling and quantification by FACS 
Alternatively, a new assay involving bio-orthogonal labeling of the presented epitope was 
translated for the use on human DCs.[40] An amino acid position inside the epitope which 
is inessential for binding to MHC and optionally recognition by T cells is exchanged for 
artificial amino acids propargylglycine or azidohomoalanine which can react in a 
copper(I)-catalyzed azide-alkyne cycloaddition, also known as click-reaction. 





by several orders of magnitude upon formation of the triazole,[217] reducing background 
fluorescence of excess dye significantly. For this assay, cells must be fixed with 
paraformaldehyde and analyzed by fluorescence-activated cell sorting (FACS) or more 
broadly referred to as flow cytometry. FACS is a powerful technology used to study cell 
populations in modern biology laboratories.[218] The underlying principle is fairly simple, 
however high-throughput real-time analysis of large amounts of data make FACS 
machines an indispensable tool in immunology research. Cell suspensions are passed 
through a flow chamber and focused with a sheath fluid to flow one cell at a time through 
a laser beam (Scheme 5.3 left). Analyzing forward scatter and side scatter caused by each 
cell, the size and internal complexity can be determined, indicating the identity of the cell. 
At the same time, fluorescence can be measured, a dichroic mirror setup allowing for 
simultaneous detection of several fluorophores. Statistical analysis provides information 
about the type and number of cells present in a sample and correlates the number of cells 
carrying one or several types of fluorescent markers. Additionally, physical sorting of the 
cells can be performed by previously defined optical parameters. Modern FACS machines 
process several thousand cells per second. 
  
Scheme 5.3: Left: Scheme of flow cytometry and its critical components described in the text.[219] Right: Calfluor 488 
before and after copper-catalyzed cycloaddition to MHC bound epitope on the cell surface. The azide and alkyne 
positions could also be exchanged. The fluorescence quantum yield is increased by a factor of 250 after click 
reaction.[220] 
To account for cells that did not survive the treatment with the artificial antigens, cells 
were additionally treated with a viability dye eFluor™ 780 (λexc = 633 nm, λexc = 780 nm) 
prior to fixation. The amine reactive dye is able to permeate cellular membranes of dead 
cells while it can only react with surface bound amines in live cells. Thus, dead cells can 
be excluded in the FACS analysis by a high intensity of 780 nm fluorescence.   
 
Confocal microscopy 
To complement the quantification assays, cells were observed by confocal microscopy, 
which allows to follow the trafficking of antigen over the course of cellular processing. 
Reaction with Calfluor488 was not suited for intracellular staining. Therefore, peptides 
for this purpose were either N-terminally conjugated to Atto647 prior to incubation with 
the cells or marked by intracellular staining with AF568 picolyl azide after incubation 




with the cells. The latter carries its own copper-chelating motif (Figure 5.1), which 
increases the local Cu(I) concentration, enhances the efficiency of the click reaction and 
makes it more biocompatible.[221]    
 
Figure 5.1: Cu(I) complexed by AF568 picolyl azide, alkyne and a click-ligand like THPTA. 
 
5.1 Tracking cross-presentation with bio-orthogonal labeling 
 
Verifying presentation and cross-presentation of antigen on the surface of dendritic cells 
is a lengthy and labor-intensive process which takes weeks until results can be obtained. 
Typical immunological assays require additional cell types, cytotoxic T cells, which 
secrete measurable cytokines upon recognition of epitopes bound to MHC molecules. 
Extra cells that need to be cultivated, nurtured and treated appropriately for the 
experiments can be a source of deviations in the obtained results. PAWLAK et al. published 
an assay that can complement conventional measuring methods by eliminating the detour 
via T-cells.[40] They equipped well established antigen model OVA[257-264] SIINFEKL 
with bio-orthogonal groups, either via propargylglycine or azidohomoalanine, that could 
be addressed with copper(I)-catalyzed azide-alkyne cycloaddition. They found that 
individual positions of the epitope could be exchanged for the unnatural residues and still 
be bound to MHC I in a mouse cell line. Also, some of the positions were sufficiently 
exposed to the exterior to be accessible for reaction with Calfluor488 equipped with a 
moiety for click-reaction, which favorably increases fluorescence quantum yield by a 
factor of 250 after conjugation.[220] Binding to MHC I could be validated by quantification 
of Calfluor488 fluorescence on the surface of the cells. This method could be interesting 
for complementing immunological studies of clinically relevant epitopes when translating 
it for use on human dendritic cells.  
A selection of known epitopes from tumor antigens that would be cross-presented on 
MHC I in haplotype HLA-A2 dendritic cells was screened for being verifiable both by T 










50 NY-ESO1_short* SLLMWITQV 
51 NY-ESO1_long* LQQLSLLMWITQCFL 
52 NY-ESO1_short_pra5 SLLM{pra}ITQV 
3 NY-ESO1_long_pra5 LQQLSLLM{pra}ITQCFL 
53 NY-ESO1_short_pra7* SLLMWI{pra}QV 
54 NY-ESO1_long_pra7* LQQLSLLMWI{pra}QCFL 
55 NY-ESO1_short_pra8* SLLMWIT{pra}V 
56 NY-ESO1_long_pra8 LQQLSLLMWIT{pra}CFL 
57 Biotin-NY-ESO1_long Biotin-aca-LQQLSLLMWIT{pra}CFL 
58 Biotin-NY-ESO1_long_pra8 Biotin-aca-LQQLSLLMWIT{pra}CFL 
59 Atto647-NY-ESO1_long_pra8 Atto647-LQQLSLLMWIT{pra}CFL 
60 gp100_long VTHTYLEPGPVTAQVVL 
61 gp100_short_pra5 YLEP{pra}VTA 
62 gp100_long_pra5 VTHTYLEP{pra}VTAQVVL 
63 gp100_short_pra7 YLEPGP{pra}TA 
64 gp100_long_pra7 VTHTYLEPGP{pra}TAQVVL 
65 gp100_short_pra8 YLEPGPV{pra}A 
66 gp100_long_pra8 VTHTYLEPGP{pra}TAQVVL 
67 Mart1_short_pra5 EAAGI{pra}ILTV 
68 Mart1_long_pra5  TTAEEAAGI{pra}ILTVILGV 
69 Mart1_short_pra8  EAAGIGI{pra}TV 
70 Mart1_long_pra8 TTAEEAAGIGI{pra}TVILGV 
71 Mart1_short_pra9 EAAGIGIL{pra}V 
72 Mart1_long_pra9 TTAEEAAGIGIL{pra}VILGV 
 
First, applicability in T cell activation assay was tested. This is important to differentiate 
between epitopes cross-presented on MHC I and residual peptides adhered to the cell 
surface. In a concentration dependent assessment of NY-ESO1, short peptides modified 
with {pra} in different positions (Figure 5.2 left) NY-ESO1_short_pra7 (54) was shown 
to be recognized by CD8+ T cells transfected with the corresponding T cell receptor just 
as well as the native sequence (50).  
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Figure 5.2: Left:  Screening for modified epitope positions by T cell activation assay. Right: Crystal structure of NY-
ESO1 inside the binding groove of MHC I haplotype HLA A2 (PDB ID: 1S9W).[222] The illustration was prepared with 
USCF Chimera. 
The crystal structure of the epitope inside the binding groove (Figure 5.2 right)[222] 
unfortunately suggests, that position 7 (threonine) is pointing to the side of the groove 
and while not essential for T-cell recognition would not be well accessible for labeling. 
Still, peptides summarized in Table 5.1 were tested for labeling with Calfluor488-azide 
after incubation with dendritic cells. Cell samples for incubation times of 0 h, 6 h, and 
12 h were prepared and combined with peptides at a final peptide concentration of 20 M. 
After  incubation at 37 °C for the assigned duration, excess peptides were washed from 
the surface and the cells were fixed with paraformaldehyde. Prior to fixation cells were 
stained with the viability dye eFluor780 (eBioscience, Thermofisher scientific, (Waltham, 
USA)). Click-reaction with Calfluor488-azide was catalyzed by 1 mM CuSO4 with 
THPTA as ligand for 2 h. Additionally, live single cells were gated by flowcytometry and 
the geometric mean of the Calfluor488/FITC channel was calculated.  
Analysis of the screening results (Figure 5.3) revealed, that most of the examined artificial 
antigens cannot be labeled when bound to MHC-I. The highest fluorescence values were 
obtained for NY-ESO1_short_pra8 (55) and NY-ESO1_long_pra8 (56), in positive 
correlation with incubation times. As expected from residue orientation, labeling at 
position 7 showed only moderate intensities with NY-ESO1_short_pra7 (53) with about 
10 x lower signal than the NY-ESO1_short_pra8 (55). However, it could still be 
considered when parallel application of T cell activation assay and bio-orthogonal 
labeling is intended.  
Further investigation of model peptide NY-ESO1_long_pra8 was performed by 
microscopy with N-terminally labeled Atto647-NY-ESO1_long_pra8 (59). 
Unfortunately, recordings of cells after incubation with the peptide and presumed removal 
of excess material by washing showed adhesion of peptides to the cell wall. This is in 
correlation with the behavior experienced during purification attempts after solid phase 
synthesis (see chapter 2). Atto647-NY-ESO1_long_pra8 (59) could barely be purified, as 
the bulky dye helped disrupt intramolecular H-bonds of the peptides. NY-






severely that it would not be fully homogenized by HFIP, appearing dissolved but not 
passing through a syringe filter, and could therefore not be purified by HPLC.  
 
Figure 5.3: Screening for "clickable" epitope positions. Fluorescence plotted against incubation time. 
To disable adhesion to the cell surface peptides were equipped with a biotin tag and 
immobilized on streptavidin coated latex beads. Latex beads constitute a more controlled 




form of peptide administration and more closely mimic typical fodder for DCs: dead cell 
material. So far, no cross-presentation for these peptides could be verified. However, 
exploiting propargylglycine for intracellular click-reaction with AF568-picolyl-azide 
allowed tracking of the peptides on their way through the cell (Figure 5.4).[221] After 2 h 
of incubation “clickable” antigen Biotin-NY-ESO1_long_pra8 (58) can be localized 
inside of lysosomes. Beads with non-clickable control peptide Biotin-NY-ESO1_long 
(57) are also recognizable by their characteristic shape but do not react with the 
fluorophore-azide.  
 
Figure 5.4: Confocal microscopy of dendritic cells treated with biotinylated antigen immobilized on streptavidin coated 
latex beads after 2 h and 6 h incubation time. Left: Biotin-NY-ESO1_long_pra8 (58) treated cells. Right: Cells treated 





5.2 Tracing cross-presentation of membrane buried epitopes 
 
As argued in section 1.2.3, membrane-buried epitopes may play a big role in restricting 
pathogens from evading adaptive immune responses by mutation. However, mechanisms 
for processing TMHs in cross-presentation have not yet been described. Therefore, 
experiments were designed to model antigens embedded inside of lipid membranes. The 
generalized procedure as shown in Scheme 5.1 was carried out with MoDCs of haplotype 
HLA-A02:01. Transmembrane peptides were administered as proteoliposomes obtained 
from extrusion of rehydrated peptide/lipid films (DOPC/DOPS 70:30, 1:80 peptide to 
lipid ratio). After incubation overnight, excess proteoliposomes were removed by 
washing with buffer and the cells were combined with naïve CD8+ T-cells transfected 
with the receptor for NY-ESO1[157-165]. After 72 h, concentration of IFNγ was 
quantified by ELISA.  
The sequences of the used transmembrane peptides were rationalized as follows: Known 
tumor antigen NY-ESO1[157-165] was flanked with few amino acids of the native 
sequence on each side and then hydrophobic amino acids allowing to form a 
transmembrane helix and to contain tryptophan in the N- and C-terminal regions to secure 
them inside the lipid bilayer. Also, the epitopes should contain a bio-orthogonal group, 
alkyne or azide, for future labeling with a fluorescent dye. The positioning of epitope 
inside the TM was varied and the flanking amino acids were adapted to predict an α-
helical TM peptide and to be anchored. As control, a section of syntaxin-3 transmembrane 
domain was equipped with a {pra} position and edited to match the artificial TMPs in 
length and flanking amino acids. Peptides prepared for this chapter are summarized in 
Table 5.2, indicating peptides that were synthesized for future experiments but not yet 
used on grey background. Peptides marked with an asterisk (*) were obtained from 
commercial sources. 
 







54 NY-ESO1_long_pra7* LQQLSLLMWI{pra}QCFL 
73 TM1 AAAWCLQQLSLLMWITQCFLPVFLAWAAA 
74 TM1_pra5 AAAWCLQQLSLLM{pra}ITQCFLPVFLAWAAA 
75 TM1_azi7 AAAWCLQQLSLLMWI{az}QCFLPVFLAWAAA 
76 TM1_pra7 AAAWCLQQLSLLMWI{pra}QCFLPVFLAWAAA 
77 TM1_pra8 AAAWCLQQLSLLMWIT{pra}CFLPVFLAWAAA 
78 TM7_pra7 AAAWLLCLVVLSLLMWI{pra}QCFLPVFWAAA 
79 TM8_pra7 AAAWFVLLCLVVLSLLMWI{pra}QCFPWAA 
80 TM9 AAAWPFVLLCLQQLSLLMWITQCFLWAAA 
81 TM9_pra5 AAAWPFVLLCLQQLSLLM{pra}ITQCFLWAAA 
82 TM9_pra7 AAAWPFVLLCLVVLSLLMWI{pra}QCFLWAAA 
83 TM9_azi7 AAAWPFVLLCLVVLSLLMWI{az}QCFLWAAA 
1 TM9_pra8 AAAWPFVLLCLQQLSLLMWIT{pra}CFLWAAA 




84 ControlWW AAAWLIIIIVIVVVLLGI{pra}LALIIGLWAAA 
85 ICP47 MSWALEMADTFLDTMRVGPRTYADVRDEINKRGRE 
 
Selected peptides were tested for their secondary structure inside of lipid membranes by 
CD spectrometry. Peptide/lipid films were rehydrated and homogenized by extrusion 
through polycarbonate membranes (Ø = 100 nm) to produce proteoliposomes (2 mg/mL 
lipids (70% DOPC, 30% DOPS), 0.1 mg/mL peptide, 10 mM phosphate buffer pH 7). 
CD signals measured between 190 and 250 nm are plotted in Figure 5.5. With minima at 
around 210 nm and 222 nm, the curves represent the characteristic shape produced by an 
α-helix. ControlWW (84) and TM1 variants (75 and 76) produce overall more intense 
signals than TM9 variants (82 and 83). 



























Figure 5.5: Secondary structure of artificial transmembrane peptides inside of liposomes was verified by CD 
spectroscopy. Proteoliposome suspensions with a peptide to lipid ratio of 1:80 and a final peptide concentration of 
0.1 mg/mL were measured in 10 mM phosphate buffer at pH 7.  
Before any mechanistic investigations could take place, a functioning model TM peptide 
needed to be found that would be effectively cross-presented in undisturbed cells. 
Proteoliposomes were added to the MoDCs at different concentrations between 0.1 µM 
and 10 µM final peptide concentrations and removed after overnight incubation. As a 
comparison, MoDCs were treated with soluble peptides. Figure 5.6 depicts the relations 






Figure 5.6: Concentration dependent cross-presentation of artificial peptides. Left: Transmembrane peptides were 
administered as proteoliposome suspension. Right: Soluble peptides were added as solution. 
A dose-dependent TCR response is distinctly measurable for TM1_pra7 (76) while the 
other TMPs do not show any measurable effect. Cross-presentation of soluble peptides 
NY-ESO1_short_pra7 (53) which does not need processing to be bound to MHC-I and 
NY-ESO1_long_pra7 (54) that does require trimming before being loaded on the antigen 
presenting complex likewise shows a dose-response to applied peptide. Interestingly, the 
overall response to soluble peptide is about fivefold compared to the TMP. Nonetheless, 
TM1_pra7 (76) and the corresponding soluble analogs were deemed as useful tool to 
compare mechanisms of cross-presentation of soluble and membrane buried antigens. 
As mentioned in section 1.2.2, proteasome and TAP are good targets to differentiate 
between the two cross-presentation pathways that are most prominently discussed to date. 
MG132 is a potent synthetic proteasome inhibitor from the family of peptide 
aldehydes.[223] It was administered to cell populations that would be treated with the three 
previously identified model peptides at different concentrations (Figure 5.7). While high 
concentrations >0.1 µM of inhibitor caused cell death in all populations, at 0.1 µM a 
difference in response by the different populations could be noted. Cross-presentation of 
soluble antigens, both short and long variant were reduced in comparison to uninhibited 
cells whereas cross-presentation of membrane-buried antigen remained undisturbed.  





Figure 5.7: Influence of proteasome inhibitor MG132 on cross-presentation of soluble and membrane-buried antigen. 
This could be a first hint to TM protein-derived antigens not being cross-presented by the 
P2C pathway. To supplement this finding future control experiments will be performed 
with TM1 which does not carry modifications in the epitope. Furthermore, it is planned 
to use TAP inhibitor ICP47 (85) as next step as proteasome inhibition alone is not 
sufficient to distinguish if membrane proteins are presented via P2C or the vacuolar 
pathway.   
 
5.3 Presentation on MHC-II verified by bio-orthogonal labeling  
 
In contrast to MHC-I molecules, which can be found on the surface of all types of cells 
in the human body, MHC-II is only expressed in specialized antigen presenting cells like 
dendritic cells. While their function is similar, the MHC-II presented antigens usually 
originate from outside of the organism, like from bacteria or viruses, and are processed 
to epitopes of 14 amino acids length. After uptake of foreign material early endosomes 
and phagosomes must fuse with other compartments, recruit cytosolic proteins to their 
membrane, and transform to lysosomes by a process called maturation. Lysosomes have 
a lower pH than their predecessors which is achieved by protein pumps and activates 
proteases such as cathepsin-S breakdown of the ingested material. Appropriately sized 
peptides are loaded on MHC-II and transferred to the cell surface to be recognized by 
CD4+ T-cells and trigger adaptive immune responses.[159] 
Maturation of early endosomes is accompanied by a change in composition of 
phosphoinositide lipids in their membrane as a marker for the change in organellar 
identity (Scheme 5.4).[224] Conversion of phosphatidylinositol-4,5-bisphosphate 
(PI(4,5)P2) to phosphatidylinositol 3-phosphate (PI(3)P) can be accomplished by various 
kinases and phosphatases, but for the progression to phosphatidylinositol 3,5-





catalyst.[225,224] Despite the plausible link of PI(3,5)P2 and PIKfyve with antigen 
presentation on MHC-II, a direct connection had not been shown previously.  
 
Scheme 5.4: Conversion of phosphoinositide lipids in the course of early endosome maturation to lysosomes. 
The influence of PIKfyve on MHC-II presentation was tested with the help of apilimod 
and YM201636, both selective inhibitors of PIKfyve.[41,226,227] In donor blood derived 
dendritic cells, presentation of OVA[323-339] with and without inhibitors was compared 
by T cell activation assay. A reduction of ~25% in IFNγ excretion was observed over 
time. However, long exposure time to the inhibitors also reduced viability in both DCs 
and CD4+ T-cells and could distort the results. As a complementary and more direct 
analysis method, the bio-orthogonal labeling assay[40] described in previous chapters was 
adapted for MHC-II presentation in human dendritic cells. As a model antigen, epitope 
of hemagglutinin HA[322-334] from influenza A virus was extended by four native 
amino acids on both sides (HA[318-338]). Position K326 was chosen for exchange with 
{pra}. Model antigen HA_long_clickable (86) and control peptides HA_short non-
clickable (87), HA_short_clickable (88) and HA_long_non-clickable (89) were 
synthesized (Table 5.3). Short control peptides were chosen consisting only of the epitope 
sequence. Only peptides that are processed inside the lysosome and need to be trimmed 
to size are actively loaded to MHC-II. Thus, the short peptides were not expected to be 
presented on the cell surface. 
 




87 HA_short non-clickable PKYVKQNTLKLAT 
88 HA_short_clickable PKYV{pra}QNTLKLAT 
89 HA_long_non-clickable YGACPKYVKQNTLKLATGMRN 
86 HA_long_clickable YGACPKYV{pra}QNTLKLATGMRN 
 
First, model antigen HA_long_clickable (86) was tested for being accessible for labeling 
with Calfluor488-azide. Solutions of antigen and control peptides were added to HLA-




DR1 DCs and incubated for 1 h, 2 h, 3 h, 4 h, 5 h, and 24 h. Excess peptide was removed 
by washing and the cells were fixed with paraformaldehyde. Click-reaction with 
CalFluor488-azide was performed and MHC-II molecules were additionally marked with 
immunostaining. Cells were analyzed by flow cytometry. CalFluor488 fluorescence of 
HA_long_clickable (86) was found to increase over the course of five hours and drop at 
the 24 h datapoint (Figure 5.8, left). The drop could be explained by internalization and 
degradation of MHC-II molecules with the bound epitopes by the cells. In contrast, the 
fluorescence in all control peptide treated cell populations stayed at a constant 
background level.  
For testing the influence of PIKfyve inhibition on MHC-II presentation, antigen solution 
was added to HLA-DR1 DCs and incubated for 2 h. Inhibitors apilimod or YM201636, 
or DMSO as control were added and incubated with the cells for 3 h before washing, 
fixing and labeling with CalFluor488. Instead of adding inhibitor, trypsin could be added 
to remove epitopes from MHC-II after five total hours of incubation with the antigen. 
Fluorescence was analyzed by FACS. Depending on the donor, fluorescence was reduced 
by 20-80% through inhibition of PIKfyve with apilimod and YM201636 (Figure 5.8 
right). For apilimod the effect was less pronounced (20-40% reduction) but more closely 
distributed over the donors.   
 
Figure 5.8:Left: Testing of model antigen for being accessible for biorthogonal labeling. Right: Fluorescence after 
treatment of DCs with inhibitors. Figures were published in iScience 2019, 11, 160.[41] 
Overall, bio-orthogonal labeling was established as complementary assay to study MHC-
II presentation. A direct influence of PIKfyve inhibition on MHC-II presentation 
previously found by T-cell activation assay could be confirmed by bio-orthogonal 









In this chapter we contributed artificially modified peptides to a rather ambitious project 
in immunology research. Two main aspects were in the center of this project: the question 
of how membrane buried epitopes are cross-presented in dendritic cells and the aim to 
study it with a bio-orthogonal labeling strategy as a complementary method to established 
but laborious immunological assays.  
In section 5.1 the translation of the method previously reported by PAWLAK et. al.[40] for 
mouse models to the investigation of clinically relevant soluble epitopes in human cells 
was described. Screening known tumor antigens for suitable residues to exchange for bio-
orthogonal alkyne linkers for labeling with “clickable” fluorophore Calfluo488 azide 
provided one promising hit with NY-ESO1_pra8 in the long and short version. For these 
peptides, T cell activation could not be verified, so true cross-presentation could not yet 
be confirmed. On the other hand, in NY-ESO1_pra7, T cell activation was in the range 
of the native sequence, while labeling was about 10 times less efficient than in the best 
hit. With all peptides derived from the NY-ESO1 antigen severe adhesion to the cell 
surface complicated the evaluation of the labeling results. The aim to label the antigen 
inside of the MHC-I binding groove was abandoned for the time being and the alkyne 
linker was used for intracellular staining of antigen conjugated to latex beads by 
biotin/streptavidin interactions. The stained peptides on beads could be observed by 
confocal microscopy in different compartments of the cells over the course of cellular 
processing and will be used as a tool to track antigen in future applications. 
While the linker (alkyne or azide) for bio-orthogonal labeling was integrated in the 
membrane buried epitopes investigated in section 5.2 for future analysis, cross-
presentation was primarily verified by T cell activation. Artificial transmembrane 
peptides were designed and synthesized with the NY-ESO1 epitope integrated in different 
positions of the sequence. One of the constructs was verified on MHC-I by the classic 
immunological assay and could be used to explore the yet unknown processing pathways 
of membrane buried epitopes. Inhibition with GM132 suggested that TMP processing is 
independent of proteasomes, indicating that TM proteins do not take the phagosome-to-
cytosol pathway. This finding will be verified by inhibition of TAP with ICP47 in 
upcoming experiments.  
Finally, bio-orthogonal labeling found a relevant application in a related project described 
in section 5.3, verifying presentation of antigen on MHC-II. PIKfyve, an enzyme which 
catalyzes the conversion of membrane lipid PI(3)P to PI(3,5)P2, had been shown to be 
indispensable for lysosome maturation and subsequent antigen presentation on MHC-II 
by T cell activation. However, the results were questioned because of the adverse effect 
of the used inhibitors on T cell viability. Thus, the T cell independent labeling assay was 
used to provide complementary information. In the used model antigen derived from 
hemagglutinin from influenza A virus no conflict was found between accessibility for 
bio-orthogonal labeling and recognition by the T cell receptor. Inhibition with 
pharmaceuticals apilimod and YM201636 for different durations and correlation with 
labeling efficiency of click-reaction with Calfluor488 azide confirmed the direct 




influence of PIKfyve on antigen presentation on MHC-II. The results could be published 





6 Summary and outlook  
 
In this thesis, artificially modified peptides were synthesized to study SNARE-mediated 
membrane fusion in vitro and antigen processing by antigen presenting cells ex vivo. 
Apart from vesicle trafficking being part of both processes, the projects were connected 
by the challenging peptide sequences – in parts buried inside lipid membranes – that 
needed to be provided in good purities to obtain reliable results. Optimizing and 
streamlining the handling of aggregation prone peptides in solid phase peptide synthesis 
by Fmoc strategy and RP-HPLC purification was a central task of this work and could be 
successfully accomplished for most peptides. Treatment of HPLC samples with HFIP 
proved to be a crucial step so that peptide aggregates could be monomerized prior to 
purification. With proper pretreatment of the samples, only minor changes to standard 
HPLC procedures were needed to isolate the SPPS products.  
 
For the SNARE project, a set of fully peptidic model fusogens developed in the 
DIEDERICHSEN group by KARSTEN MEYENBERG was to be refined with photocleavable 
protecting groups to provide temporal control over the fusion of lipid vesicles. The 
E3Syb/K3Sx fusion pair was previously designed to closely mimic SNARE mediated 
fusion by exchanging the SNARE motif for heterodimeric parallel coiled coils E3 and K3 
and conserving the linker and transmembrane domain of synaptic SNAREs syntaxin-1A 
and synaptobrevin-2.[26] The aim of this work was to develop a photoprotection strategy 
that would reversibly halt the vesicles in intermediate stages preceding full fusion – 
docking and hemifusion – to study different factors important to the transition between 
those stages. The caging should be effective in preventing lipid mixing but at the same 
time minimally intrusive to still allow interaction of the recognition units for docking of 
the reconstituted vesicles. Furthermore, the activity of the fusogens was to be recovered 
fast by uncaging with UV irradiation so that time resolved measurements could provide 
high information value.  
Disturbing coiled coil interactions in a precise manner was challenging because the tightly 
packed hydrophobic core formed by the peptide pair is mostly stabilized by non-selective 
hydrophobic interactions. Furthermore, the amino acids in question – leucin and 
isoleucine – cannot be covalently protected in a reversible way. Instead, the flanking 
glutamic acids and lysins were used to introduce steric hindrance close to the hydrophobic 
core. Literature known caging groups NVOC, DMNPB and DEACM were used to 
synthesize a selection of E3Syb and K3Sx derivatives protected with one or two caging 
groups in the membrane proximal heptads of the recognition units. Combinations of 
complementary peptide pairs were studied in a total lipid mixing assay based on FRET. 
The assay was useful to determine if interaction of the recognition pairs could be 
suppressed and if activity could be recovered in comparison to the positive control 
E3Syb/K3Sx. The combination of E3(DMNPB)2Syb and K3(NVOC)2Sx (28 + 27) 
showed a promising inhibitory effect on the fusogenicity of the SNARE mimetics and 
lipid mixing could be verified after irradiation with 347-400 nm. However, long 
irradiation times (2 min) required to uncage the peptides negatively impacted the assay 




by photobleaching and restricted access to fluorescence data at the onset of lipid mixing. 
Efforts to remedy this drawback by the more efficiently released DEACM were cut off 
by the synthesis failure of E3(DEACM)2Syb (30) most likely by pyroglutamate 
formation. 
Alternatively, a novel protection strategy was developed which would place bulky and 
photolysis-efficient DEACM in between the coiled coils, thus more precisely targeting 
the hydrophobic interactions. Inspired by stapled peptides intramolecularly linked by 
alkene metathesis, DEACM was equipped an allyl linker which could connect two caged 
lysine or glutamic acid residues spanning two DEACM groups over the relevant 
isoleucine and leucine positions. Photolysis kinetics and the produced side products were 
studied with the help of soluble derivatives of the SPPS building blocks dimerized by 
metathesis. Two stapled E3 derivatives were synthesized to establish a synthesis strategy 
and to examine the structural impact of the linkers. While an influence on coiled coil 
interactions remains to be confirmed, an induction of α-helical secondary structure of the 
otherwise unstructured isolated E3 could be verified by CD spectroscopy in peptide 32. 
Transferred to a stapled SNARE mimetic, this could be beneficial to promote docking of 
vesicles by preorganization of the recognition unit.  
Synthesis and purification of stapled K3(DEACM)2
butenylSx (49) could be achieved 
implementing lessons learned in the synthesis of the stapled test-peptides and  purification 
of other SNARE mimetics. LC-MS analysis proved useful in identifying product 
containing fractions obtained from HPLC separation. In combination with non-caged 
E3Syb, the pair is now ready to be tested as minimally perturbed caged fusion pair. 
Following a total lipid mixing assay, the exact fusion states before and after irradiation 
will be distinguished in future experiments with the help of an inner lipid mixing assay 
and fluorescence correlation spectroscopy (FCCS). FCCS can verify docked vesicles 
which are not visible in lipid mixing assays by spatially correlating fluorophores now 
placed in both vesicle populations.[228] Content mixing – exploiting self-quenching of 
encapsulated fluorophores such as fluorescein derivatives which is relieved upon fusion 
with empty vesicles – may help verify complete fusion of vesicles after uncaging. The 
caged fusion pair will be useful to test the influence of lipid composition on the model 
membrane and comprehend the role of specific amino acids of linker and transmembrane 
domains on the transition between fusion states. 
 
In collaboration with the VAN DEN BOGAART group processing of model antigens was 
investigated in antigen presenting cells derived from donor blood. A selection of artificial 
transmembrane peptides was designed to incorporate known tumor epitope NY-ESO1 
and obtained from SPPS and RP-HPLC in good purity. Bio-orthogonal azide and alkyne 
moieties were shown to not interfere with cellular processing and were included in the 
peptide sequences for future fluorescent labeling by copper-catalyzed cycloaddition. In a 
pioneering investigation, cross-presentation on MHC-I of dendritic cells could be verified 
for membrane buried epitopes by a classic T cell activation assay. The functional model 
system was used to follow the pathway by which the antigen was processed to be 
presented on MHC-I. Administration of selective proteasomal inhibitor GM132 showed 





degrading machinery in contrast to soluble versions of the same epitope. One of the major 
known processing pathways is the phagosome-to-cytosol (P2C) pathway which is 
dependent on proteasomal degradation and TAP. Not needing proteasomes for cross-
presentation could indicate that membrane buried epitopes are processed by a different 
pathway than P2C. This finding will be complemented by TAP inhibition in future 
experiments.  
A novel assay based on bio-orthogonal labeling of epitopes bound to MHC was to be 
translated to study clinically relevant epitopes in human antigen presenting cells.[40] 
Fluorescent labeling inside the binding grove of MHC would circumvent the need for 
additional cell types and provide a quick and easy readout for pharmaceutical 
manipulations and related investigations. Regarding cross-presentation on MHC-I HLA-
A2 the chosen epitopes proved to be inadequate to verify processed epitopes on the cell 
surface due to inaccessibility of the labeling site and aggregation. Instead, the modified 
epitopes were conjugated to latex beads and tracked by intracellular staining and confocal 
microscopy (Figure 6.1). On the other hand, click-reaction following cellular processing 
was successful for an antigen presented on MHC-II. The method was applied as a valuable 
supplementary measurement investigating the role of phosphoinositide kinase PIKfyve 
for MHC-II antigen-presentation. A direct link between PIKfyve inhibition reduced 
antigen presentation was demonstrated by T cell activation assay and could be confirmed 
by quantifying bio-orthogonal fluorescent labeling of the presenting epitope.[41]  
 
Figure 6.1: Confocal microscopy of dendritic cells processing antigen conjucated to latex beads. The labeled peptides 












7.1.1 Reagents and solvents 
All reagents were purchased in the highest purity available and used as supplied. Amino 
acid derivatives and coupling reagents were obtained from GL Biochem (Shanghai, 
China), Iris Biotech (Marktredwitz, Germany), and Roth (Karlsruhe, Germany). Resins 
for SPPS were aquired from Novabiochem (Darmstadt, Germany) and Sigma Aldrich (St. 
Louis, USA). Unlabeled and labeled lipids were purchased from Avanti (Alabaster, 
USA). All other Chemicals were obtained from varying commercial sources. Solvents for 
reactions were of the grade pro analysi (p.a.) or absolute. Technical grade solvents for 
flash chromatography were distilled prior to use. Solvents for HPLC and spectroscopic 
applications were of HPLC grade while LC-MS was conducted with LC-MS grade 
solvents, including LC-MS grade water. Demineralized water was further purified using 
either a Simplicity water purification system by Merck Millipore (Billerica, USA) or an 
arium mini lab water system by Sartorius (Göttingen, Germany) to obtain ultrapure water.   
 
7.1.2 Reactions  
Air and moisture sensitive reactions were conducted under nitrogen or argon atmosphere 
in dry solvent. Glassware was therefore heated with a heat gun under reduced pressure 
and purged with the inert gas using SCHLENK-type techniques. If indicated, light-sensitive 




Aqueous or dioxane solutions were frozen in liquid nitrogen and freeze-dried using a 
Christ Alpha 2-4 LD plus lyophilizer (Osterode im Harz, Germany) connected to a high 
vacuum pump. In fractions collected from the HPLC the organic content was reduced to 
a minimum amount with a flow of nitrogen and they were likewise freeze-dried. For small 
volumes (< 2 mL) a Christ RVC 2-18 CD plus vacuum centrifuge (Osterode im Harz, 
Germany) connected to the lyophilizer was used. Small volumes (< 2 mL) of poorly 
soluble transmembrane peptides were lyophilized from neat HFIP.  
 
7.1.4 Storage 
Chemicals and resins for SPPS were stored according to suppliers’ recommendations 
at -18 °C, 2 °C or room temperature and under argon when appropriate. Synthesized 
compounds and cleaved and purified peptides were stored at -18 °C while on-resin-
peptides and compounds meant for the determination of extinction coefficients were kept 







Method a) Photolytic cleavage of NVOC and DMNPB was performed in a UV cuvette 
(1 cm) using an Ark Lamp Source (66924) from Newport, consisting of a 1000 W Arc 
Housing-IGN F/1.0 (66921), a 1000 W Hg-Xe lamp (6295NS), a power supply (69920), 
a dichroic mirror (280-400 nm, 66226), and a 347 nm longwave cut-on filter (20CGA-
345). Samples were irradiated at 1000 W for 10 s to 10 min. Method b) Coumarin based 
protecting groups were usually cleaved in a stirrable UV cuvette (1 cm)  placed on a 
magnetic stirrer using a 400-415 nm laser (75 mW) from Laser 2000 (Wessling, 
Germany). Method c) During total lipid mixing experiments of coumarin protected 
proteoliposomes a 405 nm (100 mW) laser pointer distributed by starklasers.com 





7.2.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H- and 13C-NMR spectra were recorded on a Varian (Palo Alto, USA) instrument 
(Mercury-VX 300, VNMRS-300 or INOVA-500). The measurement frequency and the 
utilized deuterated solvent are indicated with each compound. Residual proton signals of 
the solvents served as an internal standard. Chemical shifts δ are given in parts per million 
(ppm) and coupling constants nJ are given in Hertz (Hz), where n indicates the order of 
coupling. Multiplicities are described with the following abbreviations: s (singlet), d 
(doublet), t (triplet), q (quartet) or m (multiplet). Signals were partially attributed with the 
help of COSY- (Correlated Spectroscopy), HSQC- (Heteronuclear Single Quantum 
Coherence) and HMBC- (Heteronuclear Multiple Bond Correlation) spectra. 
 
7.2.2 Mass Spectrometry 
All compounds were characterized by electron spray ionization mass spectrometry (ESI-
MS) and high resolution ESI (HR-MS) on a maXis or MicroTOF spectrometer from 
Bruker (Bremen Germany). Values are given in m/z. 
 
7.2.3 UV-Vis 
A nanodrop ND-2000c spectrometer from Thermo Fischer Scientific (Waltham, USA) 
with a Quartz SUPRASIL QS cuvette of 1.0 cm path length was used for all UV/Vis 





with c being the compound concentration (M), A the absorption of the sample, ε the molar 
extinction coefficient (M-1 cm-1) and d the path length (cm).  




Molar extinction coefficients of new compounds were measured from solutions with 
known concentrations. For each determined value, three separate aliquots of about 5 mg 
were lyophilized inside of Eppendorf tubes and weighed immediately after removal from 
the lyophilizer because the compounds were very hygroscopic. Dilution series in MilliQ 
and MeCN were prepared with three independent samples for each concentration and 
from each aliquot. Concentrations were calculated assuming the molar weight of the 
neutral compounds as there was no evidence of TFA salts (that could have formed upon 
HPLC purification) in 13C-NMR. The averaged measured absorptions were plotted 
against the concentrations. The extinction coefficient was obtained as the slope of the 
linear fit with the y-intercept set to 0. The plots can be seen in the appendix Figure-A 8 
and Figure-A 9.  
Peptide concentrations were calculated from absorptions and literature known or 
measured molar extinction coefficients. For peptides with more than one chromophore 
the ε at the corresponding wavelength was calculated by summation. 
 Absorption 
wavelength λ [nm] 
Extinction coefficient 
ε [M-1 cm-1] 
Reference 
Tryptophan 280 5690 [229] 
Tyrosine 280 1280 [229] 
Cysteine 280 120 [229] 
NVOC 350 5485 [230] 
DMNPB 350 4500 [184] 
DEACM 385 16000 [194] 
DEACMallyl 380 17018 in MeCN,  
17155 in H2O 
measured 
(DEACM)2
butenyl 380 25972 in MeCN,  




Fluorescence measurements were performed in a FP-6200 spectrofluorometer from 
JASCO (Tokyo, Japan). The temperature was controlled by an ETC-272 peltier 
thermostat by JASCO connected to a Thermo Haake WKL26 water recirculatory by 
Thermo Electron Corp. (Waltham, USA). The samples were placed in a quartz glass 
cuvette with a light path of 10 x 4 mm (excitation 10 mm, emission 4 mm) from Hellma 
Analytics (Müllheim, Germany). Data was acquired and analyzed with the Spectra 
Manager software by JASCO. In lipid mixing experiments, temperature was adjusted to 
25 °C and stirring was set to 900 rpm. Fluorophores were excited at 460 nm with a 
bandwidth of 5 nm and emission was measured with 5 nm bandwidth. Sensitivity was set 
to “high” with a data pitch of 1 nm. For time resolved measurements, emission at 530 nm 
was followed over 1200 s to 7200s. Data was collected every 1 s in 1200 s measurements 
and every 10 s in longer measurements.   
 
7.2.5 Circular dichroism (CD) spectroscopy 
CD spectroscopic measurements were carried out on a J-1500 CD spectrometer from 





Germany) under continuous flushing with nitrogen. Samples were analyzed in a Quartz 
SUPRASIL QS cuvette with 0.1 cm pathlength from Hellma Analytics (Mühlheim, 
Germany). Individual spectra were recorded at 20 °C in a wavelength range of 190-
260 nm with a bandwidth of 1 nm, response time of 1.0 s, data pitch of 1 nm and scanning 
speed of 100 nm/min in “continuous mode”. Data was accumulated over 10 
measurements. Temperature dependent measurements were performed between 5 °C and 
95 °C and followed by the CD signal at 222 nm. Data was collected at each full °C and 
measurement was started when the temperature stayed within ± 0.20 °C for 10 s. 
For better comparability of peptides with different numbers of chromophores (amide 
bonds) measured, the CD signal was converted to mean residue ellipticity [θ]  in deg cm2 
dmol-1 by the following formula: 
[𝜃] =  
𝜃𝑜𝑏𝑠 ∙ 𝑀𝑅𝑊
10 ∙ 𝑑 ∙ 𝑐
 
where θobs is the observed ellipticity (deg), MRW is the mean residue molar weight (g mol
-
1) calculated from the molar weight of the peptide divided by the number of amide bonds,  
d is the pathlength (cm) and c is the concentration in (g mL-1). 
 
7.3 Chromatography 
7.3.1 Thin Layer Chromatography 
The progression of reactions was monitored by thin layer chromatography on Merck 
(Darmstadt, Germany) silica gel 60 F254 coated aluminum sheets. Spots were detected 
by fluorescence quenching at 254 nm or fluorescence at 366 nm or visualized by TLC 
staining solutions and heating with a heat gun. Amines were identified with ninhydrin 
solution (1.5 g ninhydrin and 3 mL acetic acid in 100 mL n-butanol) while a cerium 
ammonium molybdate (CAM) solution (2.0 g Cer(IV)SO4 and 5.0 g (NH4)2MoO4 in 
200 mL 10% aq. H2SO4) was used as a universal stain. 
 
7.3.2 Flash Chromatography 
Purification by flash chromatography was performed using Merck (Darmstadt, Germany) 
silica gel type 60 (particle size 40-63 µm) and a pressure of 0.1-1 bar. Silica gel was 
suspended in the eluent of choice and packed in an appropriately sized glass column 
equipped with a glass frit. Crude samples were loaded in a thin layer preabsorbed to the 
fivefold amount by weight of silica gel.  
 
7.3.3 Reversed Phase High Performance Liquid Chromatography (RP-HPLC) 
Analytic RP-HPLC of soluble compounds was carried out on a UPLC system UltiMate 
3000 from Thermo Fischer Scientific (Waltham, USA) consisting of autosampler-, 
pumps-, column oven-, detector, and diode array modules of the 3000 series. Compounds 
that required eluent systems VI, VII and VIII (see below) were analyzed on a JASCO 
(Tokyo, Japan) system with two pump modules (PU-2080 Plus), a photo diode array 
detector (MD-4015), and a degasser (DG-2080-53). Semi-preparative and preparative 




HPLC purification was carried out on either a ÄKTA basic 10 system by Amersham 
Pharmacia Biotech (Umeå, Sweden), equipped with a pump module (P-900) and a UV 
detection module (UV-900) or a JASCO (Tokyo, Japan) system consisting of two pump 
modules (PU 2080 Plus), degasser (DG-2080-53) and a multi wavelength detector (MD-
2010 Plus). If needed, a fraction collector (CHF122SC) from Advantec (Multiplas, USA) 
was coupled to the JASCO (Tokyo, Japan) system by a connector module (FC-2088-30). 
If required, the setup was complemented with a 2155 column oven by PHARMACIA 
LKB (Upsala, Sweden). If not otherwise noted, the purification was conducted at room 
temperature.  
The following columns were used for compound retention: 
Column 1: ACE Excel 2 C18 100A-2-C18 100 mm x 2.1 mm, 2 µm UPLC 
Column 2: MN Nucleodur RP-C18-ec 100-5-C18, 250 mm x 4.6 mm, 5 µm analytical 
Column 3: MN Nucleodur RP-C18-ec 100-5-C18, 250 mm x 10 mm, 5 µm  semi-prep. 
Column 4: MN Nucleodur RP-C18-ec 300-5-C18, 250 mm x 10 mm, 5 µm semi-prep. 
Column 5: MN Nucleodur RP-C18-ec 100-5-C18, 250 mm x 21 mm, 5 µm preparative 
Column 6: ACE Excel 2 C18 100A-5-C18, 150 mm x 21.2 mm, 5µm preparative 
 
Applying a flow rate of 0.30-0.8 mL/min (UPLC), 1 mL/min (analytical), 3 mL/min 
(semipreparative) or 10 mL/min (preparative) a linear gradient of solvent A to solvent B 
from the eluent systems listed below was conducted.     
Eluent 
system 
Solvent A Solvent B 
I H2O + 0.1% TFA MeCN + 0.085% TFA 
II H2O + 0.1% TFA  MeOH + 0.085% TFA 
III H2O + 0.1% TFA MeCN/H2O 4:1 + 0.1% TFA 
IV H2O + 0.1% TFA MeCN + 0.1% TFA 
V H2O + 0.1% TFA MeOH + 0.1% TFA 
VI H2O + 0.1% TFA MeOH/1-PrOH 4:1 + 0. 1% TFA 
VII TEAA buffer 0.1 M pH 7.0 MeCN/TEAA buffer 3:2 
VIII H2O + 0.1% TFA  MeOH/1-PrOH 3:2 + 0.1% TFA 
 
Peptides constructed only from proteinogenic amino acids were detected at 215 nm, 
254 nm, and 280 nm. NVOC and DMNPB containing compounds were observed at 
347 nm while chromatograms of coumarin derivatives were recorded at 390 nm. UPLC 
analysis was conducted at 50 °C. 
Prior to injection the analytes were dissolved in a minimal amount of a solvent mixture 
corresponding to the starting conditions of the HPLC run. Poorly soluble transmembrane 
peptides were dissolved in HFIP and then diluted to the fivefold volume with H2O to 
avoid premature elution. The solutions were filtrated through a Chromafil syringe filter 
(0.45µm pore size) by Macherey Nagel (Düren, Germany). 
 
7.3.4 LC-MS 
LC-MS measurements were conducted on an LTQ XL ion trap mass spectrometer from 





from Thermo Fischer  Scientific (Waltham, USA) consisting of autosampler-, pumps-, 
column oven-, detector, and diode array modules of the 3000 series. As eluents, H2O (LC-
MS grade) + 0.1% FA (solvent A) and MeCN (LC-MS grade) + 0.1% FA (solvent B) 
were used. Separation was achieved by an ACE Excel (100A-2-C18 100 mm x 2.1 mm, 
2 µm) column and a linear gradient of solvents A and B using a flow rate of 0.35 mL/min 
at 40 °C. UV detection was performed at the wavelengths described above. 
Chromatograms are mostly shown as a representation of the total ion count (TIC). 
 
7.4 Fusion experiments 
7.4.1 Preparation of peptide/lipid films 
Stock solutions of unlabeled lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (18:1, Δ9-
cis, DOPC), 1,2-dioleoylsn-glycero-3-phosphoethanolamine (18:1, Δ9-cis, DOPE) and 
cholesterol were prepared in chloroform at a concentration of 20 mg/mL. Labeled lipids 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) 
(ammonium salt) (NBD-DOPE) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (ammonium salt) (Rh-DOPE) were prepared as 
2 mg/mL stock solutions and stored in brown glass vials. Peptides were dissolved in TFE 
and their concentration was measured by UV/VIS at 280 nm for uncaged peptides and at 
the absorption maximum of the corresponding PPG for caged peptides. Peptide/lipid films 
were prepared in small glass test tubes and during mixing all test tubes, stock solutions 
and solvents were cooled with ice. Appropriate volumes of lipid solutions were combined 
to a total lipid amount of 2.5 µmol. For unlabeled peptide/lipid films the lipids were 
mixed to give a ratio of DOPC/DOPE/Cholesterol 50:25:25. Labeled peptide/lipid 
mixtures were combined at a ratio of DOPC/DOPE/Cholesterol/NBD-DOPE/Rh-DOPE 
50:22:25:1.5:1.5. The lipid mixtures were topped with cholesterol to give a total volume 
of 500 µL. Peptides were added to the lipid solution to give a lipid/ peptide ratio of 200/1 
and the solutions were topped with TFE to a total TFE volume of 500 µL. The mixtures 
were allowed to warm up to room temperature and vortexed for 10 s. Then, the solutions 
were heated to 50 °C and the solvents were removed in a faint N2 stream. The resulting 
clear films on the bottom of the test tubes were stored in a vacuum oven at 50 °C for an 
least 12 h before use to complete solvent removal.  
 
7.4.2 Vesicle preparation by extrusion  
Vesicles were prepared by extrusion of rehydrated peptide/lipid films[231] through a 
polycarbonate membrane (100 nm pore diameter, 19 mm disc diameter) by Avestin 
(Ottawa, Canada) with Whatman polyester drain discs by GE healthcare (Little Chalfont, 
UK) mounted on both sides of the membrane in a LiposoFast-Basic extruder by Avestin. 
Before the extruder was assembled and equilibrated by passing through HEPES buffer 
(20 mM, 100 mM KCl, 1 mM EDTA, 1 mM DTT, pH 7.4). The buffer was prepared 
freshy on the day of use by diluting a 10-fold stock solution of HEPES, KCl and EDTA 
with ultrapure water and adjusting the pH with 1 M KOH. After addition of DTT the 
buffer was thoroughly mixed and passed through a Chromafil syringe filter (0.45µm pore 
size) by Macherey Nagel (Düren, Germany). 500 µL HEPES buffer and ~10 glass beads 




(Ø 2mm) were added to the peptide/lipid films. The films were incubated at 50 °C for 1 h 
and subsequently resuspended by vortexing for 30 s and treatment in an ultrasonic bath 
for few seconds. The homogenous emulsion was loaded into one syringe of the prepared 
extruder and extruded 31 times. Between different lipid films, the extruder was 
completely disassembled and rinsed with EtOH and ultrapure water.   
 
7.4.3 Total lipid mixing assay 
 
Detection of fluorescence change upon lipid mixing was carried out on a JASCO 
spectrofluorometer. Donor fluorophores were excited at 460 nm and emission was 
monitored at 535 nm in a time course measurement over 20 min to 2 h. At the beginning 
of each experiment, 1300 µL of HEPES buffer were added to a stirrable fluorescence 
cuvette (Hellma analytics, semi-micro, 1500 µL) and 40 µL of labeled vesicle suspension 
were added and an emission spectrum (ext. 460 nm) was measured to check the liposome 
quality. The time course measurement was started and after 180 s the unlabeled vesicles 
were added in 4-fold excess (160 µL) to obtain a theoretical final lipid concentration of 
180 µM. For photocleavage of PPGs by method a), the cuvette was removed from the 
spectrometer and carried to the uncaging setup in an adjacent laboratory. By method c) 
the uncaging was performed directly in the spectrometer after opening the lid.  In the end 
of the experiment, 25 µL TX-100 (10% in HEPES buffer (v/v)) were added and the 
fluorescence at 535 nm was observed until equilibration of the signal. 
The fluorescence signal was normalized by the following equation: 
𝐹 [%] =  
𝐹𝑡 − 𝐹0
𝐹𝑡𝑜𝑡𝑎𝑙 − 𝐹𝑜
 ∙ 100 
Where Ft is the measured signal, F0 is calculated from the average signal of 30 s before 
addition of unlabeled vesicles and Ftotal is calculated from the average 30 s of fluorescence 
signal after addition of TX-100. The timeline was adjusted to start with t = 0 s at the first 










Under inert atmosphere 3,4-dimethoxyphenylacetone (10.0 g, 55.0 mmol, 1.0 eq) was 
added dropwise to a suspension of sodium hydride (2.10 g NaH 60% in paraffin, 
52.0 mmol, 1.0 eq) in dry THF (75 mL) and stirred for 30 min at room temperature. After 
cooling with an ice bath to 0 °C methyl iodide was added, and the suspension was stirred 
for 30 min at 0 °C and for 1 h at rt. The reaction mixture was quenched by addition of sat. 
aq. NaHCO3 (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic 
layers were washed with brine (2 x 200 mL) and dried over MgSO4. After removal of the 
solvent under reduced pressure the product (8.70 g, 42.0 mmol, 81%) was obtained as a 
yellow oil and used without further purification. 
TLC: Rf = 0.19 (pentane/EtOAc 6:1). 
1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.83 (d, 
3JHH = 8.2 Hz, 1 H, CHar), 6.77 (dd, 
3J 
= 8.1 Hz, 4J = 2.0 Hz, 1 H, CHar), 6.68 (d, 
4JHH = 2.1 Hz, 1 H, CHar), 3.86 (s, 6 H, 2 x 
OCH3), 3.68 (q, 
3J = 7.1 Hz, 1 H, CH-3), 2.05 (s, 3 H, CH3-1), 1.37 (d, 
3J = 7.1 Hz, 3 H, 
CH3-4). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 209.0 (CO), 149.3 (Cq,ar), 148.4 (Cq,ar),  132.9 
(Cq,ar), 120.0 (CHar), 111.6 (CHar), 110.6 (CHar), 56.0 (2 x OCH3), 53.2 (CH-3), 28.4 
(CH3-1), 17.1 (CH3-4). 
ESI-MS m/z : 231.1 [M+Na]+, 439.2 [2M+Na]+.  
 
HR-MS (ESI): calcd. for C12H16NaO3, ([M+Na]














To an ice-cold solution of 10 (5.00 g, 24.0 mmol, 1.0 eq) in acetic acid (50 mL) fuming 
nitric acid (4.8 mL, 0.12 mol, 4.8 eq) was added dropwise. After stirring the solution for 
10 min the ice bath was removed and stirring was continued for 20 min. The reaction 
mixture was poured over crushed ice (200 mL) and after complete melting of the ice 
extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with 
sat. aq. NaHCO3 (2 x 100 mL) and brine (2 x 100 mL) and dried over MgSO4. Removal 
of the solvent yielded the product (5.90, 23.3 mmol, 97%) as a brown solid. 
 
TLC: Rf = 0.23 (pentane/EtOAc 5:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.55 (s, 1 H, CHar), 6.68 (s, 1 H, CHar), 4.51 (q, 
3J = 7.1 Hz, 1 H, CH-3), 3.91 (s, 6 H, 2 x OCH3), 2.17 (s, 3 H, CH3-1), 1.44 (d, 
3J = 
7.1 Hz, 3 H, CH3-4). 
13C-NMR (125 MHz, CDCl3): δ (ppm) = 207.4 (CO), 153.1 (Cq,ar), 147.6.4 (Cq,ar),  141.1 
(Cq,ar), 123.0 (Cq,ar), 110.5 (CHar), 108.2 (CHar), 56.3 (2 x OCH3), 48.1 (CH-3), 28.8 (CH3-
1), 16.8 (CH3-4). 
ESI-MS m/z: 276.1 [M+Na]+, 529.2 [2M+Na]+.  
HR-MS (ESI): calcd. for C12H16NO5, ([M+H]















Sodium borohydride (2.1 g, 55.0 mmol, 1.4 eq) was added to a solution of 11 (10.0 g, 
39.0 mmol, 1.0 eq) in THF/2-propanol (3:2, 50 mL). After 1 h of stirring the reaction was 
quenched with aq. HCl (1 M, 100 mL) and extracted with EtOAc (3 x 100 mL). The 
combined organic layers were washed with sat. NaHCO3 solution (100 mL) and brine 
(100 mL). Removal of the solvent yielded the product (7.00 g, 28.0 mmol, 72%) as a 
mixture of diastereomers. 
TLC: Rf = 0.20 (pentane/EtOAc 5:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.41-7.33 (m, 1 H, CHar), 6.97-6.88 (m, 1 H, 
CHar), 3.99-3.85 (m, 7 H, 2 x OCH3, CH-2), 3.58-3.45 (m, 1 H, CH-3), 1.34-1.12 (m, 
6 H, CH3-4, CH3-1). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 152.6 (Cq,ar), 147.0 (Cq,ar),  141.1 (Cq,ar), 123.0 
(Cq,ar), 110.5 (CHar), 108.2 (CHar), 72.3 (CH-2), 56.3 (2 x OCH3), 48.1 (CH-2), 28.8 (CH3-
1), 16.8 (CH3-4). 
ESI-MS m/z : 278.1 [M+Na]+, 533.2 [2M+Na]+.  
HR-MS (ESI): calcd. for C12H17N1NaO5, ([M+H]


















3-(4,5-dimethoxy-2-nitrophenyl)butan-2-ol (8.00 g, 31.3 mmol, 1 eq) was dissolved in 
dry DCM (300 mL) under inert atmosphere. Boc-L-Glu-OtBu (10.4 g, 34.4 mmol, 
1.1 eq), DCC (7.1 g, 34.4 mmol, 1.1 eq) and DMAP (0.31 g, 2.5 mmol, 0.08 eq) were 
added. The reaction mixture was stirred at room temperature for 12 h, quenched with sat. 
NaHCO3 (200 mL) and extracted with EtOAc (3 x 150 mL). The combined organic layers 
were washed with water (200 mL) and brine (200 mL) and dried over MgSO4. After 
removal of the solvent under reduced pressure the crude product was purified by column 
chromatography (pentane/EtOAc 4:1). The solid product (14.0 g, 26 mmol, 83%) was 
obtained as a mixture of diastereomers.  
TLC: Rf = 0.17 (pentane/EtOAc 4:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.39-7.33 (m, 1 H, CHar), 6.85-6.75 (m, 1 H, 
CHar), 5.17-5.08 (m, 1 H, CH-2DMNPB), 3.97-3.87 (m, 6 H, 2 x OCH3), 3.78-3.69 (m, 1 H, 
CH-3DMNPB), 2.24-1.86 (m, 4 H, δ-CH2, γ-CH2), 1.46-1.38 (m, 18 H, CH3,Boc, CH3,tBu), 
1.34-1.28 (m, 3 H, CH3-1DMNPB), 1.25-1.21 (m, 3 H, CH3-4DMNPB). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 172.2 (γ-CO), 172.2 (α-CO), 155.4 (Cq,arom), 
152.6 (COBoc-carbamat), 147.2 (Cq,arom), 142.8 (Cq,ar), 132.3 (CHar), 121.5 (Cq,ar), 112.0 
(CHar), 82.30 (CH3,tBu), 79.7 (CH3,Boc), 73.9 (CH-2DMNPB), 56.5 (α-CH), 56.4 (OCH3), 
56.3 (OCH3), 38.5 (CH-3DMNPB), 30.7 (γ-CH2), 28.41 (CH3,tBu), 28.11 (CH3,Boc), 21.2 (β-
CH2), 18.6 (CH3-4DMNPB), 16.97 (CH3-4DMNPB). 
ESI-MS m/z : 563.3 [M+Na]+, 541.3 [M+H]+.  
HR-MS (ESI): calcd. for C26H40N2NaO10, ([M+Na]











13 (14.0 g, 26 mmol, 1 eq) was dissolved TFA/DCM (1:1, 120 mL) and stirred at room 
temperature for 1 h. The solvents were removed in an N2 stream and residual TFA was 
coevaporated with DCM (20 mL). The product (9.90 g, 26.0 mmol, quant.) was obtained 
as a light brown solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.43-7.21 (m, 1 H, CHar), 6.83-6.63 (m, 1 H, 
CHar), 5.14-5.04 (m, 1 H, CH-2DMNPB), 3.94-3.86 (m, 6 H, 2 x OCH3), 3.78-3.69 (m, 1 H, 
CH-3DMNPB), 2.65-2.10 (m, 4 H, δ-CH2, γ-CH2), 1.32-1.28 (CH3-1DMNPB), 1.21-1.04 (m, 
3 H, CH3-4DMNPB). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 174.0 (CO2H), 173.5 (γ-CO), 152.8 (Cq,arom), 
147.5 (Cq,arom), 147.4 (Cq,arom), 131.9 (CHar), 118.7 (Cq,arom), 114.0 (CHar), 75.8 (CH-
2DMNPB), 56.4 (α-CH), 56.3 (2 x OCH3), 37.9 (CH-3DMNPB), 27.8 (γ-CH2), 24.8 (β-CH2), 
17.3 (CH3-4DMNPB), 16.6 (CH3-4DMNPB). 
ESI-MS m/z = 385.2 [M+H]+, 407.2 [M+Na]+.  
HR-MS (ESI): calcd. for C17H23N2O8, ([M+H]
















90 (9.90 g, 26 mmol, 1 eq) was dissolved in aqueous K2CO3 solution (9%, 100 mL). 
Fmoc-OSu (8.77 g, 26 mmol, 1 eq) in dioxane (100 mL) was added at 0 °C. The reaction 
mixture was stirred for 1 h at 0 °C and allowed to come to room temperature overnight. 
The mixture was extracted with diethyl ether (3 x 100 mL) and the combined organic 
layers were discarded. The aqueous phase was adjusted to pH 2 with aqueous HCl (2 M) 
and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with 
water (100 mL) and brine (100 mL) and dried over MgSO4. After removal of the solvent 
under reduced pressure the crude product was purified by column chromatography 
(pentane/EtOAc/AcOH, 70:30:1). The product (6.80 g, 11.0 mmol, 42%) was obtained as 
a light brown solid.  
TLC: Rf = 0.13 (pentane/EtOAc/AcOH, 70:30:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.73 (d, 
3J = 7.4 Hz, 2 H, 2 x CHar,Fmoc), 7.60-
7.53 (m, 2 H, 2 x CHar,Fmoc), 7.40-7.25 (m, 5 H, 4 x CHar,Fmoc, CHar,DMNPB), 6.83-6.73 (m, 
1 H, CHar,DMNPB), 5.16-5.03 (m, 1 H, CH-2DMNPB), 4.44-4.32 (m, 2 H, CH2,sp3,Fmoc), 4.28-
4.07 (m, 2 H, CHsp3,Fmoc, α-CH), 3.94-3.79 (m, 6 H, 2 x OCH3), 3.78-3.69 (m, 1 H, CH-
3DMNPB), 2.47-1.64 (m, 4 H, δ-CH2, γ-CH2), 1.35-1.00 (m, 6 H, CH3-1DMNPB, CH3-
4DMNPB). 
13C-NMR (125 MHz, CDCl3): δ (ppm) = 176.0 (CO2H), 172.5 (γ-CO), 162.8 (COFmoc-
carbamate), 156.0 (Cq,arom), 153.5 (Cq,ar), 147.2 (Cq,ar), 143.9 (Cq,ar), 141.4 (Cq,ar), 132.1 
(CHar), 127.8 (CHar), 127.2 (CHar), 125.2 (CHar), 118.7 (Cq,ar), 109.8 (CHar), 107.7 (Cq,ar), 
74.4 (CH-2DMNPB), 67.3 (CH2,Fmoc), 56.4 (α-CH), 56.2 (2 x OCH3), 47.1 (CHsp3,Fmoc), 38.1 
(CH-3DMNPB), 30.6 (γ-CH2), 27.4 (β-CH2), 18.3 (CH3-4DMNPB), 17.8 (CH3-4DMNPB). 
ESI-MS m/z = 629.2 [M+Na]+, 1235.4 [2M+Na]+.  
HR-MS (ESI): calcd. for C32H34N2NaO10, ([M+Na]








7-Diethylamino-4-methylcoumarin (4.21 g, 18.2 mmol, 1.0 eq) and selenium dioxide 
(2.10 g, 18.9 mmol, 1.04 eq) were dissolved in xylene (350 mL) and heated to reflux for 
48 h. The completely cooled mixture was filtered, and the filtrate was reduced in vacuo. 
The residue was dissolved in methanol (400 mL), NaBH4 (0.64 g, 17.0 mmol, 0.9 eq) was 
added and the mixture was stirred at room temperature for 4 h. Water (150 mL) was added 
and the unreacted NaBH4 was quenched by neutralizing with 1 M HCl. Methanol was 
removed at reduced pressure and the aqueous phase was extracted with DCM (5 x 
100 mL). The combined organic layers were dried over MgSO4 and the solvent was 
removed under reduced pressure. The crude product was purified by column 
chromatography (gradient of DCM to DCM/acetone 1:1). The product (1.92 g, 7.8 mmol, 
43%) was obtained as a brown solid. 
TLC: Rf = 0.35 (DCM/acetone 10:1) 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.31 (d, 
3JHH = 9.0 Hz, 1 H, H-5coum), 6.55 (dd, 
3JHH = 9.0 Hz, 
4JHH  = 2.6 Hz, 1 H, H-6coum), 6.48 (d, 
4JHH = 2.6 Hz, 1 H, H-8coum), 6.26 
(t, 4JHH = 1.3 Hz, 1 H, H-3coum), 4.82 (d, J = 4.4 Hz, 1 H, CH2OH), 3.44 (q, J = 7.1 Hz, 
4 H, CH2CH3), 2.61 (t, J = 5.6 Hz,1 H, OH), 1.19 (t, J = 7.1 Hz, 6 H, CH2CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 162.7 (C-2coum), 156.1 (C-8acoum), 154.9 (C-
7coum), 150.5 (C-4coum), 124.4 (C-5coum), 108.6 (C-3coum), 106.3 (C-4acoum), 105.3 (C-
6coum), 97.7 (C-8coum), 60.9 (CH2OH), 44.7 (CH2CH3), 12.40 (CH2CH3). 
ESI-MS m/z : 248.1 [M+H]+, 517.2 [2M+Na]+, 764.4 [3M+Na]+.  
 
HR-MS (ESI): calcd. for C14H17NO3, ([M+H]












(7-Diethylaminocoumarin-4-yl)methyl (4-nitrophenyl) carbonate  
 
16 (0.99 g, 4.0 mmol, 1.0 eq) and 4-nitrophenyl chloroformate (1.25 g, 6.2 mmol, 1.5 eq) 
were suspended in DCM (25 mL), cooled with an ice bath and DIPEA (0.70 mL, 
4.0 mmol, 1.0 eq) was added yielding a clear solution. The reaction mixture was stirred 
for 8 h, allowing it to come to room temperature gradually. The newly formed precipitate 
was dissolved by addition of DIPEA (0.70 mL, 4.0 mmol, 1.0 eq) and the solution was 
stirred for 1 h. The reaction mixture was directly adsorbed on silica and the crude product 
was purified by column chromatography (gradient DCM to DCM/acetone 10:1). The 
product (0.85 g, 2.0 mmol, 50%) was obtained as a yellow solid. 
TCL: Rf = 0.14 (DCM) 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 8.30 (dt, 
3JHH = 9.2 Hz, 
4JHH = 2.2 Hz, 2 H, H-
3pNP), 7.42 (dt, 
3JHH = 9.2 Hz, 
5JHH = 2.2 Hz, 1 H, H-2pNP), 7.32 (d, 
3JHH = 9.0 Hz, 1 H, 
H-5coum), 6.62 (dd, 
3JHH = 9.0 Hz, 
4JHH = 2.6 Hz, 1 H, H-6coum), 6.53 (d, 
4JHH = 2.6 Hz, 1 
H, H-8coum), 6.23 (t, 
4JHH = 1.1 Hz, 1 H, H-3coum), 5.41 (d, 
4JHH = 1.1 Hz, 1 H, CH2O), 
3.42 (q, 3JHH = 7.1 Hz, 4 H, CH2CH3), 1.22 (t, 
3JHH = 7.1 Hz, 6 H, CH2CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 161.9 (C-2coum), 156.2 (C-1pNP), 155.1 (C-8acoum), 
152.0 (COcarbonate), 150.8 (C-7coum), 148.0 (C-4coum), 145.6 (C-4pNP), 126.1 (C-5coum), 
125.3 (C-3pNP), 121.6 (C-2pNP), 115.6 (C-3coum), 109.0 (C-4acoum), 106.7 (C-6coum), 97.9 
(C-8coum), 65.7 (CH2O), 44.9 (CH2CH3), 12.5 (CH2CH3). 
ESI-MS m/z : 413.1 [M+H]+, 435.1 [M+Na]+.  
 
HR-MS (ESI): calcd. for C21H21N2O7, ([M+H]
+): 413.1346, found: 248.1343; calcd. for 
C21H20N2NaO7, ([M+Na]














17 (0.850 g, 2.07 mmol, 1.0 eq) suspended in DMF/DCM (1:1, 30 mL) was combined 
with Fmoc-L-Lys-OH (0.737 g, 2.00 mmol, 0.97 eq) suspended in toluene/DCM (3:2, 
65 mL) and cooled in an ice bath. DIPEA (347 µL, 2.0 mmol, 1.0 eq) was added and the 
reaction mixture was stirred for 12 h allowing it to slowly come to room temperature. 
Further DIPEA (100 µL, 0.6 mmol, 0.3 eq) was added and the reaction mixture was 
stirred at rt for 1 h. The solvents were removed under reduced pressure. The residue was 
dissolved in DCM (100 mL), adsorbed to silica (5 g), and purified by column 
chromatography (DCM/MeOH/AcOH, 95:5:0.1). After lyophilization from dioxane the 
product (1.12 g, 1.70 mmol, 87%) was obtained as a yellow powder.  
 
TLC: Rf = 0.26 (DCM/MeOH/AcOH, 95:5:0.1) 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.86 (d, 
3JHH = 7.4 Hz, 2 H, CHar,Fmoc), 7.71 
(d, 3JHH = 7.4 Hz, 2 H, CHar,Fmoc), 7.43-7.36 (m, 3 H, H-5coum, CHar,Fmoc), 7.32 (dt, 
3JHH = 
7.4 Hz, 4JHH = 1.1 Hz, 2 H, CHar,Fmoc), 6.65 (dd, 
3JHH = 9.0 Hz, 
4JHH = 2.5 Hz, 1 H, H-
6coum), 6.51 (d, 
4JHH = 2.5 Hz, 1 H, H-8coum), 5.98 (s, 1 H, H-3coum), 5.19 (s, 1 H, CH2O), 
4.32 (m, 3 H, CHsp3,Fmoc, CH2,Fmoc), 4.00-3.91 (m, 2 H, α-CH2), 3.40 (q, 
3JHH = 7.0 Hz, 
4 H, CH2CH3), 3.09-3.00 (m, 2 H, ε-CH2), 1.81-1.55 (m, 2 H, -CH2), 1.53-1.23 (m, 4 H, 
-CH2, -CH2), 1.22 (t, 
3JHH = 7.1 Hz, 6 H, CH2CH3). 
13C-NMR (125 MHz, CDCl3): δ (ppm) = 173.6 (CO2H), 161.5 (C-2coum), 155.9 (COcoum-
carbamate) 155.5 (C-8acoum), 155.2 (COFmoc-carbamate), 151.6 (C-7coum), 150.2 (C-4coum), 143.6 
(Cq,Fmoc), 140.5 (Fmoc-Cq,Fmoc), 127.4 (CHar,Fmoc), 126.8 (CHar,Fmoc), 125.0 (CHar,Fmoc, C-
5coum), 119.8 (CHar,Fmoc), 108.6 (C-3coum), 105.2 (C-6coum), 104.4 (C-4acoum), 96.7 (C-
8coum), 65.5 (CH2,Fmoc), 60.7 (CH2O), 53.7 (α-CH2), 46.6 (CHsp3,Fmoc), 43.9 (CH2CH3), 
40.1 (ε-CH2), 30.4 (-CH2), 28.8 (-CH2), 22.8 (-CH2), 12.2 (CH2CH3). 
ESI-MS m/z: 413.1 [M+H]+, 435.1 [M+Na]+.  
 
HR-MS (ESI): calcd. for C36H40N3O8, ([M+H]
+): 642.2816, found: 642.2810; calcd. for 
C36H39N3NaO8, ([M+Na]
+): 664.2642, found: 664.2629. 






To a solution of 16 (0.60 g, 2.09 mmol, 1.00 eq) and Fmoc-L-Glu-OtBu (0.98 g, 
2.30 mmol, 1.10 eq) in anhydrous DCM (50 mL) DCC (0.47 g, 2.30 mmol, 1.10 eq) and 
DMAP (26 mg, 0.21 mmol, 0.10 eq) were added. The solution was stirred for 12 h at 
room temperature. Then, the reaction mixture was washed with saturated NaHCO3 
solution (3 x 50 mL), dried over MgSO4, and adsorbed onto silica (3 g). Purification by 
column chromatography (DCM/MeOH, 99:1) yielded the product (1.03 g, 1.93 mmol, 
96%) as a yellow solid.  
TLC: Rf = 0.55 (DCM/MeOH, 98:2). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.87 (d, 3JHH = 7.5 Hz, 2 H, CHar,Fmoc), 7.71 
(d, 3JHH = 7.4 Hz, 2 H, CHar,Fmoc), 7.66 (d, 
3JHH = 8.04 Hz, 1 H, NH), 7.44 (d, 
3JHH = 
9.03 Hz, 1 H, H-5coum), 7.40 (t, 
3JHH = 7.4 Hz, 2 H, CHar,Fmoc), 7.31 (dt, 
3JHH = 7.4 Hz, 
4JHH = 0.7 Hz, 2 H, CHar,Fmoc), 6.66 (dd, 
3JHH = 9.0 Hz, 
4JHH = 2.6 Hz, 1 H, H-6coum), 6.53 
(d, 3JHH = 2.5 Hz, 1 H, H-8coum), 6.00 (s, 1 H, H-3coum), 5.28 (s, 2 H, CH2O), 4.35-4.17 
(m, 3 H, α-CH, CH2,Fmoc), 4.04-3.94 (m, 1 H, CHsp3,Fmoc), 3.41 (q, 
3JHH = 7.0 Hz, 4 H, 
CH2CH3), 2.60-2.50 (m, 2 H, γ-CH2), 1.98-1.64 (m, 2 H, β-CH2), 1.47 (s, 3 H, 
tBu-CH3)  
1.19 (t, 3JHH = 7.2 Hz, 6 H, CH2CH3). 
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 171.4 (CO2H), 170.7 (γ-CO), 160.3 (C-
2coum), 155.8 (COFmoc-carbamate),  155.5 (C-8acoum), 150.2 (C-4coum), 150.1 (C-7coum), 143.5 
(Cq,Fmoc), 140.5 (Cq,Fmoc), 127.3 (CHar,Fmoc), 126.8 (CHar,Fmoc), 125.2 (C-5coum), 124.9 
(CHar,Fmoc), 119.8 (CHar,Fmoc), 108.5 (C-6coum), 105.1 (C-4acoum, C-3coum), 96.7 (C-8coum), 
80.6 (tBu-Cq), 65.5 (CH2,Fmoc), 61.1 (CH2Ocoum), 53.5 (α-CH), 46.6 (CHsp3,Fmoc), 43.8 
(CH2CH3), 33.2 (γ-CH2), 27.5 (
tBu-CH3), 24.3 (β-CH2), 12.2 (CH2CH3). 
ESI-MS m/z : 695.3 [M+H]+, 717.3 [M+Na]+.  
 
HR-MS (ESI): calcd. for C41H47N2O8, ([M+H]
+): 695.3327, found: 639.3325; calcd. for 
C41H46N2NaO8, ([M+Na]








22 (1.17 g, 1.79 mmol, 1.00 eq) was dissolved in DCM/TFA (1:1, 60 mL) and stirred at 
rt for 1 h. The solvents were removed in a N2 stream, residual TFA was coevaporated 
under reduced pressure with DCM (3 x 50 mL). The product (1.07 g, 1.79 mmol, quant.) 
was obtained as a yellow solid.  
TLC: Rf = 0.32 (DCM/MeOH/AcOH 95:5:0.1). 
1H-NMR (400 MHz, CD3OD): δ (ppm) = 7.71 (d, 
3JHH = 7.5 Hz, 2 H, CHar,Fmoc), 7.60 
(dd, 3JHH = 7.5 Hz, 
4JHH = 3.3 Hz, 2 H, CHar,Fmoc), 7.36-7.28 (m, 3 H, CHar,Fmoc, H-5coum), 
), 7.24 (dt, 3JHH = 7.5 Hz, 
4JHH = 1.2 Hz, 2 H, CHar,Fmoc), 6.64 (dd, 
3JHH = 9.0 Hz, 
4JHH  = 
2.5 Hz, 1 H, H-6coum), 6.49 (d, 
4JHH = 2.2 Hz, 1 H, H-8coum), 6.04 (s, 1 H, H-3coum), 5.17 
(d, 4JHH = 1.0 Hz, 2 H, CH2Ocoum), 4.32-4.20 (m, 3 H, α-CH, CH2,Fmoc), 4.09 (t, 
3JHH = 
7.1 Hz, CHsp3,Fmoc) 3.35 (q, 
3JHH = 7.1 Hz, 4 H, CH2CH3), 2.53 (m, 2 H, γ-CH2), 2.29-
2.18 (m, 2 H, β-CH2) 1.09 (t, 
3JHH = 7.1 Hz, 6 H, CH2CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 175.1 (CO2H), 173.5 (γ-CO), 164.0 (C-2coum), 
158.6 (COFmoc-carbamate),  157.3 (C-8acoum), 154.3 (C-7coum), 145.2 (C-4coum), 145.1 
(Cq,Fmoc), 142.5 (Cq,Fmoc), 128.8 (CHar,Fmoc), 126.3 (CHar,Fmoc), 126.2 (C-5coum), 120.9 
(CHar,Fmoc), 111.0 (C-3coum), 108.1 (C-4acoum), 107.0 (C-6coum), 99.1 (C-8coum), 68.1 
(CH2,Fmoc), 62.6 (CH2Ocoum), 54.4 (α-CH), 48.4 (CHsp3,Fmoc),  46.3 (CH2CH3), 31.2 (γ-
CH2), 27.9 (β-CH2),  12.6 (CH2CH3). 
ESI-MS m/z: 599.3 [M+H]+, 621.2 [M+Na]+.  
 
HR-MS (ESI): calcd. for C34H35N2O8, ([M+H]
+): 599.2388, found: 599.2384; calcd. for 
C34H34N2NaO8, ([M+Na]











7-Diethylamino-4-methylcoumarin (4.21 g, 18.2 mmol, 1.0 eq) and selenium dioxide 
(2.10 g, 18.9 mmol, 1.04 eq) were dissolved in xylene (350 mL) and heated to reflux for 
48 h. The completely cooled mixture was filtered and the filtrate was reduced in vacuo. 
The residue was dissolved in DCM (100 mL), adsorbed to silica (10 g) and purified by 
column chromatography (DCM). The product (2.24 g, 9.1 mmol, 51%) was obtained as 
a red oily solid. 
TLC: Rf = 0.28 (DCM)  
1H-NMR (400 MHz, CDCl3): δ (ppm) = 10.0 (s, 1 H, CHO), 8.28 (d, 
3JHH = 9.2 Hz, 1 H, 
H-5coum), 6.61 (dd, 
3JHH = 9.2 Hz, 
4JHH = 2.6 Hz, 1 H, H-6coum), 6.50 (d, 
4JHH = 2.6 Hz, 1 
H, H-8coum), 6.43 (s, 1 H, H-3coum), 3.41 (q, 
3JHH = 7.2 Hz, 4 H, CH2CH3), 1.21 (t, 
3JHH = 
7.1 Hz, 6 H, CH2CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 192.4 (CHO), 161.8 (C-4coum), 157.3 (C-2coum), 
151.0 (C-8acoum), 143.8 (C-7coum), 128.8 (C-5coum), 117.2 (C-3coum), 109.5 (C-4acoum), 
103.6 (C-6coum), 97.5 (C-8coum), 44.7 (CH2CH3), 12.40 (CH2CH3). 
ESI-MS m/z : 246.1 [M+H]+, 268.1 [M+Na]+. 
 
HR-MS (ESI): calcd. for C14H16NO3, ([M+H]
+): 246.1127, found: 246.1126; calcd. for 
C14H15NNaO3, ([M+Na]








To a solution of 34 (1.14 g, 4.64 mmol, 1.00 eq) in MeCN/H2O (4:1, 20 mL) ZnCl2 
(1.01 g, 7.40 mmol, 1.60 eq) and allyltributylstannane (2.30 mL, 2.46 g, 7.42 mmol, 
1.60 eq) were added and the reaction mixture was stirred for 12 h. MeCN was removed 
under reduced pressure and H2O (20 mL) was added. The aqueous suspension was 
extracted with DCM (3x20 mL). The combined organic phases were washed with brine 
(10 mL), dried over MgSO4 and adsorbed onto silica (2 g). Purification by column 
chromatography (hexane/EtOAc 5:1 to hexane/EtOAc 3:1) gave the product (1.23 g, 
4.30 mmol, 93%) as a brown viscous oil.  
 
TLC: Rf = 0.43 (hexane/EtOAc 1:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.37 (d, 
3JHH = 9.1 Hz, 1 H, H-5coum), 6.57 (dd, 
3JHH = 9.1 Hz, 
4JHH  = 2.6 Hz, 1 H, H-6coum), 6.48 (d, 
4JHH = 2.6 Hz, 1 H, H-8coum), 6.24 
(t, 4JHH = 1.3 Hz, 1 H, H-3coum), 5.95-5.80 (m, 1 H, CHallyl), 5.24-5.15 (m, 2 H, 
CH2,sp2,allyl), 5.01 (dd, 
3JHH = 7.89 Hz, 
3JHH = 3.7 Hz, CHOHcoum), 3.39 (q, J = 7.1 Hz, 4 H, 
CH2CH3), 2.71-2.38 (m, 2 H, CH2,sp3,allyl), 1.19 (t, J = 7.1 Hz, 6 H, CH2CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 162.4 (C-2coum), 157.3 (C-8acoum), 156.3 (C-
4coum), 150.2 (C-7coum), 133.2 (CHallyl), 124.8 (C-5coum), 119.1, CH2,sp2,allyl), 108.5 (C-
6coum), 106.1 (C-4acoum), 105.4 (C-3coum), 98.0 (C-8coum), 68.8 (CHOHcoum), 44.7 
(CH2CH3), 12.5 (CH2CH3). 
ESI-MS m/z: 288.2 [M+H]+, 310.2 [M+Na]+, 575.3 [2M+H]+.  
 
HR-MS (ESI): calc. for C17H22NO3, ([M+H]
+): 288.1594, found: 288.1594; calc. for 
C17H21NNaO3, ([M+Na]




To a solution of 33 (0.60 g, 2.09 mmol, 1.00 eq) and Fmoc-L-Glu-OtBu (0.98 g, 
2.30 mmol, 1.10 eq) in anhydrous DCM (50 mL) DCC (0.47 g, 2.30 mmol, 1.10 eq) and 




DMAP (26 mg, 0.21 mmol, 0.10 eq) were added. The solution was stirred for 12 h at rt. 
Then, the reaction mixture was washed with saturated NaHCO3 solution (3 x 50 mL), 
dried over MgSO4, and adsorbed onto silica (3 g). Purification by column 
chromatography (DCM/MeOH, 95:5) yielded the product (1.03 g, 1.93 mmol, 96%) as a 
yellow solid.  
TLC: Rf = 0.34 (DCM/MeOH 95:5). 
1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.76 (d, 
3JHH = 7.5 Hz, 2 H, CHar,Fmoc), 7.60 (d, 
3JHH = 7.6 Hz, 2 H, CHar,Fmoc), 7.43-7.37 (m, 3 H, H-5coum, CHar,Fmoc), 7.34-7.28 (m, 2 H, 
CHar,Fmoc), 6.60-6.55 (m, 1 H, H-6coum), 6.51-6.49 (m, 1 H, H-8coum), 6.09-6-01 (m, 2 H, 
CHOcoum, H-3coum), 5.81-5.69 (m, 1 H, CHsp2,allyl), 5.14-5.07 (m, 2 H, CH2,sp2,allyl), 4.43-
4.27 (m, 3 H, α-CH, CH2,Fmoc), 4.25-4.18 (m, 1 H, CHsp3,Fmoc), 3.39 (q, 
3JHH = 7.0 Hz, 4 H, 
CH2CH3), 2.72-2.38 (m, 4 H, CH2,sp3,allyl, γ-CH2), 1.98-1.64 (m, 2 H, β-CH2), 1.47 (s, 3 
H, CH3,tBu)  1.19 (t, 
3JHH = 7.2 Hz, 6 H, CH2CH3). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 171.8 (CO2,tBu), 171.0 (γ-CO), 162.1 (C-2coum), 
156.7 (COFmoc-carbamate),  157.8 (C-8acoum), 153.7 (C-4coum), 150.7 (C-7coum), 143.9 
(Cq,Fmoc), 141.4 (Cq,Fmoc), 132.3 (CHsp2,allyl), 127.8 (CHar,Fmoc), 127.2 (CHar,Fmoc), 125.3 (C-
5coum), 124.9 (CHar,Fmoc), 120.1 (CHar,Fmoc), 119.1 (CH2,sp2,allyl), 108.9 (C-6coum), 106.0 (C-
4acoum), 105.8 (C-3coum), 98.2 (C-8coum), 82.1 (Cq,tBu) 70.6 (CHOcoum), 67.2 (CH2,Fmoc), 
53.8 (α-CH), 47.3 (CHsp3,Fmoc), 44.9 (CH2CH3), 39.2 (CH2,sp3,allyl), 32.1 (γ-CH2), 28.2 
(CH3,tBu), 28.1 (β-CH2), 12.6 (CH2CH3). 
ESI-MS m/z : 695.3 [M+H]+, 717.3 [M+Na]+.  
 
HR-MS (ESI): calcd. for C41H47N2O8, ([M+H]
+): 695.3327, found: 639.3325; calcd. for 
C41H46N2NaO8, ([M+Na]




91 (1.37 g, 1.97 mmol, 1.0 eq) was dissolved in DCM/TFA (1:1, 60 mL) and stirred at rt 





reduced pressure with DCM (3 x 50 mL). The product (1.26 g, 1.97 mmol, quant.) was 
obtained as a yellow solid.  
TLC: Rf = 0.34 (DCM/MeOH/AcOH 95:5:0.1). 
1H-NMR (600 MHz, CD3OD): δ (ppm) = 7.76 (d, 
3JHH = 7.6 Hz, 2 H, CHFmoc), 7.62 (d, 
3JHH = 7.6 Hz, 2 H, CHFmoc), 7.52 (d, 
3JHH = 9.2 Hz, 1 H, H-5coum), 7.38-7.33 (m, 2 H, 
CHFmoc), 7.31-7.25 (m, 2 H, CHFmoc), 6.68 (dd, 
3JHH = 9.1 Hz, 
4JHH  = 2.6 Hz, 1 H, H-
6coum), 6.47 (d, 
4JHH = 2.4 Hz, 1 H, H-8coum), 6.11-6-07 (m, 1 H, CHOcoum), 6.02 (s, 1 H, 
H-3coum), 5.86-5.76 (m, 1 H, CHsp2,allyl), 5.12-5.04 (m, 2 H, CH2,sp2,allyl), 4.37-4.22 (m, 3 
H, α-CH, CH2,Fmoc), 4.19-4.13 (m, 1 H, CHsp3,Fmoc), 3.41 (q, 
3JHH = 7.2 Hz, 4 H, CH2CH3), 
2.71-2.51 (m, 4 H, CH2,sp3,allyl, γ-CH2), 2.28-1.92 (m, 2 H, β-CH2),  1.16 (t, 
3JHH = 7.2 Hz, 
6 H, CH2CH3). 
13C-NMR (75 MHz, CD3OD): δ (ppm) = 174.4 (CO2H), 173.0 (γ-CO), 164.2 (C-2coum), 
158.4 (COFmoc-carbamate),  157.6 (C-8acoum), 156.5 (C-4coum), 152.2 (C-7coum), 145.1 
(Cq,Fmoc), 142.4 (Cq,Fmoc), 133.5 (CHsp2,allyl), 128.7 (CHar,Fmoc), 128.0 (CHar,Fmoc), 126.4 (C-
5coum), 126.3 (CHar,Fmoc), 120.8 (CHar,Fmoc), 119.2 (CH2,sp2,allyl), 110.5 (C-6coum), 106.9 (C-
4acoum), 105.5 (C-3coum), 98.5 (C-8coum), 71.9 (CHOcoum), 67.9 (CH2,Fmoc), 54.4 (α-CH), 
48.4 (CHsp3,Fmoc), 45.6 (CH2CH3), 40.1 (CH2,sp3,allyl), 31.4 (γ-CH2), 27.8 (β-CH2), 12.8 
(CH2CH3). 
ESI-MS m/z: 639.4 [M+H]+, 661.3 [M+Na]+.  
 
HR-MS (ESI): calcd. for C37H39N2O8, ([M+H]
+): 639.2701, found: 639.2694; calcd. for 
C37H38N2NaO8, ([M+Na]
+): 661.2520, found: 661.2506. 
 
1-(7-Diethylaminocoumarin-4-yl)but-3-en-1-yl (4-nitrophenyl) carbonate  
 
33 (1.08 g, 3.76 mmol, 1.00 eq) and 4-nitrophenyl chloroformate (1.14 g, 5.64 mmol, 
1.50 eq) were suspended in DCM (25 mL), cooled with an ice bath, and DIPEA (0.65 mL, 
3.76 mmol, 1.00 eq) was added yielding a clear solution. The solution was stirred for 
12 h, allowing it to come to room temperature gradually. The newly formed precipitate 
was dissolved by addition of DIPEA (0.65 mL, 4.0 mmol, 1.0 eq) and the solution was 
stirred for 1 h. The reaction mixture was directly adsorbed on silica and the crude product 
was purified by column chromatography (gradient DCM to DCM/acetone 10:1). The 
product (0.544 g, 1.20 mmol, 32%) was obtained as a yellow solid. 




TCL: Rf = 0.16 (DCM) 
1H-NMR (500 MHz, CDCl3): δ (ppm) = 8.30 (dt, 
3JHH = 9.2 Hz, 
4JHH = 2.2 Hz, 2 H, H-
3pNP, H-5pNP), 7.42 (d, 
3JHH = 9.1 Hz, 1 H, H-5coum), 7.38 (dt, 
3JHH = 9.2 Hz, 
5JHH = 2.2 Hz, 
2 H, H-5pNP, H-6pNP), 6.60 (dd, 
3JHH = 9.1 Hz, 
4JHH = 2.6 Hz, 1 H, H-6coum), 6.51 (d, 
4JHH 
= 2.6 Hz, 1 H, H-8coum), 6.17 (s, 1 H, H-3coum), 5.95 (dd, 
3JHH = 7.6 Hz, 
3JHH = 4.8 Hz, 1 
H, CHOcoum),  5.88-5.78 (m, 1 H, CHsp2,allyl), 5.24-5.17 (m, 2 H, CH2,sp2,allyl), 3.40 (q, 
3JHH 
= 7.1 Hz, 4 H, CH2CH3), 2.80-2.67 (m, 2 H, CH2,sp3,allyl), 1.19 (t, 
3JHH = 7.1 Hz, 6 H, 
CH2CH3). 
13C-NMR (125 MHz, CDCl3): δ (ppm) = 161.8 (C-2coum), 156.6 (C-8acoum), 155.2 (C-
1pNP), 152.4 (C-4coum), 151.7 (COcarbonate), 150.7 (C-7coum), 145.5 (C-4pNP), 131.6 (allylsp2-
CH), 125.3 (C-3pNP, C-5pNP), 124.6 (C-5coum), 121.7 (C-2pNP, C-6pNP), 119.8 (CH2,sp2,allyl), 
108.9 (C-6coum), 105.6 (C-3coum), 105.4 (C-4acoum), 98.1 (C-8coum), 75.6 (CHOcoum), 44.9 
(CH2CH3), 39.0 (CH2,sp3,allyl), 12.4 (CH2CH3). 
ESI-MS m/z: 453.2 [M+H]+, 475.2 [M+Na]+.  
 
HR-MS (ESI): calcd. for C24H25N2O7, ([M+H]
+): 453.1656, found: 453.1655; calcd. for 
C24H24N2NaO7, ([M+Na]




36 (0.54 g, 1.24 mmol, 1.00 eq) suspended in DMF/DCM 1:1 (20 mL) was combined 
with Fmoc-L-Lys-OH (0.46 g, 1.24 mmol, 1.00 eq) suspended in toluene/DCM 3:2 
(30 mL) and cooled in an ice bath. DIPEA (216 µL, 1.24 mmol, 1.00 eq) was added and 
the reaction mixture was stirred for 12 h allowing it to slowly come to room temperature. 
Further DIPEA (50 µL, 0.29 mmol, 0.23 eq) was added and the reaction mixture was 
stirred at rt for 1 h. The solvents were removed under reduced pressure. The residue was 
dissolved in DCM (50 mL), adsorbed to silica (3 g), and purified by column 
chromatography (DCM/MeOH/AcOH, 95:5:0.1). The product (178 mg, 1.70 mmol, 





TLC: Rf = 0.29 (DCM/MeOH/AcOH 95:5:0.1). 
1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.72 (d, 
3JHH = 7.5 Hz, 2 H, CHar,Fmoc), 7.62-7.52 
(m, 2 H, CHar,Fmoc), 7.41-7.32 (m, 3 H, H-5coum, CHar,Fmoc), 7.31-7.24 (t, 
3JHH = 7.5 Hz, 2 
H, CHar,Fmoc), 6.64-6.52 (m, 1 H, H-6coum), 6.52-6.47 (m, 1 H, H-8coum), 6.10 (s, 1 H, H-
3coum), 5.95-5.87 (m, 1 H, CHOcoum), 5.79-5.72 (m, 1 H, CHsp2,allyl), 5.14-5.03 (m, 2 H, 
CH2,sp2,allyl), 4.44-4.29 (m, 3 H, α-CH, CH2,Fmoc), 4.21-4.14 (m, 1 H, CHsp3,Fmoc), 3.38 (q, 
3JHH = 7.0 Hz, 4 H, CH2CH3), 3.30-2.96 (m, 2 H, δ-CH2), 2.70-2.40 (m, 2 H, CH2,sp3,allyl), 
1.96-1.71 (m, 2 H, β-CH2),  1.64-1.27 (m, 4 H, δ-CH2, δ-CH2), 1.16 (t, 
3JHH = 7.2 Hz, 
6 H, CH2CH3). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 173.7 (CO2H), 163.9 (C-2coum), 156.4 (COcoum-
carbamate), 156.2 (C-8acoum),  155.9 (COFmoc-carbamate), 155.3 (C-7coum), 150.6 (C-4coum), 143.8 
(Cq,Fmoc), 141.3 (Cq,Fmoc), 132.4 (CHsp2,allyl), 127.7 (CHar,Fmoc), 127.1 (CHar,Fmoc), 125.2 (C-
5coum), 124.8 (CHar,Fmoc), 119.9 (CHar,Fmoc), 118.5 (CH2,sp2,allyl), 109.2 (C-3coum), 106.1 (C-
6coum), 104.0 (C-4acoum), 98.2 (C-8coum), 70.4 (CHOcoum), 67.0 (CH2,Fmoc), 53.6 (α-CH), 
47.1 (Fmocsp3-CH), 44.9 (CH2CH3), 40.4 (allylsp3-CH2), 39.0 (ε-CH2), 32.0 (β-CH2), 28.9 
(β-CH2), 21.6 (γ-CH2), 12.6 (CH2CH3). 
ESI-MS m/z: 639.4 [M+H]+, 661.3 [M+Na]+.  
 
HR-MS (ESI): calcd. for C37H39N2O8, ([M+H]
+): 639.2701, found: 639.2694; calcd. for 
C37H38N2NaO8, ([M+Na]




37 (100 mg, 0.14 mmol, 1.00 eq) was dissolved in piperidin/DMF (1:4, 10 mL) and 
stirred at rt for 20 min. The solvents were removed under reduced pressure. The residue 
was suspended in H2O (30 mL), centrifuged (5 min, 9000 rt/min, 20 °C) and the 
supernatant was lyophilized. After purification by HPLC and lyophilization the product 
(46 mg, 0.10 mmol, 71%) was obtained as a fine yellow powder.  
HPLC: Rt = 9.15 min. 




1H-NMR (400 MHz, CD3OD): δ (ppm) = 7.59 (d, 
3JHH = 9.2 Hz, 2 H, H-5coum), 6.78 (dd,
 
3JHH = 9.2 Hz, 
4JHH = 2.6 Hz, 1 H, H-6coum), 6.55 (d, 
3JHH = 2.6 Hz, 1 H, H-8coum), 6.03 
(s, 1 H, H-3coum), 5.98-5.92 (m, 1 H, CHOcoum), 5.91-5.80 (m, 1 H, CHsp2,allyl), 5.16-5.08 
(m, 2 H, CH2,sp2,allyl), 3.84-3.77 (m, 1 H, α-CH), 3.49 (q, 
3JHH = 7.1 Hz, 4 H, CH2CH3), 
3.21-3.07 (m, 2 H, ε-CH2), 2.74-2.54 (m, 2 H, CH2,sp3,allyl), 2.02-1.77 (m, 2 H, β-CH2),  
1.64-1.27 (m, 4 H, γ-CH2, δ-CH2), 1.16 (t, 
3JHH = 7.2 Hz, 6 H, CH2CH3). 
13C-NMR (100 MHz, CD3OD): δ (ppm) = 173.7 (CO2H), 164.8 (C-2coum), 158.1 (C-
8acoum) 157.8 (COcarbamat), 157.6 (C-4coum), 152.5 (C-7coum), 133.9 (CHsp2,allyl), 126.5 (C-
5coum), 118.9 (CH2,sp2,allyl), 110.6 (C-6coum), 106.9 (C-4acoum), 104.7 (C-3coum), 98.4 (C-
8coum), 72.2 (CHOcoum), 54.6 (α-CH), 45.6 (CH2CH3), 41.3 (ε-CH2),  40.3 (allylsp3-CH2), 
31.4 (β-CH2), 30.4 (δ-CH2), 23.4 (γ-CH2), 17.7 (CH2CH3). 
ESI-MS m/z: 460.2 [M+H]+, 482.2 [M+Na]+, 919.5 [2M+H]+, 941.5 [2M+Na]+. 
 
HR-MS (ESI): calcd. for C24H34N3O6, ([M+H]
+): 460.2441, found: 460.2442; calcd. for 
C24H33N3NaO6, ([M+Na]




37 (150 mg, 0.22 mmol, 1.00 eq) and Grubbs I catalyst (10 mg) dissolved in anhydrous 
DCM (15 mL) were heated to reflux for 8 h. The solvent was removed under reduced 
pressure. The residue was dissolved in piperidin/DMF (1:4) and stirred at rt for 20 min.  
The solvents were removed under reduced pressure. The residue was suspended in H2O 
(30 mL), centrifuged (5 min, 9000 rt/min, 20 °C) and the supernatant was lyophilized. 
After purification by HPLC and lyophilization the product (53 mg, 59 µmol, 54%) was 
obtained as a fine yellow powder. For NMR analysis only the cis-isomers were isolated. 





1H-NMR (400 MHz, CD3OD): δ (ppm) = 7.49 (d, 
3J = 9.2 Hz, 2 H, H-5coum), 6.69 (dd,
 3J 
= 9.2 Hz, 4J = 2.6 Hz, 1 H, H-6coum), 6.52 (d, 
3J = 2.6 Hz, 1 H, H-8coum), 5.93 (d,
 4J 
=1.44 Hz, 1 H, H-3coum), 5.89-5.83 (m, 1 H, CHOcoum), 5.60 (t, 
3JHH = 4.8 Hz, 1 H, 
CHbutenyl), 3.91 (q, 
3J = 5.5 Hz, 1 H, α-CH), 3.45 (q, 3J = 7.4 Hz, 4 H, CH2CH3), 3.20-
3.04 (m, 2 H, ε-CH2), 2.62-2.37 (m, 2 H, CH2,butenyl), 2.00-1.79 (m, 2 H, β-CH2),  1.63-
1.37 (m, 4 H, γ-CH2, δ-CH2), 1.13 (t, 
3J = 7.1 Hz, 6 H, CH2CH3). 
13C-NMR (100 MHz, CD3OD): δ (ppm) = 171.9 (CO2H), 164.8 (C-2coum), 157.8 (C-
8acoum) 157.7 (COcarbamat), 157.6 (C-4coum), 152.4 (C-7coum), 128.3 (CHbutenyl), 126.5 (C-
5coum), 110.6 (C-6coum), 106.8 (C-4acoum), 104.7 (C-3coum), 98.5 (C-8coum), 72.3 (CHOcoum), 
53.9 (α-CH), 45.6 (CH2CH3), 41.3 (ε-CH2), 33.7 (CH2,butenyl), 31.2 (β-CH2), 30.3 (δ-CH2), 
23.3 (γ-CH2), 12.7 (CH2CH3). 
ESI-MS m/z: 891.5 [M+H]+, 446.2 [M+2H]2+. 
 
HR-MS (ESI): calcd. for C46H63N6O12, ([M+H]
+): 891.4499, found: 891.4498; calcd. for 
C46H64N6O12, ([M+2H]
2+): 446.2282, found: 446.2286. 
  




7.6 Peptide synthesis and related reactions 
7.6.1 Solid phase peptide synthesis (SPPS) 
Peptides were synthesized on a on a pre-loaded Wang resin (0.27-0.32 mmol/g, Nova 
Biochem (Darmstadt, Germany)) for carboxy C-termini or a Rink amide resin 
(0.5 mmol/g) for amide C-termini. The following commercially available L-amino acid 
(aa) building blocks were used in automated microwave assisted SPPS (see below): 
Fmoc-Ala-OH (A) Fmoc-Ile-OH (I) Fmoc-Thr(tBu)-OH (T) 
Fmoc-Arg(Pbf)-OH (R)  Fmoc-Leu-OH (L) Fmoc-Trp(Boc)-OH (W) 
Fmoc-Asn(Trt)-OH (N) Fmoc-Lys(Boc)-OH (K) Fmoc-Tyr(tBu)-OH (Y) 
Fmoc-Cys(Trt)-OH (C) Fmoc-Met-OH (M) Fmoc-Val-OH (V) 
Fmoc-Gln(Trt)-OH (Q) Fmoc-Phe-OH (F) Fmoc-Pra-OH ({pra}) 
Fmoc-Glu(OtBu)-OH (E) Fmoc-Pro-OH (P) Fmoc-AHA-OH ({az}) 
Fmoc-Gly-OH (G) Fmoc-Ser(tBu)-OH (S)  
 
Building blocks synthesized for this work were coupled by manual microwave assisted 
SPPS (see below) after transfer of the resin from the synthesizer reaction vessel to a 
Discardit II syringe by Becton Dickinson (Heidelberg, Germany) equipped with a 
polyethylene frit, in the following referred to as BD syringe. After coupling, the excess 
building block was recovered by quenching and precipitation with water. Centrifugation 






Furthermore, when opportune for the following of coupling efficiency or side reactions, 
commercially available amino acids were also coupled by manual SPPS. Commonly 
repeated processes are successively summarized as standard operating procedures 
(SOPs).  
 
7.6.2 Automated solid phase peptide synthesis 
Automated SPPS was performed 0.05 mmol scale on a Liberty Blue CEM (Matthews, 
USA) microwave assisted peptide synthesizer. SOP1: For peptides of up to 30 aas length, 
the synthesis was conducted via a standard Fmoc/tBu-protocol using the recommended 
(single) coupling (5 eq. aa, 5 eq. DIC, 5 eq. OxymaPure and 0.5 eq. DIPEA in DMF, 1: 
75 °C, 170 W, 15 s, 2: 90 °C, 30 W, 105 s) and deprotection methods (piperidine/DMF, 
1:4, v/v, 1: 75 °C, 155W, 15 s, 2: 90 °C, 30W, 50 s). SOP2: Peptides of more than 30 aas 
length were coupled twice per aa using the modified CarbomaMAX™ coupling (5 eq. aa, 
10 eq. DIC, 5 eq. OxymaPure, 0.5 eq. DIPEA in DMF, 1: 75 °C, 170 W, 15 s, 2: 90 °C, 
30 W, 105 s) method. Special care was taken for the incorporation of Cys, and Arg 
residues. For cysteine, the temperature of the microwave assisted coupling was reduced 





was always introduced by double coupling ((a) 1: 25 °C, 0 W, 1500 s, 2: 75 °C, 30 W, 
120 s, (b) 1: 75 °C, 30 W, 300 s). 
 
7.6.3 Manual SPPS 
Manual coupling was performed using a Discover microwave reaction cavity by CEM 
(Matthews, USA). The resin was placed in a BD syringe. SOP3: Double coupling of 
caged aas was achieved by treatment with the coupling cocktail (5 eq. aa, 5 eq. HATU, 
4.5 eq, HOAt, 10 eq. DIPEA in DMF) and supported by microwave irradiation (50 °C, 
25 W, 10 min). SOP4: Standard aas were introduced at higher temperatures (75 °C, 
30 W, 5 min). Fmoc was removed with piperidine (20% in DMF, 1: 50 °C, 35 W, 30 s, 
2: 75 °C, 25 W, 180 s). Between all steps, the resin was washed (5 x DMF).  
 
7.6.4 N-terminal acylation 
SOP5: To obtain an uncharged N-terminus the resin bound peptide was treated with the 
acylation cocktail (10% Ac2O, 5% DIPEA in DMF) for 10 min at room temperature. The 
process was repeated twice.  
 
7.6.5 On resin metathesis 
SOP6: Macrocyclization of the N-terminally protected or acylated peptides was 
performed on resin. After SPPS the resin was washed successively with DMF (5 x), 
MeOH (5 x), and DCM (5 x) and dried in a desiccator. A two neck round bottom flask 
equipped with a reflux condenser containing the resin (10-100 mg) and the catalyst 
(0.25 mg/ mg of resin) were carefully purged with argon using the SCHLENK technique. 
Degassed DCE (2 mL/mg resin) was added and the mixture was stirred at 50 °C for 2 h. 
The resin was filtered off and the process was repeated with fresh catalyst and solvent to 
complete the reaction. After filtration and thorough washing of the resin with DCE (10 x) 
and DMF (10 x),  Fmoc deprotection (20% piperidine in DMF, 2 x 10 min at room 
temperature) was performed if necessary.   
 
7.6.6 Cleavage 
SOP7: After synthesis, the resin was filtered off, washed successively with DMF (5 x), 
MeOH (5 x) and DCM (10 x) and dried in vacuo. Acidic cleavage from the resin was 
achieved by treatment with a mixture of a) trifluoroacetic acid 
(TFA)/triisopropylsilane/water (95:2.5:2.5, 5 mL, 3 h, cleavage) for sequences without 
cysteine or b) TFA/triisopropylsilane/ethanedithiol/water (94:2.5:2.5:1, 5 mL, 3 h) for 
cysteine containing peptides. The resin was extracted with additional TFA (5 mL) and the 
combined extracts were concentrated to 2 mL under a flow of nitrogen. The crude peptide 
was then precipitated in cold diethyl ether (30 mL) and isolated by centrifugation and 
decantation of the supernatant. The precipitate was washed twice with ice-cold diethyl 
ether and subsequently lyophilized. 




For test cleavage usually a small spatula-tipfull of resin was placed in a 2 mL BD syringe 
and treated as described above only with adjusted volumes (300 µL cleavage cocktail, 
1 mL diethyl ether). After lyophilization the peptide was analyzed by UPLC and mass 
spectrometry. 
 
7.6.7 KAISER test 
For qualitative verification of coupling completion, the KAISER test was carried out. The 
test detects primary amino groups. A small amount of resin was placed in a screw top 
glass and 50 µL of each of the following solutions was added: 
A: ninhydrin (5 g) in ethanol (100 mL) 
B: phenol (80 g) in ethanol (20 mL) 
C: KCN (1 mM in water, 2 mL) in pyridine (96 mL) 
The sample was incubated at 100 °C for 5 min. The presence of primary amino groups 









7.6.8 Synthesized peptides 
 
DEACM-test-peptide a  
 
The peptide was synthesized at a 10 µmol scale by manual SPPS (SOP3 and SOP4). 
After cleavage (SOP7) and lyophilization the crude product was purified by semi-
preparative HPLC utilizing column 3 with a linear gradient of eluent system V (10-80% 
B in 30 min). 
UPLC (column 1, Eluent system II, 10-95% in 20 min) : Rt = 13.0 min. 
ESI-MS m/z: 1133.6 [M+H]+, 578.3 [M+H+Na]2+. 
 
HR-MS (ESI): calcd. for C51H81N12O17, ([M+H]
+): 1133.5837, found: 1133.5822; calcd. 
for C51H81N12NaO17, ([M+H+Na]
2+): 578.2865, found: 578.2861. 
 
DEACM test-peptide b  
 
The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. Fmoc-Lys(DEACM)-OH was coupled by 
manual SPPS (SOP3). After cleavage (SOP7) and lyophilization the crude product was 




purified by preparative HPLC utilizing column 5 with a linear gradient of eluent system 
V (60-80% B in 30 min). 
UPLC (column 1, Eluent system II, 20-95% in 20 min) : Rt = 15.45 min. 
ESI-MS m/z: 805.5 [M+5H]5+, 671.4 [M+6H+]6+. 
 
HR-MS (ESI): calcd. for C187H315N52O46, ([M+5H]
+): 805.0776, found: 805.0784; calcd. 
for C187H316N52O46, ([M+7H]
7+): 671.0659, found: 671.0661. 
 
Test-peptide c  
 
The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. Fmoc-Lys(DEACM)-OH was coupled by 
manual SPPS (SOP3). After cleavage (SOP7) and lyophilization the crude product was 
purified by preparative HPLC utilizing column 5 with a linear gradient of eluent system 
V (60-80% B in 30 min). 
UPLC (column 1, Eluent system II, 20-95% in 20 min) : Rt = 13.3 min. 
ESI-MS m/z: 750.9 [M+5H]5+, 625.9 [M+6H+]6+. 
 
HR-MS (ESI): calcd. for C172H300N51O42, ([M+5H]
5+): 750.4576, found: 750.4569; calcd. 
for C172H301N51O42,, ([M+6H]
6+): 625.5492, found: 625.5483. 
 
Test-peptide d  
 
The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. After cleavage (SOP7) and lyophilization 
the crude product was purified by preparative HPLC utilizing column 5 with a linear 
gradient of eluent system V (50-90% B in 30 min). 
UPLC (column 1, Eluent system II, 20-95% in 20 min) : Rt = 16.20 min. 
ESI-MS m/z: 1234.7 [M+3H]3+, 926.3 [M+3H]4+. 
HR-MS (ESI): calcd. for C171H278N43O48, ([M+3H]
3+): 1234.0206, found: 1234.0200; 
calcd. for C171H279N43O48,, ([M+6H]





E3((DEACM)2butenyl) a  
 
The peptide was synthesized at a 25 µmolar scale on a Rink amid resin. The first 16 aas 
were coupled by automated SPPS (SOP1). All following aas were added by manual SPPS 
(SOP3 and SOP4) and the reactions around the caged aa were followed by KAISER test 
and test cleavages. The final Fmoc deprotection was carried out and the N-terminus was 
acylated (SOP5). After thorough washing of the resin Grubbs-catalyzed macrocyclization 
was performed (SOP6). The peptide was cleaved (SOP7) and after lyophilization the 
crude product was purified by a two-step semi-preparative HPLC utilizing column 3. 
First, truncated peptides from pyroglutamate formation were separated with a linear 
gradient of eluent system VII (60-100% B in 30 min). Following lyophilization the target 
peptide was isolated using a linear gradient of eluent system IV (50-70% B in 30 min). 
UPLC (column 1, Eluent system I, 50-80% in 15 min) : Rt = 4.87 min. 
ESI-MS m/z: 1474.8 [M+2H]2+, 983.5 [M+3H+]3+. 
 
HR-MS (ESI): calcd. for C140H221N29O40, ([M+2H]
2+): 1474.3070, found: 1474.3063; 
calcd. for C140H222N29O40, ([M+3H]
3+): 983.2071, found: 983.2079. 
 
E3((DEACM)2butenyl) b  
 




The peptide was synthesized at a 25 µmolar scale on a Rink amid resin. The first 9 aas 
were coupled by automated SPPS (SOP1). All following aas were added by manual SPPS 
(SOP3 and SOP4) and after the final Fmoc deprotection the N-terminus was acylated 
(SOP5). After thorough washing of the resin Grubbs-catalyzed macrocyclization was 
performed (SOP6). The peptide was cleaved (SOP7) and after lyophilization the crude 
product was purified by semi-preparative HPLC utilizing column 3 with a linear gradient 
of eluent system IV (60-80% B in 30 min). Two peaks with masses corresponding to the 
target peptide were isolated. 
UPLC (column 1, eluent system I, 40-80% in 15 min) : Rt = 8.5 min, 8.8 min.  
ESI-MS m/z: 1518.8 [M+2H]2+, 1012.9 [M+3H+]3+. 
 
HR-MS (ESI): calcd. for C142H221N29O44, ([M+2H]
2+): 1518.2968, found: 1518.2966; 
calcd. for C142H221N29O44,, ([M+3H]




The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. After cleavage (SOP7) and lyophilization 
the crude product was purified by preparative HPLC utilizing column 5 with a linear 
gradient of eluent system VI (70-95% B in 30 min). 
UPLC (column 1, Eluent system II, 70-99% in 8 min) : Rt = 6.25 min. 
ESI-MS m/z: 1202.5 [M+5H]5+, 1002.4 [M+6H]6+. 
 
HR-MS (ESI): calcd. for C279H484N73O66S3, ([M+5H]
5+): 1201.9179 found: 1201.9201; 
calcd. for C279H485N73O66S3, ([M+6H]








The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. After cleavage (SOP7) and lyophilization 
the crude product was purified by preparative HPLC utilizing column 5 with a linear 
gradient of eluent system VI (80-100% B in 30 min). 
UPLC (column 1, Eluent system II, 80-99% in 8 min) : Rt = 6.40 min. 
ESI-MS m/z: 1215.5 [M+5H]5+, 1013.9 [M+6H]6+. 
 
HR-MS (ESI): calcd. for C288H478N73O65S3, ([M+5H]
5+): 1215.8985 found: 1215.8985; 
calcd. for C288H479N73O65S3, ([M+6H]




The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. Fmoc-Lys(NVOC)-OH was introduced 
manually (SOP3). After cleavage (SOP7) and lyophilization the crude product was 
purified by semi-preparative HPLC utilizing column 4 with a linear gradient of eluent 
system VI (70-95% B in 30 min). 
UPLC (column 1, Eluent system II, 70-99% in 8 min) : Rt = 6.10 min. 
ESI-MS m/z: 1250.5 [M+5H]5+, 1042.1 [M+6H]6+. 
 
HR-MS (ESI): calcd. for C289H493N74O72S3, ([M+5H]
5+): 1249.7265 found: 1249.7229; 
calcd. for C289H494N74O72S3, ([M+6H]













The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. Fmoc-Lys(NVOC)-OH was introduced 
manually (SOP3). After cleavage (SOP7) and lyophilization the crude product was 
purified by semi-preparative HPLC utilizing column 4 with a linear gradient of eluent 
system VI (70-95% B in 30 min). 
UPLC (column 1, Eluent system II, 70-99% in 8 min) : Rt = 6.80 min. 
ESI-MS m/z: 1298.1 [M+5H]5+, 1082.1 [M+6H]6+. 
 
HR-MS (ESI): calcd. for C279H484N73O66S3, ([M+5H]
5+): 1297.5351 found: 1297.5342; 
calcd. for C279H485N73O66S3, ([M+6H]




The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. Fmoc-Glu(DMNPB)-OH was introduced 
manually (SOP3). After cleavage (SOP7) and lyophilization the crude product was 
purified by semi-preparative HPLC utilizing column 4 with a linear gradient of eluent 





UPLC (column 1, Eluent system II, 80-99% in 8 min) : Rt = 5.90 min. 
ESI-MS m/z: 1311.5 [M+5H]5+, 1093.1 [M+6H]6+. 
 
HR-MS (ESI): calcd. for C312H503N67O79S3, ([M+5H]
5+): 1310.7386 found: 1310.7420; 
calcd. for C288H479N73O65S3, ([M+6H]




The peptide was synthesized at a 50 µmolar scale by automated SPPS (SOP2) following 
the protocol for peptides longer than 30 aas. Fmoc-Lys(DEACM)-OH was coupled 
manually (SOP3). After cleavage (SOP7) and lyophilization the crude product was 
purified by preparative HPLC utilizing column 5 with a linear gradient of eluent system 
VI (80-100% B in 30 min). 
UPLC (column 1, Eluent system II, 70-99% in 8 min) : Rt = 7.10 min. 
ESI-MS m/z: 1312.0 [M+5H]5+, 1093.5 [M+6H]6+. 
 
HR-MS (ESI): calcd. for C309H514N75O74S3, ([M+5H]
5+): 1310.1580 found: 1310.1589; 
calcd. for C309H515N75O74S3, ([M+6H]














The peptide was synthesized at a 50 µmolar scale on a preloaded Wang resin. All aas 
except for Fmoc-Lys(DEACMallyl)-OH were coupled by automated SPPS (SOP2). The 
caged lysine was introduced by manual SPPS (SOP3). N-terminal Fmoc was kept on the 
peptide for the following metathesis. After thorough washing and drying of the resin 
Grubbs-catalyzed macrocyclization was performed on 100 mg of resin (SOP6). The 
peptide was cleaved (SOP7) and after lyophilization the crude product was purified by 
two-step HPLC. The bulk of impurities was removed on column 5 with a linear gradient 
of eluent V (70-100% B in 15 min) and the target peptide was isolated from column 3 
with a linear gradient of eluent system V (75-90% B in 30 min). Fractions containing the 
product were identified by LC-MS. 
LC-MS: Rt = 6.39 min. 
ESI-MS m/z: 1322.4 [M+5H]5+, 1102.1 [M+6H]6+, 944.9 [M+7H]7+. 
 
HR-MS (ESI): calcd. for C313H513N75O74S3, ([M+5H]
5+): 1321.56, found: 1321.55; calcd. 
for C315H513N75O74S3, ([M+7H]




The peptide was synthesized at a 50 µmolar scale on a preloaded Wang resin (SOP1). 
50 mg of the on-resin peptide were reserved for the synthesis of NY-ESO-1_long_biotin. 
After cleavage (SOP7) additional washing steps with Et2O (5 x 40 mL in total) were 
executed and the peptide was lyophilized. As the peptide is highly prone to aggregation 





ESI-MS m/z: 1838.0 [M+2H]2+, 930.5 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C86H139N18NaO21S2, ([M+2H]
+): 1836.9751, found: 1836.9702; 
calcd. for C86H140N18NaO21S2, ([M+Na+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) additional washing steps with Et2O (5 x 40 mL in total) were executed 
and the peptide was lyophilized. As the peptide is highly prone to aggregation in all tested 
solvents no HPLC purification or analysis could be performed.  
ESI-MS m/z: 999.5 [M+H]+, 511.3 [M+Na+H]2+. 
 
HR-MS (ESI): calcd. for C45H79N10O13S, ([M+H]
+): 999.5543, found: 999.5540; calcd. 
for C45H79N10NaO13S, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) additional washing steps with Et2O (5 x 40 mL in total) were executed 
and the peptide was lyophilized. As the peptide is highly prone to aggregation in all tested 
solvents no HPLC purification or analysis could be performed.  
ESI-MS m/z: 1746.9 [M+H]+, 873.5 [M+2H]2+. 
 
HR-MS (ESI): calcd. for C80H133N18O21S2, ([M+H]
+): 1745.9329, found: 1745.9332; 
calcd. for C80H134N18O21S2, ([M+2H]








The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). 50 mg 
of the on-resin peptide were reserved for the synthesis of NY-ESO-1_long_8_biotin. 
After cleavage (SOP7) additional washing steps with Et2O (5 x 40 mL in total) were 
executed and the peptide was lyophilized. As the peptide is highly prone to aggregation 
in all tested solvents no HPLC purification or analysis could be performed.  
ESI-MS m/z: 921.9 [M+K+H]2+, 614.6 [M+K+2H]3+. 
 
HR-MS (ESI): calcd. for C86H135N18O20S2K1, ([M+K+H]
2+): 921.4584, found: 921.4554; 
calcd. for C86H136N18O20S2K1, ([M+K+2H]




50 mg (~ 8 µmol) of the resin-bound peptide NY-ESO-1_long (51) were manually 
coupled with Fmoc-amino-caproic acid (SOP4). Following the removal of Fmoc, biotin 
was added analogous to the cystein coupling conditions (SOP3). After cleavage (SOP7), 
additional washing steps with Et2O (5 x 20 mL in total) were executed and the peptide 
was lyophilized. As the peptide is highly prone to aggregation in all tested solvents no 
HPLC purification or analysis could be performed.  
ESI-MS m/z: 1111.1 [M+2Na]2+, 748.4 [M+3Na]3+. 
 
HR-MS (ESI): calcd. for C102H161N21O23S3, ([M+2H]
+): 1099.5630, found: 1099.5641; 
calcd. for C102H162N21O23S3, ([M+Na+2H]








50 mg (~ 8 µmol) of the resin-bound peptide NY-ESO-1_long_pra8 (56) were manually 
coupled with Fmoc-amino-caproic acid (SOP4). Following the removal of Fmoc, biotin 
was added analogous to the cystein coupling conditions (SOP3). After cleavage (SOP7), 
additional washing steps with Et2O (5 x 20 mL in total) were executed and the peptide 
was lyophilized. As the peptide is highly prone to aggregation in all tested solvents no 
HPLC purification or analysis could be performed.  
ESI-MS m/z: 1072.7 [M+2H]2+, 715.5 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C102H161N21O23S3, ([M+2H]
+): 1072.0613, found: 1072.0608; 
calcd. for C102H162N21O23S3, ([M+3H]




10 mg (~ 1.6 µmol) of the resin-bound peptide NY-ESO-1_long_8 was added to a 1.5 mL 
Eppendorf tube and flushed with argon. DIPEA (2.8 µL, 16 µmol, 10 eq) in dry and 
degassed DMF (100 µL) was added to the resin under argon stream and the resin was 
gently agitated at rt for 1 h. The Atto647-NHS-ester (1 mg, 1.23 µmol, 0.7 eq with respect 
to the peptide) in dry DMF (100 µL) was added to the resin and gently agitated in the 
dark for 12 h. The resin was transferred to a BD syringe, washed thoroughly (DMF, DCM, 
DMF 3x2 mL each, DCM 7x2 mL) and dried in vacuo. After cleavage (SOP7) and 
lyophilization the crude product was purified by HPLC utilizing column 3 with a linear 
gradient of eluent system V (75-100% B in 30 min, 55 °C). The product peak was 
identified by following the absorption at 647 nm. At the time of synthesis and purification, 
the molecular formula of Atto 647 was not yet published, thus, no HR-MS analysis was 
performed. 
HPLC: (column 3, eluent system V, 75-100% B in 30 min, 1 mL/min) Rt = 17.7 min. 








The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a linear gradient of eluent system IV (40-80% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 10.94 min. 
ESI-MS m/z: 913.0 [M+2H]+, 609.0 [M+3H]2+. 
 
HR-MS (ESI): calcd. for C84H136N20O25, ([M+2H]
2+): 912.4987, found: 912.4990; calcd. 
for C84H137N20O25, ([M+3H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (30-70% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 7.45 min. 
ESI-MS m/z: 984.5 [M+H]+, 503.7 [M+Na+H]2+. 
 
HR-MS (ESI): calcd. for C47H70N9O14, ([M+H]
+): 984.5037, found: 984.5034; calcd. for 
C47H71N9NaO14, ([M+Na+H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a linear gradient of eluent system IV (50-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 11.36 min. 
ESI-MS m/z: 1863.2 [M+H]+, 932.2 [M+2H]2+. 
 
HR-MS (ESI): calcd. for C87H137N20O25, ([M+H]
+): 1862.0058, found: 1862.0047; calcd. 
for C87H138N20O25, ([M+2H]









The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (30-70% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 5.63 min. 
ESI-MS m/z: 942.5 [M+H]+, 482.7 [M+Na+H]2+. 
 
HR-MS (ESI): calcd. for C44H64N9O14, ([M+H]
+): 942.4567, found: 942.4571; calcd. for 
C44H65N9O14, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a linear gradient of eluent system IV (50-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 10.44 min. 
ESI-MS m/z: 1821.2 [M+H]+, 910.7 [M+2H]2+. 
 
HR-MS (ESI): calcd. for C84H131N20O25, ([M+H]
+): 1819.9581, found: 1819.9581; calcd. 
for C84H132N20O25, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (30-70% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 7.03 min. 
ESI-MS m/z: 940.4 [M+H]+, 489.7 [M+K+H]2+. 





HR-MS (ESI): calcd. for C45H66N9O13, ([M+H]
+): 940.4775, found: 940.4778; calcd. for 
C45H66N9NaO13, ([M+Na+H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a linear gradient of eluent system IV (50-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 11.37 min. 
ESI-MS m/z: 909.4 [M+2H]2+, 614.3 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C85H134N20O24, ([M+5H]
5+): 909.4934, found: 909.4947; calcd. 
for C85H135N20O24, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (50-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B, 0.40 mL/min) Rt = 11.81 min. 
ESI-MS m/z: 981.7 [M+H]+, 502.4 [M+Na+H]2+. 
 
HR-MS (ESI): calcd. for C45H77N10O14, ([M+H]
+): 981.5615, found: 981.5608; calcd. for 
C45H77N10NaO14, ([M+Na+H]








The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VII (30-100% B in 30 min).  
Analytical HPLC: (column 2, eluent system VII, 40-100% B in 30 min, 1.0 mL/min) Rt 
= 20.89 min. 
ESI-MS m/z: 1766.8 [M+H]+, 883.4 [M+2H]2+. 
 
HR-MS (ESI): calcd. for C80H137N18O26, ([M+H]
+): 1765.9946, found: 1765.9932; calcd. 
for C80H138N18O26, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (40-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B, 0.40 mL/min) Rt = 9.31 min. 
ESI-MS m/z: 1165.8 [M+H]+, 583.5 [M+2H]2+. 
 
HR-MS (ESI): calcd. for C309H515N75O74S3, ([M+5H]
5+): 1165.6074, found: 1165.6071; 
calcd. for C309H516N75O74S3, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VII (30-100% B in 30 min).  
Analytical HPLC: (column 2, eluent system VII, 40-100% B in 30 min, 1.0 mL/min) Rt 
= 15.95 min. 
ESI-MS m/z: 1732.9 [M+Na]+, 866.5 [M+Na+H]2+. 
 
HR-MS (ESI): calcd. for C76H128N18NaO26, ([M+Na]
+): 1731.9139 , found: 1731.9135; 
calcd. for C76H129N18NaO26, ([M+Na+H]
2+): 866.4606, found: 866.4613. 






The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (50-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B, 0.40 mL/min) Rt = 11.54 min. 
ESI-MS m/z: 937.5 [M+H]+, 480.2 [M+Na+H]2+. 
 
HR-MS (ESI): calcd. for C43H73N10O13, ([M+H]
+): 937.5353, found: 937.5351; calcd. for 
C43H74N10O13, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VII (30-100% B in 30 min).  
Analytical HPLC: (column 2, eluent system VII, 40-100% B in 30 min, 1.0 mL/min) Rt 
= 19.96 min. 
ESI-MS m/z: 1723.0 [M+H]+, 880.5 [M+K+H]2+. 
 
HR-MS (ESI): calcd. for C78H133N18O25, ([M+H]
+): 1721.9684 , found: 1721.9671; calcd. 
for C78H134N18O25, ([M+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 





Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 15.27 min. 
ESI-MS m/z: 1634.3 [M+2H]2+, 1097.2 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C157H235N35O35S3, ([M+2H]
2+): 1633.3418, found: 1633.3409; 
calcd. for C157H235N35NaO35S3, ([M+Na+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 18.20 min. 
ESI-MS m/z: 1588.9 [M+2H]2+, 1059.6 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C151H230N34O35S3, ([M+2H]
+): 1587.8207, found: 1587.8197; 
calcd. for C151H231N34O35S3, ([M+3H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (70-100% B in 30 min, 50 °C).  
Analytical HPLC: (column 2, Eluent system VI, 70-100% B in 60 min, 1.0 mL/min, 
50 °C) Rt = 25.90 min. 
ESI-MS m/z: 1657.8 [M+Na+H]2+, 1100.8 [M+K+2H]3+. 
 
HR-MS (ESI): calcd. for C157H233N35O34S3Na, ([M+Na+H]
2+): 1656.8360, found: 
1656.8356; calcd. for C158H234N35O33S3Na, ([M+Na+2H]
3+): 1104.8931, found: 
1104.8913. 
 






The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (70-100% B in 30 min, 50 °C).  
Analytical HPLC: (column 2, eluent system VI, 70-100% B in 60 min, 1.0 mL/min, 
50 °C) Rt = 27.1 min. 
ESI-MS m/z: 1630.8 [M+2H]2+, 1100.2 [M+K+2H]3+. 
 
HR-MS (ESI): calcd. for C158H233N35O34S3, ([M+2H]
2+): 1630.3365, found: 1630.3373; 
calcd. for C158H232N35O33S3Na, ([M+Na+H]
2+): 1641.3275, found: 1641.3282; calcd. for 
C158H233N35O33S3K, ([M+K+H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 22.6 min. 
ESI-MS m/z: 1628.8 [M+Na+H]2+, 1091.6 [M+K+2H]3+. 
 
HR-MS (ESI): calcd. for C157H232N34O34S3, ([M+H]
+): 1616.8311, found: 1616.8308; 
calcd. for C157H233N34O34S3, ([M+3H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 





Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 15.3 min. 
ESI-MS m/z: 1634.3 [M+2H]2+, 1097.2 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C161H239N33O32S3, ([M+2H]
2+): 1622.3698, found: 1622.3683; 
calcd. for C161H239N33O32S3, ([M+Na+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 70-100% B in 60 min, 1.0 mL/min) Rt 
= 27.8 min. 
ESI-MS m/z: 1634.3 [M+2H]2+, 1097.2 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C161H239N33O32S3, ([M+2H]
2+): 1633.3418, found: 1633.3409; 
calcd. for C161H239N33O32S3, ([M+Na+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 16.5 min. 
ESI-MS m/z: 1666.3 [M+Na+H]2+, 1111.2 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C160H241N35O35S3, ([M+2H]
2+): 1654.3653, found: 1654.3637; 
calcd. for C160H241N35NaO35S3, ([M+Na+2H]
3+): 1110.5733, found: 1110.5705. 
 
 






The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 19.7 min. 
ESI-MS m/z: 1620.7 [M+Na+H]2+, 1080.8 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C154H236N34O35S3, ([M+2H]
+): 1608.8442, found: 1608.8426; 
calcd. for C154H236N34NaO35S3, ([M+Na+2H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 70-100% B in 60 min, 1.0 mL/min) Rt 
= 27.2 min. 
ESI-MS m/z: 1634.4 [M+Na+H]2+, 1095.2 [M+K+2H]3+. 
 
HR-MS (ESI): calcd. for C161H240N33NaO32S3, ([M+Na+H]
2+): 1633.3614, found: 
1633.3623; calcd. for C161H240KN34O34S3, ([M+K+H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 





Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 21.2 min. 
ESI-MS m/z: 1105.6 [M+K+2H]3+. 
 
HR-MS (ESI): calcd. for C161H242N36O32S3, ([M+2H]
2+): 1637.8784, found: 1637.8789; 
calcd. for C161H243N34O34S3, ([M+3H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VI (60-100% B in 30 min).  
Analytical HPLC: (column 2, Eluent system VI, 50-100% B in 30 min, 1.0 mL/min) Rt 
= 22.59 min. 
ESI-MS m/z: 1649.7 [M+Na+H]2+, 1100.1 [M+Na+2H]3+. 
 
HR-MS (ESI): calcd. for C160H238N34O34S3, ([M+2H]
+): 1637.8545, found: 1637.8518; 
calcd. for C160H239N34O34S3, ([M+3H]




The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system VIII (75-100% B in 30 min, 50 °C).  
Analytical HPLC: (column 2, Eluent system VIII, 75-100% B in 30 min, 1.0 mL/min, 
50 °C) Rt = 15.27 min. 
ESI-MS m/z: 1634.3 [M+2H]2+, 1097.2 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C156H260N32O31, ([M+2H]
2+): 1538.9871, found: 1538.9851; 
calcd. for C156H261N32O31, ([M+3H]
3+): 1026.3271, found: 1026.3265. 
 
 






The peptide was built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (50-90% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B in 15 min, 0.40 mL/min) Rt = 13.98 min. 
ESI-MS m/z: 1033.8 [M+4H]4+, 827.2 [M+5H]5+. 
 
HR-MS (ESI): calcd. for C176H285N53O56S3, ([M+4H]
4+): 1033.2556, found: 1033.2568; 
calcd. for C176H286N53O56S3, ([M+5H]




The peptide built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV 30-70% B in 30 min).  
UPLC: (column 1, eluent system II, 20-90% B, 0.40 mL/min) Rt = 8.99 min. 
ESI-MS m/z: 1162.6 [M+2H]2+, 775.4 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C102H166N29O29S2, ([M+3H]




The peptide built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (30-70% B in 30 min).  
UPLC: (Eluent system II, 20-90% B, 0.40 mL/min) Rt = 7.57 min. 






HR-MS (ESI): calcd. for C103H172N30O29S2, ([M+2H]
2+): 1178.6168, found: 1178.6183, 
calcd. for C103H173N30O29S2, ([M+3H]




The peptide built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (30-70% B in 30 min).  
UPLC: (Eluent system II, 20-90% B, 0.40 mL/min) Rt = 6.65 min. 
ESI-MS m/z: 752.4 [M+2H]2+, 501.9 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C69H120N18O19, ([M+2H]
2+): 752.4483, found: 752.4491, calcd. 
for C69H121N18O19, ([M+3H]




The peptide built up at a 50 µmolar scale on a preloaded Wang resin (SOP1). After 
cleavage (SOP7) and lyophilization the crude product was purified by preparative HPLC 
on column 5 with a gradient of eluent system IV (30-70% B in 30 min).  
UPLC: (Eluent system II, 20-90% B, 0.40 mL/min) Rt = 7.94 min. 
ESI-MS m/z: 735.9 [M+2H]2+, 490.9 [M+3H]3+. 
 
HR-MS (ESI): calcd. for C68H113N17O19, ([M+2H]

















Figure-A 1: Uncaging of Fmoc-L-Lys(NVOC)-OH (4) (3.4 mM in MeOH) by method a (see section 7.1.5). Samples 
were drawn at the indicated timepoints and analyzed by analytical HPLC (20-90% B in 30 min, solvent system IV, flow 













Figure-A 2: Uncaging of Fmoc-L-Glu(DMNPB)-OH (8) (3.4 mM in MeOH) by method a (see section 7.1.5). Samples 
were drawn at the indicated timepoints and analyzed by analytical HPLC (20-90% B in 30 min, solvent system IV, 

















Figure-A 3: Uncaging of 18 (3.6 µM in HEPES buffer20 mM, pH 7.4) by method a (see section 7.1.5). Samples were 
drawn at the indicated timepoints and analyzed by UPLC (20-90% B in 30 min, solvent system IV, flow 1 mL/min). 
Peaks were detected by absorption at 390 nm 
. 
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19 21
 
Figure-A 4: Uncaging of 19 in coiled coil complex with 21 (40 µM each in phosphate buffer 10 mM, pH 7) by method 
c (see section 7.1.5). Samples were drawn at the indicated timepoints and analyzed by UPLC (20-90% B in 20 min, 
solvent system II, flow 0.8 mL/min). Peaks were detected by absorption at 280 nm. As a reference, 20 and 21, which 






Figure-A 5: LC-MS analysis of compound 40 (100 µM in ultrapure water) used to study uncaging behavior of the novel 
photocleavable staple at 0 min irradiation. The 50 µL sample was diluted with 10 µL of MeCN and 5 µL were injected 
for analysis. The chromatogram was recorded as total ion count normalized to the relative abundance. The separation 
was conducted with a linear gradient of 10 to 80% B in 8 min and subsequent isocratic elution with 100% B (see 7.3.4 
for eluents). ESI-MS spectra were averaged over the width of the peaks. One main peak at 5.9 min and one less intense 








Figure-A 6: LC-MS analysis of compound 40 (100 µM in ultrapure water) used to study uncaging behavior of the novel 
photocleavable staple at 3 min irradiation by method b (see section 7.1.5). The 50 µL sample was diluted with 10 µL 
of MeCN and 5 µL were injected for analysis. The chromatogram was recorded as total ion count normalized to the 
relative abundance. The separation was conducted with a linear gradient of 10 to 80% B in 8 min and subsequent 
isocratic elution with 100% B (see 7.3.4 for eluents). ESI-MS spectra were averaged over the width of the peaks. One 









Figure-A 7: LC-MS analysis of compound 40 (100 µM in ultrapure water) used to study uncaging behavior of the novel 
photocleavable staple at 30 min irratiation. The 50 µL sample was diluted with 10 µL of MeCN and 5 µL were injected 
for analysis. The chromatogram was recorded as total ion count normalized to the relative abundance. The separation 
was conducted with a linear gradient of 10 to 80% B in 8 min and subsequent isocratic elution with 100% B (see 7.3.4 
for eluents). ESI-MS spectra were averaged over the width of the peaks. One main peak at 5.9 min and one less intense 













































Figure-A 8: Measurement of the extinction coefficient of 39 at 380 nm in MeCN (left) and H2O (right). A dilution series 
was prepared from three separately lyophilized and weighed aliquots and for each concentration three separate 
samples were prepared. The extinction coefficient was obtained as the slope of the linear fit of the data points. 
 
  



































Figure-A 9: Measurement of the extinction coefficient of 40 at 380 nm in MeCN (left) and H2O (right). A dilution series 
was prepared from three separately lyophilized and weighed aliquots and for each concentration three separate 














Proteinogenic amino acids were abbreviated using either the standard tree-letter or one-
letter code. 
δ chemical shift 
aa amino acid 
A absorption intensity 
aca aminocaproic acid 
Ac2O acetic anhydride 
aq. aqueous 
{azi} azidohomoalanine 
BD syringe syringe by Becton Dickinson equipped with a polycarbonate 
filter 
Boc tert-butyloxycarbonyl 
CD circular dichroism 
coum coumarin 
DAG diacylglycerin  




butenyl Two DEACMallyl units connected by olefin metathesis 
DIPEA N,N-diisopropylethylamine 
DLS dynamic light scattering 
DMAP 4-dimethylaminopyridine 
DMNPB 3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl 
DC dendritic cell 
DCC N,N'-dicyclohexylcarbodiimide 
DCM dichloromethane 
DMSO dimethyl sulfoxide 
DPA dipilolinic acid 
DTT dithiothreitol 
EDT 1,2-ethanedithiole 
ELISA enzyme-linked immunosorbent assay 
eq. equivalents 
ESID electronically switchable illumination and detection 
ER endoplasmic reticulum 
ERAD ER-associated degradation 
ERAP ER aminopeptidase 
ESI electron spray ionization 
EtOAc ethyl acetate 
Et2O diethyl ether 
EtOH ethanol 
F fluorescence 
FACS fluorescence-activated cell sorting 
Fmoc fluorenylmethyloxycarbonyl 
FRET Förster resonance energy transfer 
HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-





HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFIP 1,1,1,3,3,3-hexafluoro-2-propanol 
HOAt 1-hydroxy-7-azabenzotriazole 
HLA  human leucocyte antigen 
HPLC high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
IFN γ interferon gamma 
IRAP Insulin-regulate aminopeptidase 
J coupling constant 
LC-MS liquid chromatography-mass spectrometry 
LUV large unilamellar vesicles 
MeCN acetonitrile 
MeOH methanol 
MHC major histocompatibility complex 
MHz megahertz 
MoDC monocyte-derived dendritic cell 







PLC peptide loading complex 
pNP 4-nitrophenyl 
PPG photocleavable protecting group 
ppm parts per million 
{pra} propargylglycine 
quant. quantitative 
Rf retention factor 
RP reversed phase 
Rt retention time 
SNAP-25 synaptosomal nerve-associated protein 25 
SNARE soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor 
SOP standard operating procedure 
SPPS solid-phase peptide synthesis 
Su succinimide 
Sx syntaxin-1A[258-288] (linker region and transmembrane 
domain) 
Syb Synaptobrevin-2[86-106] (linker region and transmembrane 
domain) 
tBu tert-butyl 
TAP transporter associated with antigen processing 
TCR T cell receptor 
TMH transmembrane helix 
TMP transmembrane protein/peptide 
TFA trifluoroacetic acid 
THF tetrahydrofurane 





TIS triisopropylsilyl ether 
Trt trityl 
Tunfl unfolding temperature 
UPLC ultra-performance liquid chromatography 
UV ultraviolet 
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